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I 
ABSTRACT 
 
Riboflavin is an essential component of the human diet, with an established role for its 
derivative cofactors, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), in 
oxidative metabolism. It has previously been demonstrated that luminal but not systemic 
riboflavin depletion leads to a dysregulation of normal gastrointestinal development. It is 
hypothesised that riboflavin depletion of intestinal cells in culture interrupts cell signalling 
pathways, with associated adverse functional effects. The overall aim was to develop and 
characterise an intestinal cell model of riboflavin depletion using the structural analogue of 
riboflavin, lumiflavin, which inhibits riboflavin uptake, and to assess the role of riboflavin on cell 
signalling. 
 
A model of riboflavin depletion was established in three intestinal cell lines, (Caco-2, HCT116 
and HT29) through treatment with lumiflavin. Intracellular flavin concentrations and glutathione 
reductase activation coefficient (GRAC) were measured as markers of riboflavin status. 
Intracellular ATP concentration, the generation of reactive oxygen species (ROS), clonogenicity 
and apoptotic DNA fragmentation were determined. Effects of riboflavin depletion on cell 
signalling were examined in only Caco-2 cells. Changes in the phosphorylation of amino acid 
residues were determined as an indicator of effects on cell signalling, using western blot and 
high content analysis (HCA). Isobaric tagging for relative and absolute quantitation (iTRAQ) was 
used for phosphoprotein profiling, followed by validation of the findings by western blot. HCA 
and flow cytometry were used to determine changes in the cell cycle. 
 
Cell growth was inhibited by lumiflavin in all three cell lines, in a concentration-dependent 
manner. Intracellular flavin status was significantly decreased in all cell lines by 48 hours. 
Riboflavin depletion by lumiflavin led to a significant reduction in intracellular ATP 
concentration and an enhanced generation of ROS in all cell lines. A cell-specific irreversible 
loss of proliferative ability was observed. The effect of riboflavin depletion on oxidative stress 
and disruption of energy generation may have contributed to the observed effects on cell 
proliferation. There was no effect of lumiflavin on apoptotic DNA fragmentation in any cell line. 
Lumiflavin resulted in changes in the global phosphorylation of tyrosine by 3-6 hours, before 
biochemical riboflavin depletion was evident. Significant changes in mRNA processing and 
apoptosis pathways were found. Lumiflavin seemed to suppress cell signalling. Lumiflavin also 
caused arrest of cells in S phase with a subsequent G2/M phase block. 
 
In conclusion, riboflavin depletion of intestinal cells by lumiflavin had biochemical and 
functional consequences. Alterations in cell signalling and arrest in S phase with induction of 
apoptosis in response to lumiflavin may be causative of adverse consequences on intestinal 
cell proliferation. 
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1.1. Introduction 
 
 
The human body is maintained by reproducing cells through the cycle of cells’ 
duplication and division. Eukaryotic cells divide to form two genetically identical daughter cells 
through the cell cycle, and the process repeatedly occurs thus maintaining functioning organs 
of the human body (Alberts, 2008). Abnormal cell proliferation and cell death through mis-
controlling of the cell cycle can affect tissue maintenance and development which are critically 
important for tissues in which cells are rapidly renewed and replaced such as the 
gastrointestinal tract (GI tract) (Heath, 1996).  
 
Macronutrients i.e. carbohydrates, proteins, and fatty acids are essential for cell 
proliferation as sources of cellular fuel, and micronutrients also contribute to proper control of 
the cell cycle however this function is less well understood (Bohnsack and Hirschi, 2004). This 
study has a particular focus on the role of riboflavin in regulation of intestinal cell proliferation 
through an effect on cell signalling. This is a key process for cells to initiate and conduct 
various processes involved in metabolism, proliferation, differentiation, cell death and so on. 
 
This thesis explores effects of cellular riboflavin deficiency on functions relevant to the 
cell cycle and the effect of an inhibitor of riboflavin uptake into cells on cell signalling. 
 
 
1.1.1.  Riboflavin 
 
 
1.1.1.1. Riboflavin  
 
Riboflavin is a water-soluble vitamin, also known as vitamin B2, obtained from human 
diet or bacterial synthesis in large intestine. Free riboflavin (7,8-dimethyl-10-ribityl-isoalloxazine) 
consists of a conjugated isoalloxazine ring and the sugar alcohol ribitol as shown in Figure 1. 
Riboflavin is a precursor of metabolically active forms, FMN (flavin mononucleotide) and FAD 
(flavin adenine dinucleotide),  
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Figure 1 Structure of riboflavin and the flavin coenzymes  
Riboflavin and its derivatives; FMN and FAD consist of an isoalloxazine ring and ribityl chain. Riboflavin is 
converted to FMN by adding a phosphate to ribityl chain. FMN is converted to FAD by covalent bind of 
adenosine monophosphate (AMP) to ribityl chain (Bender, 2003). 
 
 
1.1.1.2. Absorption of riboflavin 
 
The absorption of riboflavin mainly occurs in the proximal small intestine, the duodenum 
and jejunum. Transport mechanism of riboflavin is not fully understood. It was reported that 
uptake of riboflavin into enterocytes involved passive diffusion at high concentration of 
riboflavin (e.g. over 95μM), and an active transporter at low concentration of riboflavin (e.g. 25 
and 42μM) (Zielinska-Dawidziak et al., 2008). In a range of concentration; 25, 42, 95μM that 
was studied, the lower concentration of riboflavin that was studied, the higher apparent 
permeability coefficient was observed in human intestinal cells, Caco-2. Also difference in 
uptake of riboflavin between apical-basolateral direction and basolateral-apical direction was 
observed. It suggests that an active transporter worked for apical-basolateral uptake of 
Riboflavin 
Flavin mononucleotide 
(FMN) 
Flavin adenine dinucleotide 
(FAD) 
Ribityl chain 
Isoalloxazine ring 
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riboflavin at low concentration. Additionally, studied concentrations were considerably higher 
level than in human plasma (i.e. >12nM which is considered as physiological level)(Preedy, 
2013) and in ordinary growth medium (i.e. 1.1μM which is a concentration in pharmacologically 
supplemented condition in human) (Nakano et al., 2011). Thus, uptake of riboflavin by an 
active transporter is thought to dominate in human who take dietary riboflavin or supplement. 
Said et al. (1994) firstly suggested the presence of carrier-mediated transport system of 
riboflavin in the human-derived intestinal cell line Caco-2, which was saturable and pH and Na- 
dependent (Said and Ma, 1994). Recently riboflavin transporter family has been identified, 
consisting of RFVT1 (SLC52A1 or also named as RFT1 (GPR172B)), RFVT2 (SLC52A2 or RFT3 
(GPR172A)) and RFVT3 (SLC52A3 or RFT2 (C20orf54)). The active transporters of riboflavin are 
saturable and Na+ and ATP-dependent. Riboflavin uptake by the transporters is significantly 
inhibited by some structural analogues of riboflavin such as lumiflavin. (Yonezawa et al., 2008). 
Each type of the transporters were expressed and localised on the different site of the 
intestinal cell membrane (Subramanian et al., 2011b; Subramanian et al., 2011a). RFVT3 was 
predominantly expressed at the apical membrane, while RFVT1 was at the basolateral 
membrane and RFVT2 was inside cells or basolateral membrane. The intestinal uptake of 
riboflavin is mainly depending on RFVT3 as it appeared that the level of RFVT3 mRNA 
expression was higher than the other two types of transporters and also RFVT3 was more 
efficient in riboflavin uptake than the other two (Subramanian et al., 2011b). In addition, recent 
in vivo studies examined the response in expression of RFVT3 to riboflavin levels (Fujimura et 
al., 2010; Ainiwaer et al., 2013). Fujimura et al. (2010) showed that feeding a riboflavin-deficient 
diet in rats resulted in up-regulated expression of RFVT3 mRNA in the small intestine. Ainiwaer 
et al. (2013) reported a decrease in expression of RFVT3 mRNA and the protein in tumour 
tissue in oesophageal squamous cell carcinoma patients who showed lower plasma riboflavin 
concentration than healthy controls. 
Huang and Swaan (2000) revealed involvement of a receptor-mediated endocytosis in 
uptake of riboflavin in the nanomolar range of concentration. They examined human intestinal 
epithelial cell model (Caco-2) and rat intestinal tissue, using an inhibitor of endocytosis, 
nocodazole. This compound caused a decrease in apical uptake of riboflavin in severe 
riboflavin-deficiency (Huang and Swaan, 2000).  
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1.1.1.3. Metabolism of riboflavin 
 
Transported riboflavin is intracellularly converted into FMN by flavokinase and then FAD 
by FAD synthetase as shown in Figure 2.  
 
 
 
 
Figure 2 Conversion of riboflavin to FMN and FAD 
Riboflavin is phosphorylated by flavokinase (EC 2.7.1.26), to form FMN also called riboflavin 
monophosphate. FAD synthetase (alternative names are FAD pyrophosphorylase and ATP:FMN 
adenylyltransferase, EC 2.7.7.2) adenylates FMN to FAD. (Bender, 2003). 
 
 
There is evidence of effective conservation of FAD availability in response to riboflavin 
deficiency (Fass and Rivlin, 1969). In severely riboflavin-deficient or chronic marginal deficiency 
status, the activity of such flavin-metabolising enzymes is changed to conserve FAD 
concentration at the expense of riboflavin and FMN. In riboflavin-deficient animals, the activity 
of flavokinase decreases to 60% of normal, while the activity of FAD synthetase is elevated to 
150% of normal. However, there is no store of riboflavin or its derivatives; thus inadequate 
intake of dietary riboflavin causes a fall in the concentration of plasma riboflavin, FMN and FAD 
(Bates et al., 1982) and also in tissue flavins (Burch et al., 1970).  
 
 
1.1.1.4. Involvement in metabolic biochemistry 
 
 
                   
Figure 3 Example of the role of the isoalloxazine ring in flavins as an electron 
acceptor  
N expressed in a red box is a binding or unbinding site for an electron. 
 
Ribityl chain Ribityl chain 
H 
Riboflavin FMN FAD 
ATP ADP 
Flavokinase 
PPi ATP 
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The isoalloxazine ring of the flavins has the ability to lose or gain electrons. Flavins thus 
act as electron carriers in a range of redox reactions such as oxidative metabolism of 
carbohydrate, amino acids and fatty acids and the electron transport chain (Powers, 2003; 
Bender, 2003). Riboflavin deficiency leads to a reduction in activity of flavin-dependent 
enzymes involved in such energy-yielding reactions, including succinate dehydrogenase(EC 
1.3.99.1)  and acyl CoA dehydrogenase (EC 1.3.99.2) (Prentice and Bates, 1981b; Olpin and 
Bates, 1982). Succinate dehydrogenase forms reduced FAD, converting succinate to fumarate 
and the reduced FAD donates electrons to complex II of the electron transport chain. The 
activity of this flavoprotein in riboflavin-deficient rats appeared tissue-specific as it sharply 
declined in the liver while there were smaller changes in brain, skin and intestine (Prentice and 
Bates, 1981b). Acyl CoA dehydrogenase is also FAD-dependent and active at the first step of 
beta-oxidation of fatty acids. Thus, diminished activity of the enzyme in riboflavin deficient rats 
leads to an altered fatty acid profile in hepatic lipids (Olpin and Bates, 1982). A reduction in 
activity of these enzymes should lead to a reduction of ATP synthesis in the electron transport 
chain. 
 
 
1.1.1.5. Riboflavin requirements and effects of deficiency 
 
Riboflavin is present in a wide variety of foodstuffs. Milk and dairy products are the most 
contributable food sources to riboflavin intake in Western diets. National dietary surveys in the 
UK reported a high contribution of milk and dairy products to riboflavin intake, which was 51% 
of riboflavin intake in preschool children, 35% in school children, 27% in adults, and 36% in the 
elderly (Powers, 2003). Meats, fish and certain fruit and dark-green leafy vegetables are also 
good sources of riboflavin. The proportional contribution to riboflavin intake from the different 
food source was approximate 35% from milk and milk products, about 32% from breakfast 
cereal and about 11% from meat (Gregory et al., 2000).  
 
Reference Nutrient Intakes (RNI) and lower RNI (LRNI) in the UK for riboflavin are 
presented in Table 1. RNI is defined as the amount of the nutrient, which is sufficient for 97.5% 
of people in the group who are thus considered to have very small risk of deficiency. LRNI is 
defined as the amount of the nutrient, which meets requirement of the nutrient for only 2.5% 
of people (Bates et al., 2011). 
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Table 1 Reference Nutrient Intakes (RNIs) and Lower RNI (LRNIs) for riboflavin, 
by sex and age 
 (mg/day) Age group (Years) 
1-3 4-6 7-10 11-14 15-18 19+ 
Males       
RNI 0.6 0.8 1.0 1.2 1.3 1.3 
LRNI 0.3 0.4 0.5 0.8 0.8 0.8 
Females       
RNI 0.6 0.8 1.0 1.1 1.1 1.1 
LRNI 0.3 0.4 0.5 0.8 0.8 0.8 
 
 
The recent National Diet and Nutritional Surveys (NDNS) (2008-2011) reported that a 
high proportion of screened people in the UK have riboflavin intakes below LRNI, and whose 
intake is therefore likely to be insufficient for their needs. The proportion with total riboflavin 
intakes below the LRNI were 21% of adolescent girls and 8% of adolescent boys aged 11 to 18 
years, 7% in adults and 2% in the elderly. Low intakes might be attributable to low 
consumption of milk, which overall was reduced compared with past surveys (1997-2001) for 
all age groups (Bates et al., 2011). For example, consumption of milk for girls aged 11 to 18 
years was reduced from 131ml per day on average in 1997 to 103ml per day in the recent 
survey; consumption for boys of the same age was 201ml per day and 166ml per day. There 
were larger decreases in adults, for women from 188ml per day in 2000/01 to 116ml per day in 
the recent survey and for men from 217ml to 159ml per day.  
 
The preferred method for determining riboflavin status in animal and human studies is 
by measuring the activity of the FAD-dependent enzyme, erythrocyte glutathione reductase, in 
the presence (stimulated) and absence (unstimulated) of added FAD. The ratio of the 
stimulated to unstimulated activities is expressed as an activation coefficient (EGRAC). EGRAC 
>1.3 is considered to indicate functional riboflavin deficiency (Powers, 2003). Riboflavin 
deficiency determined biochemically is prevalent across all age groups in the UK (Gregory et al., 
2000; Bates et al., 1999; Weichselbaum and Buttriss, 2014). Particularly schoolchildren were a 
vulnerable group as 89.2% of adolescent girls and 73.7% of boys in 11-18 years age in the 
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NDNS (2008-2011) had levels of over 1.3 EGRAC. Approximately 65% of adults aged 19 to 64 
years and 40% of the free-living elderly showed evidence of riboflavin deficiency.  
 
In spite of a high prevalence of riboflavin deficiency, since there is no clear functional 
disturbance, there has been little attention paid to the effects of riboflavin deficiency on 
human health. However, the literature suggests there may be a number of adverse effects on 
human health, including cancer, cardiovascular disease and anaemia.  
Riboflavin deficiency may be associated with carcinogenesis in the oesophagus, the 
cervix and the colon (Blot et al., 1993; Liu et al., 1993; de Vogel et al., 2008). This may be 
mediated by increased DNA strand breakage, genomic instability, aberrant regulation of the 
cell cycle and apoptosis, partly associated with a role of riboflavin as a cofactor in folate 
metabolism (van den Donk et al., 2005). This will be addressed further in section 1.1.3.3. 
Riboflavin deficiency is also associated with an increase in plasma homocysteine 
concentration which may increase risk of cardiovascular disease (Moat et al., 2003; Poddar et al., 
2001). Riboflavin is involved in remethylation of homocysteine to methionine as a cofactor for 
MTHFR (methylenetetrahydrofolate reductase, EC1.7.99.5). The enzyme metabolises folate to 
the methyl tetrahydrofolate, the form used in homocysteine methylation, and is dependent on 
FAD, thus this contributes to homocysteine homeostasis. 
The literature has suggested that riboflavin deficiency may cause low iron status (Rohner 
et al., 2007) possibly increasing a risk of anaemia. A cohort study recently showed that low 
riboflavin intake was associated with low plasma ferritin and with an increased risk of anaemia 
at five-years follow-up (Shi et al., 2014). The study suggests the importance of regular 
adequate intake of riboflavin particularly in women at risk of anaemia. Plausible mechanisms 
include a role for riboflavin in iron handling, namely the mobilization of iron from the 
intracellular store, ferritin (Powers et al., 1983). Also, iron absorption may be impaired and loss 
of iron from turnover of cells in gastrointestinal (GI) tract may be enhanced (Powers et al., 
1991). An animal study proposed  that riboflavin deficiency may enhance iron loss in the GI 
tract by accelerating small-intestinal epithelial cell turnover (Powers et al., 1993). In this context, 
animal studies have shown that riboflavin is an important nutrient for normal development of 
the GI tract during the postnatal period (Williams et al., 1995; 1996b; Yates et al., 2001; 2003). 
Intestinal epithelial cells along the crypts and villi undergo strictly controlled cell proliferation, 
differentiation and apoptosis, processes responsible for normal development and maintenance 
of the integrity and absorptive function of the gastro-intestinal system (Jankowski et al., 1994). 
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In the next section, the role of riboflavin in the normal development of the small intestine will 
be discussed. 
 
 
1.1.2. Riboflavin and structure and development of the small intestine  
 
 
1.1.2.1. Structure and normal development of the intestine 
Differentiation from stem cells is not restricted to embryogenesis but is an important 
feature of normal development for early life as well as maintenance and repair in adult organs 
such as the intestinal tract. The intestinal epithelium is organised into invasions called the 
crypts of Lieberkühn and protrusions called villi and covered with a monolayer of the intestinal 
epithelial cells which migrate up along the crypt-villus axis (van der Flier and Clevers, 2009).  
 
 
Figure 4 The intestinal epithelium.  
H&E-stained the mouse intestine (van der Flier and Clevers, 2009). 
 
 
Stem cells housed in the crypts differentiate to more specialised cells. The stem cells 
produce progenitors of four cell types of differentiated intestinal epithelial cells; the absorptive 
enterocytes, mucous-secreting goblet cells, and hormone-secreting enteroendocrine cells which 
migrate up and cover the villi, and Paneth cells which always are located at the bottom of the 
crypts. Enterocytes having absorptive function consist of up to 80% of all epithelial cells thus 
are characteristic of the small intestine (de Santa Barbara et al., 2003).  
Villus 
Crypt 
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Crypt stem cells divide near the bottom of the crypt and then the transit-amplifying 
progeny divide, migrate up to the crypt-villous junction and leave the cell cycle to undergo 
terminal differentiation. Migrating up along the crypt-villus axis, reaching the tip of the villus, 
the cells are shed into the intestinal lumen (Wong and Wright, 1999; Yen and Wright, 2006). 
Under normal circumstances most cells are shed by exfoliation into the lumen and some cells 
undergo apoptosis (Jankowski et al., 1994). However, in certain circumstances, the number of 
enterocytes lost by increased apoptosis may increase. Absence of luminal nutrients via total 
parenteral nutrition (TPN) in rats resulted in a decreased enterocyte population and increased 
apoptosis throughout the crypt and villus in the adult rat jejunum (Dahly et al., 2002). 
Newly produced intestinal epithelial cells replenish lost cells and support normal 
turnover of cells on the villi. This secures a sufficient absorptive surface of the epithelium and 
establishes the absorptive function of the intestine (Smith, 1985).  
 
The structure of the small intestine develops differently during the neonatal period in 
animals even under normal condition. Incidence of crypt bifurcation (fission) occurs more in 
early life and decreases in adulthood. Animals fed a complete diet showed increased crypt 
bifurcation during weaning period (Yates et al., 2001). Another animal study showed that the 
percentage of crypts in fission in the small intestine was decreased 25% to 7% from 21days 
postparturition to adult, and the number of crypts was increased but villus number was not 
changed by aging (St Clair and Osborne, 1985). Crypt bifurcation represents the formation of 
new crypts, which contributes to the intestinal development (Totafurno et al., 1987). Crypt 
division may occur if crypt stem cells are produced in excess. Crypt cellularity can thereby be 
kept constant by crypt bifurcation (Jankowski et al., 1994). 
 
 
1.1.2.2. Role of riboflavin in development of the small intestine 
Animal studies of riboflavin deficiency have revealed that the crypts are the first target of 
riboflavin deficiency in the weaning period. Four days of feeding a riboflavin-deficient diet to 
weanling rats resulted in no increase in incidence of crypt bifurcation but an increase in the 
depth and cellularity of the duodenal crypts with a decrease in the proliferative index (DNA 
synthesis index BrdU), compared with controls (Yates et al., 2001). In contrast, control rats fed a 
complete diet showed increased crypt bifurcation over the same period. These findings of 
Yates and colleagues suggest an inhibitory effect of riboflavin depletion on proliferation of the 
crypt stem cells associated with an interruption of the normal increase in crypt bifurcation of 
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weaning. The decrease in the duodenal BrdU labelling index in riboflavin-deficient rats implies 
an association of riboflavin depletion with impairment of the cell cycle. Since BrdU injected 
intraperitoneally into the animals is incorporated into DNA during S phase of the cell cycle, the 
BrdU-labelling index is used as a marker of proliferation (Kee et al., 2002).  
 
Prolonged riboflavin depletion for 3 weeks in weanling rats resulted in villus hypertrophy, 
associated with lower villus number but increase in villus length. Increase in villus length is 
thought to represent an adaptive response to prolonged depletion of riboflavin. The authors 
suggest that such adaptatory response would increase the absorptive cell population. They 
also observed increased transit rate of enterocytes along the villi (Williams et al., 1996a) 
implying hyperproliferative status but shorter life span of enterocytes. This implies changes in 
the cell cycle and in regulation of apoptosis induced by riboflavin deficiency. Furthermore, the 
observed changes in morphology and cytokinetics of the small intestine of weanling rats fed 
riboflavin-depleted diet for 5 weeks were irreversible following 21 days a repletion with 
riboflavin despite biochemical evidence showing correction of the deficiency (Williams et al., 
1996b). 
 
A subsequent study examined the effects of luminal depletion of riboflavin on intestinal 
development in the weaning rat (Yates et al., 2003). Weaning rats were fed a riboflavin-
deficient diet, but riboflavin was provided in the form of FMN by intraperitoneal injection. This 
maintained normal systemic riboflavin status. There thus was no difference in the EGRAC and 
liver flavin concentration between luminally riboflavin-deficient rats and control rats fed a 
complete diet. Nevertheless, the absence of luminal riboflavin induced abnormal GI 
development characteristic of dietary riboflavin depletion. Luminal riboflavin-deficient rats 
exhibited duodenum crypt hypertrophy associated with increased crypt depth and cellularity 
and also reduced crypt bifurcation by about 6 days of luminal riboflavin deprivation. These 
cytokinetic and morphological changes in luminally riboflavin-deficient rats are consistent with 
the characteristics of impaired intestinal development in dietary riboflavin depletion in 
weanling rats (Yates et al., 2003). The authors proposed the presence of an apical transporter, 
which may play a key role on GI development. They suggested that riboflavin in the lumen 
may behave like a signalling molecule for the expression of riboflavin transporter gene and/or 
certain genes involved in crypt fission.  
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1.1.3.  The cell cycle and its regulation by riboflavin  
 
 
1.1.3.1. The cell cycle  
 
The human body is maintained by reproducing cells through the cycle of cell duplication 
and division. Eukaryotic cells divide to form two genetically identical daughter cells through 
the cell cycle, and the process occurs repeatedly to maintain normal function of tissues (Alberts, 
2008). The cell cycle can be divided into four phases which are G1 (gap 1), S (synthesis), G2 
(gap 2), and M phase (mitosis) (Figure 5). Eukaryotic cell begins growth to prepare S phase for 
DNA replication in G1 phase, and the chromosomes are duplicated during S phase. The cell 
then enters to G2 phase for preparation of mitosis. The copied chromosomes are segregated 
into two daughter nuclei following five mitotic phases which are prophase, prometaphase, 
metaphase, anaphase and telophase as shown in Figure 6. The duplicated DNA molecules in 
chromosomes are disentangled and condensed into sister chromatids (prophase), and the 
sister chromatids are attached to microtubules of the mitotic spindle, and then the sister 
chromatids are pulled to opposite poles of the mitotic spindle by shortening the microtubules 
(prometaphase, metaphase, and anaphase). The separated chromosomes are decondensed and 
surrounded by nuclear membranes (telophase), and cytoplasmic division or cytokinesis finally 
completes the cell cycle producing two separated daughter cells. 
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Figure 5 Overview of the eukaryotic cell cycle.  
G1,Gap 1; S, DNA synthesis; G2, Gap 2; M, Mitosis. The eukaryotic cell begins growth at G1 phase in 
order to prepare S phase. When ready, DNA replication starts. G2 is a phase to prepare and check the 
proper condition for mitosis. Mitosis is the process of nuclear division, and the last phase of mitosis is 
followed by cytokinesis which is the division of the cytoplasm of a mother cell. Details of mitosis are 
shown in Figure 6. 
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Figure 6 Overview of mitosis 
Modified from two sources(Pasteur, 2008; Pearson-Education, 2009). Prophase; the chromatin slowly 
condenses into well-defined chromosomes which consist of two sister chromatids. The early spindle 
microtubules form outside the nucleus between separating centrosomes. Prometaphase; the nuclear 
envelope breaks down. The spindle microtubules enter the nuclear region. Mature kinetochores on each 
centromere attach to some of the spindle microtubules. Metaphase; the kinetochore microtubules align 
the chromosomes in metaphase plate. Anaphase; the kinetochore microtubule pulls each daughter 
chromosomes toward the spindle pole. Telophase; the separated daughter chromosomes arrive at the 
poles and a new nuclear envelope forms around each daughter chromosomes. Cytokinesis; the cytoplasm 
divides, and two daughter cells separate. 
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The cell cycle progresses only when the events of each phase are accurately completed 
and ready for the cell to enter into the next phase. Many cell cycle checkpoints monitor the 
progression, and they may inhibit the cell cycle proteins if necessary to prevent abnormal 
progress of the cell cycle (Johnson and Walker, 1999; Shackelford et al., 2000). Some specific 
micronutrients function as regulators through direct regulation of cell cycle or relevant 
metabolic pathways and this is briefly presented in Figure 7. In spite of their contribution to 
regulating the cell cycle progression, the role of micronutrients and the mechanism are not 
well understood. 
 
 
Figure 7 Regulation of cell cycle by some specific micronutrients; Vitamin A, 
vitamin D, vitamin C, riboflavin, folate, vitamin B12, and iron.  
In general Vitamin A induces G1 phase arrest by upregulating tumour suppressor p53 and CKIs including 
cip/wafs; p21 and p27. Vitamin D also induces G1 arrest by upregulating p53 and CKIs including cip/wafs; 
p21 and p27 and INK4s; p15, p16, and p18. Vitamin C induces transient arrests in S phase and G2/M 
transit by inhibiting localisation of Cdc25C thus by delaying the activation of CDK1 of cyclin B-CDK1 
complex. Folate serves as a methyl carrier to purines synthesis (ATP, GTP), pyrimidines synthesis (dTTP), 
and methionine synthesis. Vitamin B12 acts as a coenzyme of methionine synthetase. Iron is a cofactor of 
ribonuleotide reductase (RR) which forms deoxyribonucleotides (dNTPs) and also affects G1/S phase by 
regulating cyclin D. Riboflavin in an intestinal cell line may involve in the regulation of genes modulating 
to mitotic progression such as Aspm, Aurora kinase B, CDCA2 and 3, cyclin B1, BIRC5, CCNG2, CK2, and 
Kif23 (Bohnsack and Hirschi, 2004; Li and Clagett-Dame, 2009; Thomas et al., 2005; Nakano et al., 2011) 
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1.1.3.2. Role of riboflavin in cell cycle regulation 
 
Several in vitro studies using HepG2 human hepatocarcinoma cells reported that 
riboflavin depletion led to arrest in G1 phase of the cell cycle, associated with a reduction in 
cell proliferation (Werner et al., 2005; 2006; Manthey et al., 2005). Riboflavin deficiency may 
impair the activity of glutathione reductase (EC 1.6.4.2), causing oxidative damage which can 
mediate cell cycle arrest (Werner et al., 2005; Manthey et al., 2005). Reduced glutathione is a 
product of glutathione reductase activity, and this compound plays a role as an antioxidant 
(Hayes and McLellan, 1999). There is evidence that riboflavin deficiency induces decreased 
cellular concentrations of reduced glutathione (Camporeale and Zempleni, 2003; Manthey et al., 
2005). The activity of glutathione reductase was inversely related to reactive oxygen species 
(ROS) generation and ROS-induced apoptosis in human hepatoma cells (Kim et al., 2010). It 
was also reported that riboflavin deficiency leads to an increased oxidative damage in proteins 
and DNA. Presumably due to increased oxidative stress, the level of GADD153 is increased. This 
is a stress-related transcription factor and a mediator of cell cycle arrest (Manthey et al., 2006). 
Thus, it is thought that riboflavin deficiency in human hepatoma cells drives cell cycle arrest to 
avoid cellular damage induced by uncontrolled oxidative stress. However, effects of riboflavin 
depletion on cell proliferation and regulation of the cell cycle in intestinal cell lines has hardly 
been investigated.  
 
Nakano and colleagues carried out an investigation into effects of riboflavin depletion 
on the cell cycle in a human intestinal cell line. Caco-2 human intestinal epithelial cells were 
cultured in riboflavin–deficient medium (riboflavin-free medium and 10% dialysed FCS), 
resulting in a final riboflavin concentration of 5.5nM. Severe riboflavin depletion resulted in a 
two fold increase in cell doubling time with a significant fall in concentrations of intracellular 
riboflavin, FMN and FAD. The impaired cell growth proceeded to loss of clonogenic ability. A 
clonogenicity assay showed that following 4 days of culture in a riboflavin deficient medium, 
Caco-2 cells showed an irreversible loss of proliferative ability when reintroduced to complete 
medium. Riboflavin depletion also led to cell cycle arrest in mitosis and accumulation of 
aneuploid cells. These observations were given further support by findings of dysregulated 
profile of gene expression involved in mitosis regulation. These included downregulation of 
AspM, Aurora Kinase B, BIRC5, CDCA2 and cyclin B1, and upregulation of CCNG2 (Nakano et 
al., 2011).  
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These genes will be briefly introduced here. Firstly, AspM (abnormal spindle-like 
microcephaly-associated) protein is asymmetrically localised to spindle poles throughout all 
mitotic stages and required to focus the spindle microtubules. Its mutation or downregulation 
results in abnormal spindle structure and metaphase arrest (do Carmo Avides and Glover, 1999; 
Ripoll et al., 1985) which is consistent with mitosis arrest in riboflavin deficient cells.  
Aurora kinase B (Aurora-B) associates along chromosomes during prophase and 
phosphorylates histone H3 which is linked to mitotic chromatin condensation. Additionally, 
Aurora-A also phosphorylates histone H3 (Crosio et al., 2002). Then, Aurora-B is concentrated 
to inner centromeres during metaphase, regulating bidirectional movement of centromeres and 
stable association of kinetochore-microtubule (Murata-Hori and Wang, 2002). Afterwards at 
anaphase onset, Aurora-B transfers to the spindle midzone. Here, Aurora-B is associated with 
formation and contraction of the cleavage furrow and thus completion of cytokinesis 
(Katayama et al., 2003). Ablation of Aurora-B causes monopolar spindles due to unidirectional 
movement of centromeres, inhibited cleavage furrow formation and uncompleted cytokinesis 
resulting in cell polyploidy (Terada et al., 1998; Adams et al., 2001). BIRC5 is also known as 
survivin which is associated with roles and activity of Aurora-B, thus disruption of BIRC5 causes 
a decline in activity of Aurora-B leading to defects in chromosome alignment and cytokinesis 
(Katayama et al., 2003). 
CDCA2 cooperates with condensin for anaphase chromosome segregation. Condensin 
depletion causes loss of compact architecture of chromosomes during anaphase, but CDCA2 
rescues the characteristic architecture of chromosomes in condensing-depleted cells (Vagnarelli 
et al., 2006). Thus, down regulated CDCA2 observed in Nakano and colleagues’ study may be 
associated with instability of chromosome structure during anaphase, suggesting the possibility 
of mis-segregation of chromosomes and aneuploidy.  
During G2 phase, cyclin B accumulates and binds to CDK1, but cyclin B-CDK1 complex 
also known as MPF is at first inactivated. Cdc25 phosphatase activates MPF. Active cyclin B-
CDK1 complex initiates transition from G2 to mitosis, and it phosphorylates nuclear substrates 
thus promoting nuclear envelope breakdown. It is also responsible for the formation of the 
mitotic spindle. Expression of cyclin B peaks during metaphase transition, afterwards, 
degradation of cyclin B starts leading to inactivation of CDK1 and initiates mitotic exit. Thus, 
downregulation of cyclin B is associated with G2 phase arrest and impaired formation of 
mitotic spindle leading to declined transition from metaphase to anaphase (Lindqvist et al., 
2005; Takizawa and Morgan, 2000; Gavet and Pines, 2010).  
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CCNG2, also known as cyclin G2 is associated with p53-dependent cell cycle inhibition. It 
is expressed at modest levels in proliferating cells and peaks during the late S or early G2 
phase promoting cell cycle exit. It is significantly upregulated in response to DNA damage and 
growth inhibitory signals such as oxidative stress and differentiation. Ectopically expressed 
cyclin G2 promotes the formation of aberrant nuclei and inhibition of microtubule growth and 
depolymerisation (Arachchige Don et al., 2006). Additionally, p53 is known as a tumour 
suppressor, regulating CKIs (cyclin-dependent kinase inhibitor proteins. The formation and 
activity of cyclin and CDKs are inhibited by CKIs. p53 consequently induces cell cycle arrest and 
apoptosis in response to DNA damage (Galderisi et al., 2003). 
 
Taken together, these findings suggest that riboflavin depletion alters the expression of 
genes important for regulation of mitosis. This dysregulation of gene expression is associated 
with the following impairments according to the literature.   
 Impaired chromatin condensation, 
 Monopolar spindles, unfocused spindle microtubules,  
 Impaired chromosome alignment,  
 Mis-segregation of chromosomes, 
 Inhibited cleavage furrow formation and uncompleted cytokinesis. 
These aberrations lead to arrest in mitosis with a particularly impaired metaphase transition 
but increased number of aneuploid cells.  
 
A recent cross-sectional study investigated the association between riboflavin status and 
GI morphology in duodenal biopsies of adult gastroscopy patients (Nakano et al., 2011). Thirty 
volunteers recruited in this study comprised 9 male and 21 female subjects, and their age 
range was 36-46 year in males and 36-78year in females. Riboflavin status was measured using 
the erythrocyte glutathione reductase activation coefficient (EGRAC). EGRAC values of the 
subjects ranged between 1.11-1.87. Glutathione reductase is a FAD-dependent enzyme and its 
activation coefficient which is a measure of the saturation of the enzyme with FAD, provides a 
sensitive assessment of riboflavin status. EGRAC values are inversely related to concentrations 
of intracellular FAD and values >1.30 are conventionally considered as biochemical, functional 
riboflavin deficiency (Powers, 1999). Subjects in the lowest quartile of riboflavin status 
determined as EGRAC values >1.35 were compared with subjects in the highest quartile 
(EGRAC <1.24) for proliferative (Ki-67) and mitotic indices (pHH3) and crypt length and 
cellularity. These were used to demonstrate altered proliferation leading to the changes in total 
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crypt cell numbers and the consequence of altered proliferation via changes in the crypts. The 
proliferation index was assessed as the Ki-67 labelling index, and total positive pHH3 by 
immunohistochemistry was used to assess cells in mitosis. The markers reflect the size of the 
proliferative compartment relative to the size of the crypt. 
Subjects with the poorest riboflavin status showed fewer crypt cells in mitosis and a 
lower crypt cell proliferation than subjects with the highest riboflavin status (Nakano et al., 
2011). Also it appeared that low riboflavin status is associated with significantly decreased 
crypt length and cellularity. Thus, decreased crypt cell proliferation and mitosis might have 
proceeded to a decrease in crypt cellularity, and this may reflect a decreased number of 
progenitor cells entering the cell cycle.  
 
 
1.1.3.3. Implications for colon cancer 
 
There have been some reports of an association between low intake of riboflavin and 
increased risk of colorectal cancer (van den Donk et al., 2005; de Vogel et al., 2008). However, 
the evidence is still weak and the mechanism remains unclear. Riboflavin deficiency may exert 
an effect on colon cancer risk through interactions with depletion of other B vitamins. Mild 
depletion of dietary B vitamins, riboflavin, folate, vitamin B6 and B12 in mice for 10 weeks 
significantly increased DNA strand breaks within the Apc mutation cluster region and 
decreased expression of the tumour suppressor. Apoptosis was suppressed in B vitamin-
depleted mouse colon (Liu et al., 2007). These findings suggest an increased risk of 
development of aneuploidy which is an early event frequently observed in human colorectal 
cancers (Fodde et al., 2001). Additionally, aneuploidy implies loss of gain of chromosome 
leading to chromosomal instability (Rao and Yamada, 2013), which will be addressed later of 
this section. Such B vitamins interact biochemically, for instance, riboflavin and vitamin B12 are 
involved in folate metabolism and play a role as cofactors of a folate-metabolising enzyme 
(Powers, 2005). In Liu and colleagues’ study, riboflavin depletion exacerbated a decrease in 
expression of the Apc induced by isolated folate depletion (Liu et al., 2007).  
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Figure 8 Simplified diagram of folate metabolism and the association with 
DNA synthesis and DNA methylation. 
Riboflavin as the form of FAD and vitamin B12 are involved in folate metabolism cycles which mediate 
DNA synthesis from the de novo synthesis of purines and pyrimidine (dTMP., thymidine 
deoxymononucleotide) or DNA methylation via methionine synthesis. SAM; S-adenosyl methionine, SAH; 
S-adenosyl homocysteine, MTHFR; methylene tetrahydrofolate reductase., FAD; flavin adenine dinucleotide. 
 
 
In addition, riboflavin contributes to the availability and function of folate in the 
regulation of gene expression of cell cycle proteins through DNA methylation (Crott et al., 2008; 
Bates and Fuller, 1986). As shown in Figure 8, FAD is a cofactor for 5, 10-methylene 
tetrahydrofolate reductase (MTHFR) which forms 5-methyl tetrahydrofolate (5-methyl THF) used 
in methionine synthesis. Folate in the form of 5-methyl THF serves as a methyl donor to 
remethylation of homocysteine to form methionine, a precursor of SAM (S-adenosylmethionine) 
which is the primary methyl donor for methylation of DNA (Scott, 1999; Friso and Choi, 2002).  
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DNA methylation is an important mechanism to regulate expression of genes, including 
some that are important for regulation of the cell cycle (Razin and Riggs, 1980). For instance, 
folate deficiency in the human colon cell line SW620 resulted in hypomethylation in tumour 
suppressor gene p53, thus up-regulated transcription with upregulation of the corresponding 
mRNA expression (Wasson et al., 2006). In another study, upregulated p53 expression induced 
by folate depletion in human colonic epithelial cell NCM460, was accompanied by increased 
expression of cyclin-dependent kinase inhibitors (CKIs); p21 and p16 (Crott et al., 2008). 
Upregulated p21 blocks transition from G1 to S phase by inhibiting cyclin E-CDK2. 
Upregulation of p16 consequently arrests the cell cycle in S phase by inhibiting production of 
cyclin A and thus activation of cyclin A-CDK2 (Johnson and Walker, 1999) 
 
The work of Nakano and colleagues offers a plausible mechanism by which riboflavin 
deficiency might induce chromosomal instability and DNA aneuploidy, and thereby influence 
colon cancer risk (Nakano et al., 2011). Aneuploidy implies loss or gain of chromosomes during 
mitosis thus a result of chromosomal instability (Rao and Yamada, 2013), frequently observed 
in human diseases such as in most solid tumours (Visscher et al., 1996). Researchers showed 
that aneuploidy is related to the early stage of colorectal cancer such as ulcerative colitis or 
adenocarcinoma and the progression of the cancer. A high frequency of aneuploidy and 
chromosomal instability is a characteristic feature of the cancer, as discussed below. 
Chromosomal alterations were observed in 36% of non-dysplasia sites and 85% of cancer and 
dysplasia sites in 14 ulcerative colitis patients (Willenbucher et al., 1999). It is known that 
ulcerative colitis, which is a chronic inflammatory disease of the colon, is associated with a high 
risk of colorectal cancer (Ekbom et al., 1990). The progression from ulcerative colitis to 
colorectal cancer involves genomic instability and progressive accumulation of aneuploidy, 
evident by highly frequent chromosomal alterations (Willenbucher et al., 1997; 1999). 
Additionally, ulcerative colitis-related cancers are often developed from flat, dysplastic 
epithelium. Another study investigating 42 ulcerative colitis patients showed a significant direct 
correlation between ulcerative colitis duration and extent of aneuploidy. Interestingly, 
development and extent of aneuploidy in the subjects were significantly related to a decrease 
in serum level and the expression of p53 which is well known as a tumour suppressor protein, 
compared with healthy controls (Rosman-Urbach et al., 2004). A further study investigated the 
incidence of aneuploidy in 57 large bowel adenomas. Aneuploidy was observed in 5 out of 49 
low-grade dysplasia adenomas (10%), 7 out of 8 high-grade dysplasia adenomas, intramucous 
carcinomas or microinvasive carcinomas (87%) (Alcantara Torres et al., 2005). Karaman et al 
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(2008) performed the micronucleus assay in 21 colorectal cancer patient, 24 patients with colon 
polyps (10 neoplastic polyps and 14 non-neoplastic polyps) and 20 normal controls. 
Chromosomal instability was significantly increased in patients with colorectal cancer and 
neoplastic polyps compared with controls, whereas there was no difference between non-
neoplastic polyps and controls (Karaman et al., 2008). Thus, the authors suggested that 
chromosomal instability and aneuploidy may be a causal factor for the adenoma-carcinoma 
sequence in early colorectal cancer. Furthermore, recent study with 952 colorectal cancer 
patients showed the association of high prevalence of DNA aneuploidy with recurrence of the 
cancer, and they suggested that DNA aneuploidy is a useful predictor of early relapse among 
stage II colorectal cancer patients (Hveem et al., 2014). 
 
 
1.1.4. Riboflavin and cell signalling 
 
 
1.1.4.1. Cell signalling 
 
Cell signalling is the intracellular or intercellular exchange of signals to govern 
intracellular signal transduction pathways, intercellular communication during development, 
activation of the immune system and the functioning of the nervous system (Raggiaschi et al., 
2005). Intracellular signalling processes are critical for cell function including cell cycle 
progression, proliferation, differentiation, migration, metabolism and apoptosis (White, 2008). 
Cell signal transduction pathways are controlled by phosphorylation of proteins involved 
cellular processes. Series of phosphorylation and dephosphorylation events directly modulate 
protein enzymatic activity, and affect protein-protein interaction or cellular localization of 
proteins, thereby cellular signalling networks (Schulze, 2010). Approximately 30% of human 
proteins are under the counterbalanced controls of kinases and phosphatases. Kinases transfer 
a phosphate group from ATP to a protein while phosphatases function in dephosphorylation 
(Macek et al., 2009). Additionally, abnormal phosphorylation of proteins resulting from 
mutations in particular protein kinases and phosphatases has been linked with an increased 
risk of developing cancer, diabetes and rheumatoid arthritis (Cohen, 2001).  
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Phosphorylation of protein pathways may be induced or mediated by ROS such as H2O2. 
For instance, Mitogen-activated protein kinases (MAPKs) cascade pathways, regulate diverse 
cell functions including the cell cycle, proliferation, and apoptosis, are activated by 
phosphorylation in response to growth factor or stress stimuli such as oxidative stress and 
DNA damage (Son et al., 2011). The MAPKs comprise a family of protein kinases that 
phosphorylate the amino acids serine, threonine and tyrosine thereby leading to sequential 
transduction of biological signals from cell membrane to the nucleus. MAPK cascades are 
composed of a three-kinase signalling module; the MAPKs, an MAPK kinase (MAP2K) and an 
MAP2K kinase (MAP3K). MAP3Ks phosphorylate and activate MAP2Ks, which in turn activate 
MAPKs through dual phosphorylation on threonine and tyrosine residues. MAPKs consist of 
three subgroups which are ERKs (growth factor-regulated extracellular signal-related kinases), 
JNKs (c-jun NH2-terminal kinases) and p38 MAPKs (Pearson et al., 2001; Son et al., 2011). Some 
studies have demonstrated that ROS may be required for the activation of MAPK pathways. 
Sundaresan et al.(1995) reported that when rat vascular smooth muscle cells (VSMC) were 
stimulated by platelet-derived growth factor (PDGF), the intracellular hydrogen peroxide (H2O2) 
concentration was increased and MAPK pathways particularly ERK1/2 were activated. When the 
rise in H2O2 concentration was blocked by treatment with catalase, the stimulation of MAPKs 
was inhibited. It suggests that H2O2 mediates activation of MAPK pathways in VSMCs and 
thereby influences PDGF-induced VSMC migration and proliferation which might be early 
atherogenic changes. Likewise, uncontrolled activation of MAPK pathways may result in 
excessive production of MAPK-regulated genes and thereby possibly lead to impairments in 
cell proliferation and apoptosis (Son et al., 2011). 
 
Phosphorylation of proteins is also central to the expression of genes important for 
protein synthesis, including transcription, mRNA processing including mRNA splicing, mRNA 
export and translation. Briefly, the first step in gene expression is the transcription of mRNA 
from DNA by RNA polymerase in the nucleus (Alberts, 2008). Particularly RNA polymerase II 
binds to a single-stranded DNA gene template and transcribes the DNA sequence to mRNA. 
Pre-mRNA in eukaryotic cells undergoes mRNA processing, including 5’ capping, 3’ cleavage, 
polyadenylation and mRNA splicing. 7-methylguanosine is added to the 5’ end of pre-mRNA 
for stability of the RNA. 3’ cleavage and polyadenylation in pre-mRNA are also to protect 
degradation of RNA. mRNA splicing is the process of removal of non-coding sequences. Then, 
mature RNA is exported from the nucleus to the cytoplasm. The mRNA sequence is translated 
and a polypeptide is produced at the ribosome. 
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An example of a phosphorylation that regulates mRNA processing is phosphorylation of 
the C-terminal domains (CTD) of RNA polymerase II which play an important role in these 
processes linking to cell cycle regulatory events. When the CTD of RNA polymerase II are 
activated by phosphorylation, the CTD binds to various protein factors and promotes mRNA 
processing (Hsin and Manley, 2012). RNA polymerase II activity is regulated by the CTD 
phosphorylation depending on the cell cycle. The CTD phosphorylation status can be changed 
in response to mitogenic signals or cytostatic signals such as growth factor. Some CTD kinases 
that phosphorylate CTD are cyclin-dependent kinase 7 (CDK 7), CDK8 and CDK9, members of 
the CDK family, the MAPKs ERK1/2 and the cAbl tyrosine kinase which are involved in cell cycle 
regulation (Oelgeschlager, 2002; Venetianer et al., 1995).  
Phosphorylation of the serine/arginine-rich splicing factor (SR) proteins which are a 
family of serine, arginine-rich splicing factors is also important for pre-mRNA splicing (Shepard 
and Hertel, 2009). The SR proteins can be localised into the nucleus by the phosphorylation of 
the RS domain, allowing functions in mRNA splicing which occurs in the nucleus. 
Phosphorylation of the RS domain enhances the ability of the SR protein, important for 
spliceosome assembly in the early step of mRNA splicing. It also facilitates the recruitment of 
components of the spliceosome such as U1 small nuclear ribonucleoprotein (U1 snRNP) and 
U2AF35 to intronic splice sites. Also, SR proteins interact with CDK9, a CTD kinase, leading to 
the phosphorylation of CTD, and SR proteins bind to the phosphorylated site of the CTD of 
RNA polymerase II. This allows the SR protein to recognise pre-mRNA transcript (Long and 
Caceres, 2009). 
 
Phosphoproteomics is a part of proteomics that identifies and characterises proteins 
containing a phosphate group, providing the information of changes in activity of candidate 
proteins or pathways and signalling networks and also the information of phosphorylation sites. 
These can be achieved by advanced high-throughput phosphoproteomics through 
phosphoprotein enrichment, identification and relative quantitation by mass spectrometry and 
bioinformatics tools and biological sequences databases (Macek et al., 2009). Phosphorylation 
also can be easily detected by 1D or 2D gels-base methods including western blot by probing 
with phospho-site specific antibodies and phosphoprotein-specific gel staining, however it 
provides limited information (White, 2008; Macek et al., 2009). 
 
Recent advanced high-throughput proteomics allows the investigation of protein-specific 
alterations. The isobaric tag for relative and absolute quantification (iTRAQ) is a gel-free 
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proteomic approach that allows simultaneous identification and quantitation of proteins in 
multiplexing of up to eight labelled samples (Hultin-Rosenberg et al., 2013). This method has 
been shown to provide more accurate and reproducible quantification of peptides and proteins 
through peptides-based detection by mass spectrometry in phosphoproteomics as well (Zhang 
et al., 2005). Briefly, iTRAQ protocol contains four steps (Gafken and Lampe, 2006). First, 
prepared protein extracts from each sample are alkylated and proteolytically digested into 
peptides. Second, the peptides are labelled with a set of iTRAQ reagents individually in a 4 or 
8-plex format. Third, labelled peptides are pooled and fractionated by strong cation exchange 
(SCX) or hydrophilic interaction liquid chromatography (HILIC). Finally, the fractions are 
analysed by liquid chromatography tandem mass spectrometry (LC-MS/MS) to obtain the mass 
spectra providing peptide sequence information from peptide fragments and relative 
quantification from the reporter group ions. The tags consist of three regions; a peptide 
reactive region, a reporter region and a balance region (Ross et al., 2004). During mass 
spectrometry (MS), peptide fragments are distinguished according to peptide mass allowing 
for qualitative analysis, while during MS/MS peptide fragments with equal mass are detected 
for different intensity of the reporter group ion which corresponds to the relative amount of 
the peptides. 
 
 
1.1.4.2. Riboflavin and cell signalling 
 
Yates et al(2003) suggested the putative role of riboflavin as a signalling molecule in the 
lumen. Luminal absence of riboflavin in the presence of normal systemic riboflavin status in 
weanling rats resulted in abnormal development of GI tract, which is characteristic of dietary 
riboflavin depletion. The authors of that study hypothesised that riboflavin plays an important 
role in intestinal cell proliferation through effects on cell signalling.  
 
A plausible mechanism is through its role as a coenzyme for flavoproteins which are 
important in the production of reactive oxygen species (ROS) (Bender, 2003). Excessive ROS can 
cause molecular damage by reacting with DNA, protein and lipids to result in DNA mutation, 
protein oxidation and lipid peroxidation, all of which are relevant to the pathology of human 
disease. Nevertheless, ROS also play an important role as signalling molecules (Rhee, 2006). 
Therefore, redox balance in cells is critically important for the regulation of cell signalling 
pathways (Fruehauf and Meyskens, 2007).  
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Riboflavin plays a central role in redox regulation through its influence on the production 
of reduced glutathione (GSH) (Schafer and Buettner, 2001), which is the most abundant cellular 
antioxidant (Owen and Butterfield, 2010). Cellular redox buffering capacity can be predicted 
using the ratio of GSH : oxidised glutathione (GSSG) (Schafer and Buettner, 2001), thus it has 
been considered as an indicator of oxidative stress (Zitka et al., 2012). One of the enzymes 
modulating the glutathione redox cycle is glutathione reductase as seen in Figure 9. The 
enzyme requires FAD as a co-factor. Riboflavin deprivation leads to a significant decrease in 
activity of the enzyme, thus causing oxidative stress partially due to impaired glutathione redox 
cycle (Camporeale and Zempleni, 2003; Werner et al., 2005; Beutler, 1969). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 Glutathione redox cycle 
GSH; reduced glutathione, GSSG; oxidised glutathione. Riboflavin in the form of FAD serves as a cofactor 
for glutathione reductase which metabolises an oxidised glutathione to a reduced glutathione which is a 
cellular antioxidant. 
 
NADPH oxidase also requires FAD as a co-factor, and this enzyme generates ROS that 
function in cell signalling as a part of mechanisms of apoptotic and necrotic cell death 
(Yazdanpanah et al., 2009). A recent study showed that riboflavin deprivation in macrophage 
harvested from mice reduced tumour necrosis factor (TNF)-induced ROS production and 
decreased signalling thereby impairing anti-bacterial ability of macrophages against Listeria 
monocytogenes (Schramm et al., 2014). This can be explained by the FAD-dependence of 
NADPH oxidase and also the role of riboflavin kinase on NADPH oxidase assembly and 
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activation. When TNF stimulates TNF receptor 1 (TNFR1), riboflavin kinase mediates bridging of 
TNFR1 to NADPH oxidase and also generates and provides FAD for NADPH oxidase thereby 
ROS are produced (Yazdanpanah et al., 2009).  
 
To our knowledge there has been no investigation of the putative role of riboflavin in 
cell signalling. This study will address this gap in our understanding. 
 
 
1.1.5. Intestinal epithelial cell model of riboflavin depletion 
 
Nakano et al. (2011) developed a human intestinal epithelial cell model of riboflavin 
depletion by culturing Caco-2 cells in riboflavin-free medium containing dialysed foetal calf 
serum (FCS). Others have also achieved riboflavin depletion in other cells using a similar 
approach (Werner et al., 2005; Camporeale and Zempleni, 2003). This is approach has proved 
effective in achieving different degrees of riboflavin depletion of cells in vitro. In particular, the 
use of non-dialysed or dialysed FCS can determine whether a severely depleted state is 
achieved. For instance, intracellular concentrations of riboflavin similar to normal 
concentrations in human plasma can be achieved using riboflavin-free medium and non-
dialysed FCS. However, developing Nakano’s cell model was expensive and time-consuming. 
The cells required 3~4 passages to achieve severely riboflavin-deficient status. Furthermore, 
dialysation of FCS may lead to a short supply of other essential nutrients which may influence 
cell proliferation independent of riboflavin status.  
 
This study was designed to develop an improved model of intestinal riboflavin depletion, 
which could be applied to an investigation of effects of riboflavin depletion on aspects of cell 
function, but which could also be applied to studies of a putative role of riboflavin in cell 
signalling. The model required the use of lumiflavin, an inhibitor of riboflavin uptake into cells. 
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1.1.5.1. Lumiflavin 
 
It is well known that riboflavin is unstable under light exposure, degrading to some 
structural analogues. Lumiflavin is one of the structural analogues of riboflavin, formed by 
photodegradation at basic pH (Huang et al., 2006). 
 
 
 
 
Figure 10 Structures of riboflavin and lumiflavin. 
Lumiflavin is a structural analogue of riboflavin, obtained by photodegradation of riboflavin. The long 
ribityl chain of riboflavin binding to the isoalloxazine ring is replaced into a short methyl (Bender, 2003). 
 
 
Riboflavin uptake studies have shown that lumiflavin competitively saturates the 
riboflavin transporter, thus leading to significant inhibition of riboflavin uptake into human 
intestinal cells Caco-2 (Said et al., 1985; Said and Ma, 1994). Lumiflavin shares the same 
membrane transporter at the apical surface as riboflavin, thus it significantly inhibits the uptake 
of riboflavin into human intestinal cell line Caco-2, in a lumiflavin concentration-dependent 
manner. Exposure of Caco-2 cell for 48 hours to 32μM and 97μM of lumiflavin caused a 
progressive decrease approximately 40% and 70% decrease of riboflavin uptake, respectively 
(Said and Ma, 1994). Such findings are supported by further recent studies that identified and 
characterised a human and rat riboflavin transporter in that transporter-mediated riboflavin 
transport was specifically inhibited by lumiflavin (Yonezawa et al., 2008; Yamamoto et al., 2009). 
Riboflavin uptake by RFVT3 which is an apically expressed riboflavin transporter that 
predominantly serves to transport riboflavin uptake into cells was inhibited by lumiflavin and 
the authors proposed that RFVT3 recognised lumiflavin due to the structural similarity to 
riboflavin (Fujimura et al., 2010). However, in spite of having a similar structure to riboflavin, 
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lumiflavin itself is not phosphorylated, thus it cannot be a substrate of riboflavin kinase 
meaning that cells are unable to utilize it (McCormick, 1962). Therefore, lumiflavin specifically 
interferes with the uptake of riboflavin into cells. We proposed that the development of a cell 
model of riboflavin depletion in gastrointestinal cells using lumiflavin would be a useful tool to 
studying a putative role of riboflavin in cell signalling. Furthermore, this would obviate the 
need for multiple cell passages and dialysed FCS which are disadvantages of the existing 
model of Nakano et al. (2011). In addition, the cell model was to be used to explore 
biochemical and functional changes which may be important for the maintenance of regulation 
of intestinal cell proliferation and cell death. 
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1.2. Hypothesis, aims and objectives 
 
 
1.2.1. Hypothesis 
 
 Exposing intestinal cells to lumiflavin depletes the cells of flavins. 
 Flavin depletion of intestinal cells has adverse functional effects. 
 Lumiflavin induces changes in cell signalling in intestinal cells. 
 
 
1.2.2. Aim 
 
The overall aim of the study is to examine the biochemical and cellular consequences of 
modulating riboflavin status of intestinal cells, and to understand the underlying mechanisms. 
 
 
1.2.3. Objectives 
 
 To develop and to establish an intestinal cell model of riboflavin depletion using lumiflavin, 
which is a structural analogue of riboflavin.  
 To characterise the cell model of riboflavin depletion in terms of specific functions.  
 To study alterations in candidate signalling pathways and validate the findings. 
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2.1. Materials 
 
 
2.1.1. Cell lines 
 
Three cell lines Caco-2, HCT116 and HT29 were obtained from The Health Protection 
Agency, Porton Down, Salisbury, UK. Caco-2 cell are derived from an epithelial colorectal 
adenocarcinoma of a 72 year old Caucasian male, HCT116 cells from an epithelial colorectal 
carcinoma of an adult human male and HT29 cells from an epithelial colorectal 
adenocarcinoma of a 44 years old Caucasian female.  
 
Differentiated Caco-2 and HT29 cell lines are the most similar to the small intestine 
epithelium in terms of gene expression compared with other colon cancer-derived cell lines 
including HCT116 (Christensen et al., 2012). As Caco-2 and HT29 cell lines have been widely 
used for small intestinal cell models of drug and nutrient absorption, they were selected for 
this study. HCT116 cell line was used for comparison with Caco-2 and HT29 cell lines.  
 
 
2.1.2. Cell culture 
 
Centrifuge (Sorvall RT6000B refrigerated centrifuge, USA) 
Centrifuge (Heraeus PICO17, Thermo Scientific, Germany) 
Culture flasks and plates (Nunc) 
DMEM (GIBCO, Cat. No. 22320022 & DMEM-F12; Lonza BioWhittake, Cat. No. BE12-719F)) 
FCS (Biowest, Cat. No. S1810) 
Haemocytometer (Improved Neubauer) 
Hand tally counter 
Microscope (Diaphot: Nikon, Japan) 
PBS sterile (Lonza, BioWhittake, Cat. No. BE17-512F) 
Penicillin/ streptomycin (1% Penicillin/ streptomycin; GIBCO, Cat. No. 15140-122) 
Trypan blue stain 0.4% (GIBCO, Cat. No. 15250-061) 
Trypsin-EDTA 0.25% (GIBCO, Cat. No. 15400-054) 
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2.1.3. Preparation for lumiflavin-containing medium 
 
Lumiflavin (Sigma-Aldrich, Cat. No. L4879) 
DMEM (GIBCO, Cat. No. 22320022 & DMEM-F12; Lonza BioWhittake, Cat. No. BE12-719F)) 
0.2μm non-pyrogenic sterile filter (Nalgene, Cat. No. 83 186.001) 
Sodium hydroxide (Sigma Aldrich, Cat. No. S0899) 
 
2.1.4. Intracellular flavin assay 
 
Acetonitrile (Fisher Scientific, Cat. No. 10407440) 
Chromsystems (Chromsystems, Germany) 
FAD (Sigma-Aldrich, Cat. No. F6625) 
FMN (Sigma-Aldrich, Cat. No. F2253) 
HPLC system (Fluorescence detector, Jasco FP-920, Japan; autoinjector, Gilson 234; dynamic 
mixer, Gilson 811C; data module, Gilson 621; pump, Gilson 305 and 306, USA) 
PLRP-S column (Polymer labs, Church Stretton, UK) 
HPLC vial  
Magnesium acetate (Sigma-Aldrich, Cat. No. M2545) 
0.2μm nylon membrane filter papers (Whatman, Cat. No. 7402-004) 
Orthophosphoric acid (Sigma-Aldrich, Cat. No. 345245) 
Potassium phosphate (Sigma-Aldrich, Cat. No. P5379) 
Riboflavin (Sigma-Aldrich, Cat. No. R4500) 
Sonicator (UCD-200TM: Bioruptor diagenode, Belgium ) 
Trichloroacetic acid (TCA) (Sigma-Aldrich, Cat. No. T0699) 
 
2.1.5. Glutathione reductase activation coefficient (GRAC)  
 
COBAS Bioanalyser (Roche, Switzerland) 
EDTA (Sigma Aldrich, Cat. No. E7889) 
FAD (Sigma Aldrich, Cat. No. F6625) 
GSSG (Sigma Aldrich, Cat. No. G6654) 
NADPH (Sigma Aldrich, Cat. No. N5130) 
Potassium phosphate (Sigma Aldrich, Cat. No. P5379) 
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2.1.6. Adenosine 5’-tryphosphate (ATP) assay 
 
Apoptotic DNA ladder detection kit (abcam, Cat. No. ab66090) 
Hydrochloric acid (Fisher Scientific, CAS. No. 7647-10-0, FW=36.46) 
Luminometer (Bio-Orbit 1253, Labtech Jade) 
0.2μm non-pyrogenic sterile filter (Nalgene, Cat. No. 83 186.001) 
Polypropylene reaction vials 
 
2.1.7. Reactive oxygen species (ROS) assay 
 
Culture flasks and plates (Nunc) 
DCFDA (2’,7’-dichlorodihydrofluorescein diacetate, Sigma-Aldrich, Cat. No. D6883) 
DMEM (GIBCO, Cat. No. 22320022) 
DMSO (Sigma Aldrich, Cao. No. D2650) 
Fluorescence microplate reader (Fusion plate reader) 
PBS sterile (Lonza, BioWhittake, Cat. No. BE17-512F) 
 
2.1.8. MTT assay 
 
Microplate reader (Biotek FLX800, USA) 
MTT based Cell growth determination kit (Sigma-Aldrich, Cat .No. CGD-1) 
 
2.1.9. Clonogenic assay 
 
Centrifuge (Soval RT6000B refrigerated centrifuge, USA) 
Culture flasks and plates (Nunc) 
Haemocytometer (Improved Neubauer) 
Methanol (Fisher science, Cat. No. 67-56-1) 
Methylene blue (Sigma Aldrich, Cat. No. MB1-25G) 
Microscope (Diaphot: Nikon, Japan) 
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2.1.10.  Determination of protein concentration 
 
Bradford reagent (Bio-Rad, Cat. No. 500-0006) 
BSA (Sigma Aldrich, Cat. No. P0834) 
Microplate reader (Biotek FLX800, USA) 
 
2.1.11.  Apoptotic DNA assay 
 
Agarose (Life Technologies, Cat. No. 540-5510UA) 
Apoptotic DNA ladder detection kit (abcam, Cat. No. ab66090) 
Electrophoresis system (Bio-Rad, UK) 
Ethidium bromide (Sigma-Aldrich, Cat. No. E1510 ) 
Isopropanol (Sigma-Aldrich, Cat. No. I9516) 
Microwave 
Sodium butyrate (Calibochem, Cat. No. 567430) 
Quick-LoadTM 1kb DNA ladder (BioLabs, UK, Cat. No. N0468G) 
 
2.1.12.  Western blot 
 
Acrylamide (National Dignostics, Cat. No. EC890) 
Amicon Ultra-0.5 mL Centrifugal Filters (Millipore, Cat. No. UFC500324) 
Anti-phospho-tyrosine, clone 4G10 (Millipore, Cat. No. 05-321) 
Anti-phospho-serine/threonine (abcam, Cat. No. ab17464) 
Anti-phosphoepitope SR proteins clone 1H4 (Millipore, Cat. No. MABE50, Lot. No. 2207243) 
Anti-SR protein family (Millipore, Cat. No. MABE126, Lot. No. 2119212) 
APS (Sigma Aldrich, Cat. No. A3678) 
NaF (Sigma-Aldrich, Cat. No. S1504) 
Beta-actin (abcam, Cat. No.ab20272) 
B-Glycerophosphate (Sigma-Aldrich, Cat. No. G9891) 
ECL (Chemiluminescent HRP substrate, Immobilon Western, Millipore, Cat. No. WBKLS0500) 
EDTA (Sigma-Aldrich, Cat. No. E5513) 
EGTA (Sigma-Aldrich, Cat. No. E3889) 
Electrophoresis system (Bio-Rad, UK) 
Filter paper (Chromatography paper, Whatman, Cat. No. 3030672) 
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Fish gelatin (gelatin from cod water fish skin, Sigma, G7765-250ML) 
GeneTools program (SYNGENE, Japan) 
Heat block (FALC supplied by Scientific Ltd., UK) 
Imaging system (ChemiGenius2 BioImaging system, SYNGENE, Japan) 
Loading buffer (Laemmli buffer) 
NaVO4 (Sigma-Aldrich, Cat. No. P8340) 
Phosphoprotein purification kit (Qiagen, Cat. No. 37101)  
PMSF (Sigma-Aldrich, Cat. No. T7626) 
Polyoxyethylene sorbitan monolaurate (tween 20) (Sigma-Aldrich, Cat. No. P5927) 
Protease Inhibitor cocktail (Sigma-Aldrich, Cat. No. S6508) 
Protein standard (Precision Plus protein standard, Bio-Rad, Cat. No. 161-0373) 
PVDF membrane (Immonilon Transfer membrane, Millipore, Cat. No. IPVH00010) 
Running buffer (0.25M Tris, 1.92M Glycine, 1% SDS, National diagnostic Cat. No. EC870) 
SDS (Fisher Scientific, Cat. No. 16416) 
Secondary antibodies 
Polyclonal rabbit, anti-mouse immunoglobulin, HRP conjugated (DAKO, Cat. No. P0266) 
Polyclonal goat, anti-rabbit immunoglobulin, HRP conjugated (DAKO, Cat. No. P0448) 
Stripping buffer (Restore Western blot, Thermo Scientific, Cat. No. 21059) 
TBST (Sigma Aldrich, Cat. No. T9039) 
TEMED (Sigma Aldrich, Cat. No. T9281) 
Transfer buffer (0.25M Tris, 1.92M Glycine, National diagnostic Cat. No. EC880) 
Tris (Sigma-Aldrich, Cat. No. T1053) 
Triton X-100 (BDH lab, UK, Cat. No. 306324N) 
 
2.1.13.  High content analysis (HCA) 
 
96-well black-walled clear bottom plate (Nunc) 
Anti-phospho-tyrosine, clone 4G10 (Millipore, Cat. No. 05-321) 
Anti-phospho-serine/threonine (abcam, Cat. No. ab17464) 
Alexa Fluor 488, anti-mouse IgG secondary antibody (Invitrogen, Cat. No. A21202) 
Alexa Fluor 555, anti-rabbit IgG secondary antibody (Invitrogen, Cat. No. A31572) 
Digitonin (Sigma Aldrich, Poole Dorset, UK) 
Hoechst 33342 (Invitrogen, Paisley, UK) 
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2.1.14.  Purification of phosphoproteins 
 
Centrifuge (Soval RT6000B refrigerated centrifuge, USA) 
HBSS (Hank’s Balanced Salt solution) 
Phosphoprotein purification kit (Qiagen, Cat. No. 37101) 
Triton X-100 (BDH lab, UK, Cat. No. 306324N) 
 
2.1.15.  Pro-Q Diamond phosphoprotein gel stain and SYPRO® ruby stain 
 
Acetic acid (Sigma-Aldrich, Cat. No. 45740) 
Acetonitrile (Fisher Scientific, Cat. No. 10407440) 
Agitator (SSL4, Stuart, UK) 
Methanol (Fisher Scientific, Cat. No. 67-56-1) 
Multiplexed Proteomics® Phosphoprotein gel stain kit (Molecular Probes, Cat. No. M33306, 
Lot. No. 1164331) 
PeppermintStickTM phosphoprotein molecular weight standards (Molecular Probes, Cat. No. 
P27167) 
Sodium acetate (Sigma Aldrich, Cat. No. S2889, Lot. 63H079415) 
Triton X-100 (BDH lab, UK, Cat. No. 306324N) 
Typhoon 9400 Imager (Amersham Biosciences, USA) 
 
2.1.16.  Sample concentration by filtration 
 
Amicon® Ultra-0.5 Centrifugal filter devices (Millipore, Cat. No. UFC500324) 
Centrifuge (Mikro 22R, Hettich Zentrifugen, Germany) 
TEAB buffer (Sigma Aldrich, Cat. No. T7408) 
 
2.1.17.  Coomassie blue stain 
 
Agitator (SSL4, Stuart, UK) 
Coomassie® stain (InstantBlueTM, Expedeon, Cat. No. ISB1L) 
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2.1.18.  Isobaric tag for relative and absolute quantitation (iTRAQ)  
 
Acetonitrile (Fisher Scientific, Cat. No. 10407440) 
Agilent 1100-series HPLC (Agilent, Berkshire UK), 
Agitator  
Ammonium formate (Sigma Aldrich, Cat. No. 70221) 
Chromeleon software v.6.50 (Dionex, LC Packing, The Netherlands).  
Formic acid (Sigma Aldrich, Cat. No. F0507) 
Heat block  
HPLC grade H2O (Fisher Chemical, Cat. No. W/0106/17) 
Hydrophilic Interaction Liquid Chromatography (HILIC) (Ultimate 3000 from DIONEX, USA) 
Incubator  
Isopropanol (Sigma Aldrich, Cat. No. 19516) 
iTRAQ reagent 8PLEX Multi-plex kit (AB Sciex, Cat. No. P/N4381663, Lot. No. A1222, USA) 
LoBind tubes (Sigma Aldrich, Cat. No. Z666505) 
Methyl methane ethiosulfonate (MMTS) (Sigma Aldrich. Cat. No. 208795) 
Potassium chloride (BDH Chemicals, Cat. No. 10198 아니면 5520090A) 
Sequencing Grade Modified Trypsin (Promega, Cat. No. V5111) 
SDS-PAGE gel running apparatus (Bio-Rad) 
TEAB buffer (Sigma Aldrich, Cat. No. T7408) 
Tris-(2-carboxyethyl)phosphine hydrochloride (TCEP) (Sigma Aldrich, Cat. No. 646547) 
Trifluoroacetic acid (CHROMAsolv, Sigma Aldrich, Cat. No. 302031) 
UltraMicrospin Columns, Silica C18 Vydac (The NEST group, Cat. No. SUM SS18V) 
Vacuum concentrator (Scanvac, Lebogene, Denmark) 
Ultimate 3000 split flow HPLC system (Dionex, Surrey, UK) 
 
2.1.19.  Cell cycle analysis by flow cytometry 
 
Absolute ethanol (BDH, EC 200-578-6) 
BD LSR II (BD Biosciences) 
Centrifuge (Heraeus PICO17, Thermo Scientific, Germany) 
PI/RNase staining solution (Molecular probes, Cat. No. F10797, Lot. No. 1374366) 
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2.2. Methods 
 
 
2.2.1. Cell culture  
 
Human intestinal epithelial cells HCT116, Caco-2 and HT29 were used for this project. 
Cells were cultured in DMEM growth medium containing 10% FCS and 1% penicillin and 
streptomycin; 100units/ml penicillin and 100μg/ml streptomycin at 37℃ and 5% CO2.  
For cell culture, DMEM growth medium, PBS and trypsin-EDTA were warmed in a water 
bath at 37℃ for approximately half an hour. A culture hood, micropipettes, a pipette aid, 
disposal pipettes and 50ml sterile falcon tubes were prepared sterile by cleaning with 70% 
ethanol before tissue culturing was started.  
 
Thawing cells 
Special gloves and a helmet should have been worn for the safety reason. Cells stored in 
a nitrogen tank were taken out carefully and defrosted rapidly at 37℃ in a water bath. Cell 
suspension was transferred to 50ml tubes containing 9ml DMEM, mixed well and centrifuged 
for 5 minutes at 150xg and room temperature. Then, supernatant was removed. 8ml DMEM 
was added to cell pellet, and cells were resuspended. The cell suspension was seeded into T75 
culture flasks with 20ml of DMEM. Cells were observed daily and when it was 80-90% 
confluent, cells were split. 
 
Splitting cells 
Medium was removed with a pipette aid and disposable pipettes, and cells were rinsed 
gently twice with appropriate volume of sterile PBS; 500 ㎕/well for a 24well plate, 3ml for T25, 
5ml for T75, and 10ml for T175 flasks. Appropriate volume of 0.5% trypsin-EDTA was then 
treated depending on the confluence and incubated at 37℃ for 5 minutes; for example, 
100 ㎕/well for a 24well plate, 1ml for T25, 3-4ml for T75, and 6-7ml for T175. It was checked if 
the cells had been detached from a culture flask, and the same volume of growth medium as 
trypsin-EDTA was added in order to inactivate trypsin-EDTA. Then, cell suspension was split into 
single cells by mixing well and gently but avoiding causing froth or pipetting too harshly. Cells 
were counted using a haemocytometer. Cell counting is explained in the following section. 
After counting, the cell suspension was centrifuged at 150xg and room temperature for 5 
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minutes. The supernatant was discarded, and the cell pellet was resuspended with appropriate 
volumes of growth medium. Finally, part of cell suspension was planted into new culture plates 
or flasks. 
 
Counting cells 
Cells were counted whenever cells were split or harvested. A haemocytometer and a 
coverslip were cleaned with 70% ethanol and wiped. The surface of a coverslip was moisturised 
very slightly, and the coverslip was laid over the central of the haemocytometer and pressed 
gently to attach to the haemocytometer. After inactivation of trypsin-EDTA, the cell suspension 
was mixed thoroughly, and 20 ㎕ was taken into a microtube containing 20 ㎕ trypan blue. 
Trypan blue was used to dye dead cells and cells dyed in blue were excluded from counting. 
10 ㎕ of that was transferred to the edge of one side of the one chamber of the 
haemocytometer. The slide was then transferred onto the microscope with 10X objective and 
10X ocular. The number of cells was counted in 4 corners of 9 major squares, and the counting 
was repeated for another chamber. Finally, the number of cells was calculated by the following 
formula. 
 
Cell number/ml = Total cell number in 8 major squares  ÷  8 ｘ 2 ｘ 104 
Total cell number = Cell number/ml ｘ volume of cell suspension 
 
 
Figure 11 Counting cells using a haemocytometer.  
(Organization, 2009) 
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2.2.2. Preparation of lumiflavin-containing media 
 
Lumiflavin was dissolved in 0.1M NaOH and filtered by 0.2μm non-pyrogenic sterile filter 
to be sterile in the cell culture hood. The concentrated lumiflavin stock (10mM) was aliquoted 
and stored at -20℃. Lumiflavin was added into DMEM right before used. Final concentration of 
0.1M NaOH in lumiflavin-containing DMEM was kept as 2% of the volume of DMEM for all 
experimental cell groups. Lumiflavin-untreated DMEM also was matched for final concentration 
of 0.1M NaOH to 2%.  
 
 
2.2.3. Determination of cell growth 
 
The three intestinal cell lines were planted into a 24well plate and incubated at 37℃ and 
5% CO2 for 1 day to allow cells attached. Cells were then treated with DMEM containing 
lumiflavin in a range of 0, 10, 25, 40, 60, 75, 90 and 100μM for 24, 48 and 72 hours. At each 
time points, cells were detached by trypsinisation and counted0. Prior to the main experiment 
for determination of cell growth, preliminary experiment was performed with Caco-2. The 
concentrations of lumiflavin used for the preliminary experiment were 0, 0.1, 0.5, 1, 10, 100, 
200 and 500μM diluted in DMEM and the time course of lumiflavin treatment was 24, 48 and 
72 hours. 
 
 
2.2.4. Intracellular flavin assay  
 
Intracellular riboflavin, FAD and FMN concentrations were measured using reverse-phase 
HPLC using a modified method of Capo-chichi et al (Capo-chichi et al., 2000). Flavins are 
separated by their size and hydrophobicity passing through a column and fluorescence emitted 
by flavins are detected and converted to flavin concentration. 
 
Preparation of reagents 
10% w/v Trichloroacetic acid (TCA) was prepared. 25g TCA was weighed out and 
dissolved in approximate 200ml of distilled water. It was made up to 250ml with distilled water 
in a volumetric flask. TCA solution was kept at 4℃ and when used, it was kept on ice. 
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Flavin buffer was prepared, which consisted of 10mM potassium phosphate and 15mM 
magnesium acetate buffer, pH2.0. KH2PO4 (2.722g) and magnesium acetate (6.435g) were 
weigh out and dissolved in approximate 200ml distilled water and made up to about 1.8L. This 
solution was adjusted to pH2.0 with approximate 20ml orthophosphoric acid. Finally, it was 
made up to 2L in a volumetric flask.  
Flavin mobile buffer which is HPLC eluting buffer was prepared as 13% acetonitrile in flavin 
buffer. 130ml acetonitrile was made up to 1L with flavin buffer. This buffer was filtered to 
remove gas and dusts using 0.2um nylon membrane filter paper.  
 
Preparation of standards  
Stock of combined standard was prepared with 100μM riboflavin, 100μM FMN and 25μM 
FAD. Riboflavin (18.82mg) was weighed out, dissolved in approximate 100ml of methanol and 
poured into a 500ml volumetric flask. Weighed FMN (7.13mg) and FAD (44.1225mg) were 
dissolved in approximate 50ml ddH2O. The solution was added into riboflavin solution in a 
volumetric flask and made up to 500ml with ddH2O. The stock of combined standard was 
aliquoted with 1.3ml into microtubes and stored at -80℃.  
When required, working standards were prepared diluting 100 ㎕ stock of combined 
standard up to 100ml ddH2O. Working standard was diluted more with 1 in 2 serial dilutions 
with ddH2O. It was kept on ice and in the dark. 200 ㎕ standards were transferred into light-
protected tubes, and 100 ㎕ of ice cold TCA was added and mixed well. 150 ㎕ of that was 
placed into a HPLC vial. 
 
Preparation of cell samples  
Cultured cells were harvested and counted. After centrifuged, cells were washed with PBS, 
transferred into microtubes and centrifuged at 150xg for 5 minutes. Supernatant was removed 
and cell pellets were stored at -20℃ until analysed. 
ddH2O was added into cell pellet with 200 ㎕/10×106 HCT116, HT29 cells and 
150 ㎕/3×106 Caco-2 cells, and mixed well with vortex. Cells in water were lysed by sonication 
for 5 minutes on ice. 200 ㎕ cell lysate was taken into light-protected tubes. 100 ㎕ ice cold 
TCA was added into there, mixed well and centrifuged at 20,780xg and 4℃ for 5 minutes. 
150 ㎕ of supernatant was taken and placed into a HPLC vial.  
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Running high performance liquid chromatography (HPLC) 
Injection volume was set as 50 ㎕. Flow rate was 1.5ml/minutes. Florescence was 
detected at excitation 465nm and emission 530nm and gain 18. Pressure was 2103.1, 2146.6 
and 2175.6. 
For quality control (QC), whole blood controls; level I and II provided from 
Chromsystems were used to monitor accuracy of the analysis. 200 ㎕ of QC was mixed with 
100 ㎕ ice cold TCA and centrifuged. Supernatant was taken and loaded into a HPLC vial. QCs 
were read before and after running samples. By comparing QCs values of two different times, 
accuracy of the analysis was able to be monitored.  
Calculated flavin concentrations were adjusted by protein concentration. Sonicated cell 
lysates were centrifuged at 20,780xg and 4℃ for 5 minutes and the supernatant was used to 
determine protein concentration by Bradford protein assay explained in the section 2.2.10.  
 
 
2.2.5. Glutathione reductase activation coefficient (GRAC)  
 
Glutathione reductase (GR) is a FAD and NADPH-dependent enzyme which converts 
oxidised glutathione to the reduced form (Hill et al., 2009).  
 
GRAC is calculated from the ratio between the rate of disappearance of the NADPH in a 
sample to which an optimal amount of FAD has been added and not added. GRAC is inversely 
related to intracellular FAD concentration, thus GRAC reflects a functional riboflavin deficiency 
shown by actual fall in saturation of glutathione reductase with FAD.  
 
Preparation of reagents  
GRAC buffer was prepared. Weighed 8.7g K2HPO4 was added into 500ml ddH2O and 
6.8g KH2PO4 into another flask containing 500ml ddH2O. Using the KH2PO4 solution, the pH of 
K2HPO4 solution was brought to pH7.4. The total volume of the mixture was measured and 
then EDTA was added to obtain a concentration of 1mg/ml. 
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Stock of FAD solution was prepared adding 5mg FAD to 33ml buffer and aliquoted 1.5ml to 
microtubes. Aliquoted FAD stock was wrapped in foil and stored at -20℃. When prepared for 
use, it is diluted further with the ratio of 1:4 in buffer. 
The followings were prepared right before used. 19.6mg GSSG was weighed out and 
added to 2ml buffer and kept on ice. 6mg NADPH was added to 15ml buffer and kept on ice.  
 
Preparation of cell samples  
Cultured cells were harvested and counted by haemocytometer. Cell suspension was 
centrifuged, wash with PBS and pelleted. Cells were stored at -20℃ until analysed. ddH2O was 
added into cell pellet with 200 ㎕/10×106 HCT116, HT29 cells and 150 ㎕/3×106 Caco-2 cells, 
and mixed well with vortex. Cells were then lysed by sonication for 5 minutes on ice. Part of 
cell lysate was used for determination of intracellular flavins concentration. The remaining cell 
lysate was centrifuged at 20,780xg and 4℃ for 5 minutes. Supernatant was carefully transferred 
to new microtubes and kept on ice and in the dark. 
 
Determination of GRAC 
5 ㎕ of a sample were loaded into two blue COBAS sample cups. Into one cup, 135 ㎕ 
buffer was added, which was to determine ‘unstimulated GR activity’. Into another cup, 115 ㎕ 
buffer and 20 ㎕ FAD solution were added, which was to determine ‘stimulated GR activity’. 
After sample cups were tightly closed and mixed well by inverting 5-6 times, samples were 
incubated at 37℃ for 30 minutes.  
 
To run COBAS, it should be checked that water in a water bottle on the top is enough. A 
cuvette ring was properly retained and a lid was correctly covered. It was checked COBAS 
parameters setting. Sufficient GSSG and NADPH were added into the reagent tray. Glutathione 
reductase activity was measured by kinetic assay, determining the rate of disappearance of 
NADPH as the change in absorbance at 340nm. The activation coefficient was calculated as 
follows. 
 
GRAC =  
Stimulated GR activity 
Unstimulated GR activity 
 
Where GR = glutathione reductase. The assay was run in duplicate for each sample. 
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2.2.6. Adenosine 5’-triphosphate (ATP) assay  
 
Intracellular ATP concentrations of lumiflavin-treated cells were determined by ATP 
bioluminescent somatic cell assay kit. This assay is based on the ATP-dependence of firefly 
luciferase. D-luciferin is oxidised by firefly luciferase emitting light.  
 
 
 
In this study, the light emitted was proportional to the ATP present. The light can be quantified 
by a luminometer and then converted to ATP concentration using ATP standard curves. 
 
Reagents were prepared by following the preparation instructions of the kit. ddH2O 
filtered through 0.2μm filter was used to dissolve the reagents. Reaction vials were soaked in 
0.1N HCl overnight and rinsed with ddH2O, then left for air dry. This process removed ATP and 
bacterial contamination. ATP assay mix solution and ATP standard stock solution were 
aliquoted and stored at -20℃ and in the dark. When used, ATP assay mix was thawed and 
diluted in to the ratio of 1:25 with ATP assay mix dilution buffer provided. Diluted ATP assay 
mix was kept in ice and in the dark. ATP standards working solutions were prepared by making 
serial dilutions of the stock (2μmole). 
 
Cells were cultured in 24-well plates and incubated with DMEM containing 0, 40 and 
80μM lumiflavin. At 24, 48 and 72 hours after treatment with lumiflavin, cells were washed with 
PBS and then PBS was completely removed since PBS can quench the sensitivity. 150 ㎕ 
somatic cell ATP releasing reagent per well was dispensed directly into adherent cells and 
mixed well by gentle pipetting up and down, then detached cells were transferred to a 
microtube. The samples were kept on ice.  
 
100 ㎕ ATP assay mix solution were dispensed into a reaction vial and the reaction 
medium allowed to stand at room temperature for approximately 3 minutes. To stabilize a 
luminometer, a blank was set up as 0.0, which was prepared as follows: 100 ㎕ filtered ddH2O 
were mixed with 100 ㎕ ATP releasing reagent, and 100 ㎕ of the mixture was transferred to a 
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reaction vial already containing 100 ㎕ ATP assay mix. The reaction vial was mixed well by 
vortex and the light value of a blank was set as 0.0 in a luminometer. 
For ATP standard curves, 100 ㎕ ATP standards diluted in filtered ddH2O and 100 ㎕ ATP 
releasing reagent were mixed together. 100 ㎕ were taken into a reaction vial containing 100 ㎕ 
ATP assay mix. A vial was mixed well by vortex and the light produced in a luminometer 
measured immediately.  
Since ATP extracts from cells had already included ATP releasing reagent, 100 ㎕ of the 
extract was mixed with 100 ㎕ filtered ddH2O. The produced light was determined with the 
same procedure as done for standards. The light values were converted to ATP concentration 
using the standard curve. The remains of diluted ATP extracts were used for the measurement 
of protein concentrations, and finally ATP concentrations were corrected for protein 
concentration.  
 
 
2.2.7. Reactive oxygen species (ROS) assay  
 
The intracellular ROS concentration was determined using the cell-permeable and 
fluorogenic probe 2’,7’-dichlorodihydrofluorescein diacetate (DCFDA) in the three cell lines. 
DCFDA diffuses into cells and is deacetylated by cellular esterases to non-fluorescent DCFH, 
which is subsequently oxidised to highly fluorescent DCF by ROS, predominantly H2O2. 
Fluoregenic probing with DCFDA has been widely used as an indicator of ROS formation and 
oxidative stress (LeBel et al., 1992). 
 
DCFDA was prepared by dissolving in DMSO. 50mM stock was aliquoted and stored at -
20℃ before use. When used, 100μM DCFDA diluted in riboflavin and serum-free DMEM was 
prepared and kept in dark. 
Cells were transferred into a 96-well black-walled clear bottom plate suitable for 
fluorescence measurements with a seeding density that would lead to 80% confluence after 4 
days. After 1 day to allow cells to become attached to the surface of a plate, cells were treated 
with 0, 40 and 80μM lumiflavin-containing DMEM for 24, 48 and 72 hours.  
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H             
Figure 12 A 96-well plate layout used for ROS and MTT assay.  
Cells were seeded, and lumiflavin of 0, 40 and 80μM was treated to the cells. Three plates were prepared. 
At 24, 48 and 72 hours after treatment with lumiflavin, upper half of a plate was used for DCFDA assay. E 
lane was used for blank of DCFDA assay. Lower half (F~H lane) was used for MTT assay. 
 
 
At each time point, cells in a half of the plate were washed with PBS twice. 100 ㎕ of 
100μM DCFDA diluted in riboflavin and serum-free DMEM was added into cells and the plates 
were incubated at 37℃ for 30 minutes. For blank of DCFDA, DMSO was treated with the same 
conditions as DCFDA. Then, DCFDA and DMSO were removed and cells were washed with PBS 
twice again. 100 ㎕ riboflavin and serum-free DMEM was added to cells. The plate was read by 
a fluorescence microplate reader with excitation wavelength at 485nm and emission 
wavelength at 530nm. Fluorescence was recorded right after DCFDA was removed and then 
every 30 minutes or 1 hour up to 4 hours. Intensity was set as 10 and gain, 1. In parallel wells, 
MTT assay was performed in order to correct the difference of cell numbers. This will be 
described in the next section  
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2.2.8. MTT assay  
 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphynyltetrazolium bromide) assay is an 
alternative method to count viable cells measuring the activity of living cells through 
mitochondrial dehydrogenase activity.  Mitochondrial dehydrogenases of viable cells cleave 
the tetrazolium ring and form purple MTT formazan crystals which are soluble in acidified 
isopropanol. The resulting purple formazan solution is spectrophotometrically measured. 
Absorbances are quantified using an absorbance/cell number curve.  
 
Pre-incubated cells with lumiflavin-containing DMEM were washed with PBS. 50 ㎕ of 10% 
MTT solution diluted in lumiflavin-free DMEM was added and incubated at 37℃ for 3 hours. 
Then, the same amount of MTT solvent (50 ㎕/well) as 10% MTT solution was directly added 
into cells and mixed well by pipetting up and down. The plate was read by a plate reader at a 
wavelength of 562nm and background absorbance measured at 630nm was subtracted. 
 
Absorbance/cell number curves for three cell lines were prepared. Cultured cells were 
planted in 96-well plate with the different seeding densities in a range of 1000 to 20,000 cells 
of HCT116 and HT29 and 500 to 10,000 cells of Caco-2 in three replicates. Cells were left to 
settle down in an incubator. On the next day, MTT assay was performed as described above. 
Absorbance values and cell numbers were plotted on a graph and obtained equation was used 
to convert absorbance to cell number. 
 
 
2.2.9. Clonogenic assay  
 
The clonogenic assay measures the ability of cultured cells to form colonies. Cytotoxic 
agents may inhibit the clonogenic ability of cells. Thus, the clonogenic assay can determine the 
proliferative ability of cells and cytotoxicity after incubation with lumiflavin. The reversibility of 
any effect of lumiflavin also can be determined.  
 
Seeding cells  
The three cell lines were seeded into T25 culture flasks and incubated at 37℃ and 5% 
CO2 for 1 day to allow cells attached. Cells were treated with 0, 40 and 80μM lumiflavin-
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containing DMEM. At 24, 48 and 72 hours after treatment, cells were split. After trypsinisation, 
cell suspension was passed through a 20gage needle 5 times in order to make single cells. Cell 
numbers were counted by haemocytometer and according to the number of counted cells, cell 
suspension was diluted. The appropriated number of cells was seeded into a 6 well plate in 
four replicates, to which 2-3ml lumiflavin-free DMEM was already added. The optimal seeding 
densities for each three cell lines were selected by preliminary experiments. Then, cells were 
incubated at 37℃ and 5% CO2 until a single cell formed the proper size of a colony which 
consisted of over 50 cells. Thus, a thousand Caco-2 cells were seeded and incubated for 1 
week, five hundred HCT116 cells for 12 days, and five hundred HT29 cells for 2 weeks.  
 
Staining and counting colonies 
Colonies were stained and counted. Firstly, already existing media were removed. The 
colonies were then washed once with 2ml PBS per well and fixed with 1ml 70% methanol per 
well for 5 minutes at room temperature. After methanol was removed, 2ml 1% methylene blue 
per well was added and incubated at room temperature for 10 minutes. Stained colonies were 
washed twice with approximate 2ml distilled water per well, and allowed to dry in the air for 
over half an hour. The colonies composed of over 50cells were counted manually by naked 
eyes and by viewing under a microscope. The absolute clonogenicity (AC) by following 
equation and the relative clonogenicity (RC) of lumiflavin-treated cells against control cells 
(0μM) were calculated. 
 
AC = colony number ÷ seeded cell number × 100 
 
 
2.2.10.  Determination of protein concentration  
 
Bio-Rad Bradford reagent was diluted in to the ratio of 1:5 in ddH2O, and protein extract 
samples were diluted in to the ratio of 1:20 in ddH2O. 4 ㎕ of standards (BSA 1, 0.75, 0.5, 0.25, 
0.125 and 0.0625 mg/ml in ddH2O) and ddH2O for blank were loaded into a 96-well plate in 
duplicate. 4 ㎕ of diluted samples were dispensed in duplicate or triplicate. Then, 200 ㎕ of 
diluted Bio-Rad reagent was dispensed into the wells. After 1minute, the absorbance of them 
was measured on a microplate reader at 595nm. The absorbance values were subtracted blank 
from. Mean absorbance of standards was plotted on a graph. An equation was used to convert 
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absorbance values of samples to protein concentration and finally the result concentration 
were multiplied by diluted factor. 
 
 
2.2.11.  Apoptotic DNA assay  
 
Apoptosis was investigated using an apoptotic DNA ladder detection kit. Apoptotic DNA 
laddering assay is the method detecting DNA fragmentation which is caused by apoptosis. 
Therefore, apoptotic DNA will show multiple bands or a smear on the agarose gel while 
normal DNA will not. 
 
All required reagents were prepared following the provided manufacturer’s instruction. 
The kit contained TE lysis buffer, enzyme A solution, enzyme B (lyophilised), ammonium acetate 
solution, and DNA suspension buffer. Enzyme B was dissolved with 275 ㎕ ddH2O and mixed 
well before use. The enzyme B solution was aliquoted and stored at -80℃. In addition, ddH2O, 
PBS and isopropanol were prepared.  
 
As a positive control, sodium butyrate was used to induce apoptotic DNA fragmentation. 
1M sodium butyrate stock solution was prepared in sterile ddH2O and aliquoted then stored at 
-20℃. Three intestinal cell lines; Caco-2, HCT116 and HT29 were exposed to 10mM sodium 
butyrate for 24 hours, and detached cells as well as adherent cells were separately harvested 
by gentle trypsinisation. Cells were washed with PBS and centrifuged at 1500xg and 4℃ for 5 
minutes. Cell pellets were stored at -20℃ until analysed.  
 
The three cell lines were pre-incubated in lumiflavin-containing DMEM, when harvested, 
detached cells and adherent cells were separately collected. Floating cells in used media were 
taken and spun down, and then cell pellets were washed in PBS twice, transferring to 
microtubes. Cells were centrifuged at 1500xg and 4℃ for 5 minutes. Cell pellets were stored at 
-20℃ until analysed. Adherent cells were harvested by trypsinisation. Cell numbers were 
counted using a haemocytometer and trypan blue staining. 0.25~1×106 cells were pelleted and 
washed with PBS twice then centrifuged at 150xg and 4℃ for 5 minutes. Cell pellets were 
stored at -20℃.  
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Cells were lysed with 35 ㎕ of TE lysis buffer by gentle pipetting, provided in the kit. 5 ㎕ 
of enzyme A solution was added and mixed by gentle vortex. The mixture was incubated at 37℃ 
for 10 minutes. Then, 5 ㎕ of enzyme B solution was added and the mixture incubated at 50℃ 
for 30 minutes. 5 ㎕ ammonium acetate solution was added to each sample mixture and 50 ㎕ 
isopropanol was added and mixed well, and the mixture was kept at -20℃ for 10 minutes. The 
mixture was spun down at 600xg, 25℃ and for 10 minutes. Supernatant was removed and the 
DNA pellet was washed with 0.5ml of 70% ethanol. Trace ethanol was removed and dried in 
the air for longer than 10 minutes at room temperature. Dried DNA pellet was dissolved in 
30 ㎕ DNA suspension buffer. To take images of DNA, 1.2% agarose gel containing 0.5μg/ml 
ethidium bromide in both gel and running buffer was prepared. 15~30 ㎕ of the sample was 
loaded into the gel, and 1kb DNA ladder was also loaded as a standard of DNA size. The gel 
was run at 50V for 2 hours. Ethidium bromide-stained DNA was visualised by transillumination 
with UV light.  
 
 
2.2.12.  Western blot 
 
Western blotting is a widely used method for the detection or quantitation of proteins. 
Proteins are separated according to their size by gel electrophoresis and the proteins can then 
be identified using specific antibodies against the proteins of interest. 
 
Caco-2 cells were incubated in 40μM lumiflavin-containing DMEM for 3, 6, 17, 24 and 48 
hours and then harvested by trypsinisation. Cell number was counted using a haemocytometer 
and trypan blue staining. After removing trypsin by centrifugation at 150xg and 4℃ for 5 
minutes, cells were washed with PBS twice and pelleted.  
 
Cell lysis  
Kinase buffer was freshly prepared right before use, whose constituent is presented on 
Table 2. The volume of kinase buffer was determined with the proportion of 10 ㎕/0.1×106 cells 
or the volume of cell pellet was roughly determined by eyes, compared with already known 
volumes of water. Cell pellets were suspended in ice cold kinase buffer by pipetting gently, and 
stayed on ice for at least 20 minutes with concealment from the sunlight. Then, cell lysates 
were prepared by cell disruption using a sonicator (high pulse: 5 minutes), keeping staying on 
ice slush to avoid heat which produced by sonication. They were centrifuged at 20,780xg and 4℃ 
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for 15 minutes. The supernatants were transferred to fresh microtubes, and the protein 
concentrations were determined and the rest were stored at -80℃.  
Cell lysates were taken with the wanted volume depending on the protein concentration 
and mixed with loading buffer. The mixtures were heated at 95℃ for 5 minutes. Then cooled 
mixtures were centrifuged down and ready to load to the SDS-PAGE gel. 
 
Table 2 Preparation of kinase buffer 
Reagent quantity(㎕) Final concentration 
1M Tris, pH 7.5 500 50mM 
1M NaF 500 50mM 
1M B-Glycerophosphate 100 10mM 
0.2M EDTA 50 1mM 
0.2M EGTA 50 1mM 
10% Triton X-100 200 0.2% 
ddH2O added up to 10ml  
0.1M PMSF * 10 0.1mM 
0.1M NaVO4 * 100 1mM 
Protease Inhibitor Cocktail * 100  
* Added directly just before use 
 
 
Table 3 Preparation of SDS-PAGE gels, running buffer and blotting buffer 
Solution Stacking gel 
Resolving gel 
7.5% 10% 12% 15% 
ddH2O 6.1 ml 7.4 6.1 5.2 3.75 
Tris 
(Stacker) 0.5M pH 6.8 
(Resolve) 0.5M pH 8.8 
2.5 ml     
 3.75 3.75 3.25 3.75 
Acrylamide 1.3 ml 3.65 4.95 5.8 7.25 
10% SDS 100 ㎕ 150 150 150 150 
10% APS 100 ㎕ 75 75 75 75 
TEMED 20 ㎕ 18 18 18 18 
Running buffer(10X) Diluted to 1X with ddH2O 
Blotting buffer(10X) 
Diluted to 1X  
with the ratio of 3:1:6 of methanol:10X buffer:ddH2O 
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To prepare SDS-PAGE gels, the gel apparatus was cleaned and assembled. Following the 
gel constituents on Table 3, resolving gels were prepared and immediately loaded into the 
plate and about 1ml of ddH2O was layered on the top, and then left for about 20 minutes to 
set. After removing ddH2O, prepared stacking gel was loaded and a comb was placed in a gel, 
and then left for about 20 minutes to set.  
The plates were placed in gel running apparatus and the outer tank and 1X running 
buffer was filled ensuring the wells were covered and about half of the outer tank were filled. 
After a comb was removed, protein samples and 5 ㎕ of protein marker were loaded into wells 
with fine tipped pipette tips. The lid on the tank was placed ensuring the terminals were 
correctly aligned, red to red and black to black. Gels were run at 100V for 100 minutes.  
PVDF membrane, two blotting papers, two sponges, blotting cassettes, methanol and 
blotting buffer were prepared. PVDF membrane was soaked into methanol for 30 seconds and 
transferred to a tray that filled with blotting buffer. The blotting cassette (white side down), a 
sponge were placed ensuring all soaked into the buffer. Then, the plates were removed from 
the gel running apparatus, and the plates were carefully opened. The stacking gel was 
removed from the resolving gel. The gel was carefully demounted from the plate, and placed it 
on a wet blotting paper. A membrane was covered on the gel and then another blotting paper 
was placed on a membrane and the soaked sponge was on the top. Air bubble between the 
gel and membrane was removed, which may interrupt transferring proteins of the gel to a 
membrane. The blotting cassette assembly was closed, locked and placed in the 
electrophoresis tank with an ice pack. Blotting buffer was filled into the tank until the cassette 
was covered. It was run at 100V for 90~100 minutes. Ice pack was replaced about an hour later.  
 
Blocking and probing 
The membrane was incubated in blocking solution overnight at 4℃ with constant 
agitation.  
 0.2% gelatin in PBST (0.1% tween 20) for phospho-tyrosine 
 1% BSA in PBST(0.1% tween 20) for phospho-serine/threonine,  
 5% BSA in ddH2O with 0.05% tween 20 for SR and phospho-SR proteins 
 
Then, the membrane was incubated in primary antibody solution overnight at 4℃ with 
constant agitation. 
 Anti-phospho-tyrosine (1:200) in 0.2% fish gelatin in PBST (0.1% tween 20) 
 Anti-phospho-serine/threonine (1:300) in 1% BSA in PBST (0.1% tween 20)  
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 Anti-phospho-SR (1:1500) in 5% BSA in ddH2O with 0.05% tween 20 
 Anti-SR (1:500) in 5% BSA in ddH2O with 0.05% tween 20 
 
The membrane was rinsed four times in TBST. Secondary antibody solutions were prepared as 
following below. 
 Polyclonal rabbit anti-mouse IgG HRP conjugated antibody (1:2000) in 0.2% gelatin in 
PBST (0.1% tween 20) for phospho-tyrosine 
 Polyclonal goat anti-rabbit IgG HRP conjugated antibody (1:2000) in 1% BSA in 
PBST(0.1% tween 20) for phospho-serine/threonine,  
 Polyclonal rabbit anti-mouse IgG HRP conjugated antibody (1:5000) in 5% skimmed 
milk for SR proteins and phospho-SR proteins 
The membrane was incubated in the secondary antibody solution at room temperature for 1 
hour with constant agitation. And it was rinsed four times in TBST and washed in fresh TBST 
for 5~10 minutes with constant agitation. The protein bands on the membrane were detected 
using ECL solution (with mixing the equal volume of each two solutions) and imaging system 
(ChemiGenius2, Japan). The signals were quantified by densitometry (GeneTools program, 
Japan). 
 
The signals were normalised by detecting ß-actin as the membrane rinsed four times in 
TBST were incubated in anti-ß-actin (1 : 5000) in 1% BSA in PBST (0.1% tween 20) at room 
temperature for 1 hour with constant agitation. Then, the ß-actin bands were detected.  
 
 
2.2.13.  High content analysis (HCA) 
 
High content analysis also known as high content screening or visual screening is a 
method based on sophisticated and automated image analysis in a fluorescence-stained cell. 
This method can detect cellular phenotypic changes and quantify them using fluorescence 
staining of cells which leads to different fluorescence strength and thereby different cellular 
changes. 
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Empty 
Phospho-tyrosine 
Phospho-serine/threonine 
 
Figure 13 A 96-well plate layout used for HCA. 
 
 
Caco-2 cells were used to investigate the effect of lumiflavin in the short term on global 
phosphorylation using HCA. 7500 cells per well were planted on a 96-well black-walled clear 
bottom plate suitable for fluorescence measurement. Cells were incubated at 37℃ and 5% CO2 
for 24 hours to settle down on the plate. Prepared 40μM lumiflavin-containing DMEM was 
added into cells and all cells were washed in PBS and fixed in 10% formaldehyde at the same 
time.  
For staining with primary antibodies, antibody solutions were prepared in digitonin with 
the different concentrations; the ratio of 1:250 for phospho-tyrosine and 1:100 for phospho-
serine/threonine. After washing cells in PBS twice, 50 ㎕ of antibody solution per well was 
loaded and incubated at room temperature for 1 hour in the dark. For secondary antibody 
solutions, Alexa Fluor 488, anti-mouse secondary antibody for phospho-tyrosine and Alexa 
Fluor 555, anti-rabbit secondary antibody for phospho-serine/threonine, Hoechst and PBS were 
required. The secondary antibodies were diluted in to the ratio of 1:500 and Hoechst was 
diluted in to the ratio of 1:1250 in PBS. Cells were washed twice with 100 ㎕ of PBS. Prepared 
50 ㎕ of secondary antibody solution per well was loaded and incubated at room temperature 
for 30 minutes in the dark. Then, after washing twice with PBS again, cells were stored in 
100 ㎕ of PBS, covered the plate with a sticker and foil to keep cells wet and in the dark. The 
plate was stored at 4℃ fridge until analysed. Analysis was requested to Imagen Biotech in 
Manchester, UK. 
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2.2.14.  Purification of phosphoproteins 
 
Phosphorylated proteins are bound with high specificity to phosphoprotein purification 
resin, while unphosphorylated proteins flow through the resin. And phosphoproteins bound to 
the resin are eluted and purified. This process thus amplifies the signals of phosphoproteins.  
 
Preparation for reagents provided in the kit 
875 ㎕ CHAPS stock solution (10% [w/v]) was added to 35ml of phosphoprotein lysis 
buffer to yield ad final concentration of 0.25% (w/v) CHAPS in lysis buffer. One protease 
inhibitor tablet and 10 ㎕ of Benzonase Nuclease stock solution were added to a 5ml aliquot 
of lysis buffer containing CHAPS. Then phosphoprotein lysis buffer was ready. 75 ㎕ Triton X-
100 (10% [w/v]) was added to 3ml of phosphoprotein elution buffer.  
 
Cell lysis 
Cell lysis was performed at 4℃. Cell pellets were washed with HBSS and resuspended 
corresponding to 10×106 cells in 5ml of lysis buffer. The cell suspension was incubated at 4℃ 
for 30 minutes, vortexing briefly every 10 minutes. Then it was centrifuged down at 10,000 xg 
and 4℃ for 30 minutes. During centrifugation, phosphoprotein purification column was 
prepared by detaching the top cap, breaking off the bottom closure, and slowing the storage 
buffer to flow out. 4ml lysis buffer was applied to equilibrate the column and allowed to flow 
out. When finished centrifugation, the supernatant was taken and the protein concentration 
was determined. It was taken the volume of cell lysate containing approximately 2.5mg of total 
protein. Then, protein concentration was adjusted to 0.1mg/ml by adding lysis buffer to yield 
the final volume of 20ml cell lysate.  
 
Columning 
Half of the cell lysate was loaded into the upper reservoir of the column. When almost 
all lysate had entered the gel bed, the rest of lysate was added and allowed enough time to 
complete binding of any phosphorylated protein to the affinity column. 6ml of lysis buffer was 
applied to wash the column and allowed to flow through. Collection tubes were ready under 
the column. 500 ㎕ of elution buffer was applied to the column and the eluted fraction was 
collected. Elution process was repeated six times and the each eluted fractions were separately 
collected into six tubes. Each eluted fractions were determined for protein concentrations. 
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10 ㎕ of each eluted fraction was loaded into a 10% SDS-PAGE gel and the different amount of 
purified phosphoprotein in each eluted fraction was visualised using Pro-Q Diamond 
phosphoprotein stain. The rest of eluted tractions were stored at -80℃ until used for 
concentration by centrifugal filtration. 
 
 
2.2.15.  Staining with Pro-Q Diamond phosphoprotein and SYPRO® ruby 
 
In order to confirm purified phosphoproteins, pooled eluted fraction, flow through 
fraction and cell lysates were stained on the SPS-PAGE gel with Pro-Q Diamond 
phosphoprotein stain and also SYPRO® ruby for total protein. PeppermintStickTM 
phosphoprotein molecular weight standards were also loaded to the gel, provided in the 
Multiplexed Proteomics® Phosphoprotein gel stain kit. The standards served both as molecular 
weight markers and as positive and negative controls. 
 
Pro-Q Diamond phosphoprotein gel stain provides a method for selectively staining and 
detecting phosphate groups attached to tyrosine, serine, or threonine residues without the 
need for antibodies. SYPRO® Ruby protein gel stain is a total protein stain which is highly 
sensitive lumiscent staining. According to the instruction, determining the ratio of Pro-Q 
Diamond dye to SYPRO® Ruby dye signal intensities for each band provides a measure of the 
phosphorylation level normalised to the total amount of protein. 
 
ProQ-Diamond phosphoprotein gel stain 
Fix solution of 50% methanol and 10% acetic acid and destain solution of 20% 
acetonitrile, 50mM sodium acetate, pH4.0 were prepared. To prepare 1L of destain solution, the 
followings were combined and mixed thoroughly; 50ml of 1M sodium acetate, pH4.0, 750ml of 
ddH2O and 200ml of acetonitrile.  
The gel was fixed in about 100ml of fix solution and incubated at room temperature with 
gentle agitation for at least 30 minutes, and fixation step was repeated once more to ensure 
that all of the SDS was washed out of the gel. Then, the gel was washed in about 100ml of 
ddH2O with gentle agitation for 10 minutes to remove all of the methanol and acetic acid from 
the gel. The washing step was repeated twice more. The gel was stained by being incubated in 
50ml of Pro-Q Diamond phosphoprotein gel stain, whose volume was equivalent to 10 times 
the volume of the gel with gentle agitation in the dark for 80 minutes. Then, to destain the gel, 
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it was incubated in 80ml of destain solution with gentle agitation for 30 minutes at room 
temperature in the dark. This step was repeated two more times, and then the gel was washed 
twice in ddH2O at room temperature for 5 minutes per wash. The stained gel was visualised 
using Typhoon 9400 (Amersham Biosciences) with excitation at 532nm laser and emission at 
560nm longpass  
 
SYPRO® Ruby protein stain 
Wash solution of 10% methanol, 7% acetic acid in ddH2O was prepared. This stain was 
performed with the gel which was used for phosphoprotein stain, thus fixation and washing 
steps were skipped. The gel was rinsed twice in ddH2O for 5 minutes each, and then incubated 
in 60ml of SYPRO® Ruby gel stain at room temperature overnight with gently agitation, 
protected from light. Afterwards, the gel was transferred to a clean container and washed in 
about 100ml of wash solution for 30 minutes. Before imaging, the gel was rinsed in ddH2O two 
times for 5 minutes each. Proteins were visualised using the imager Typhoon 9400 with an 
excitation at 457nm and an emission at 610nm blue laser 
 
 
2.2.16.  Sample concentration by filtration 
 
The Millipore spin columns with 3K molecular weight cut off membrane were used to 
concentrate the eluted fractions of phosphoprotein. Samples were buffer-exchanged by 
repeated addition of 1M TEAB which is iTRAQ buffer to remove Qiagen elution buffer. This is 
also an important step to clean up an ionizing contaminant that has caused problems with 
downstream of mass spectrometry analysis. 
 
The filter device was inserted into the provided microcentrifuge tube and pre-rinsed 
three times with 0.5ml of ddH2O and spun down at 14,000xg for 10 minutes to remove the 
glycerol which was contained on the filter membrane. When checked liquid level and just 
above 50 ㎕, the liquid in the tube was discarded and further 0.5ml ddH2O was added and 
spun down.  
 
Four eluted fractions from second to fifth eluted fractions were filtered in two filter 
devices, and then combined and concentrated in one filter device to be pooled altogether. 
After pre-rinsing the filter device, up to 500 ㎕ of sample was added into the filter device. 
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Capped filter device was placed into the centrifuge rotor, aligning the cap strap toward the 
center of the rotor, and then centrifuged at 14,000xg and 4℃ for 30 minutes, checking the 
remaining liquid volume in the filter device every 10 minutes to prevent overspin that may 
lead to dry out the membrane. Then, for buffer exchange, 0.5ml of 1M TEAB buffer was added 
and centrifuged at 14,000xg and 4℃ for 15 minutes and this step was performed total four 
times. The concentrates in the two filter devices were combined to pool all eluted fractions and 
centrifuged at the same speed for 30 minutes. To recover the concentrated solute, the filter 
device was placed upside down in a clean microcentrifuge tube, and the tube was placed in 
the centrifuge, aligning open cap towards the center of the rotor. Then, it was centrifuged at 
1,000xg and 4℃ for 2 minutes and the concentrated phosphoprotein was collected into a fresh 
tube. An aliquot of it was used to determine the protein concentration and to run on the SDS-
PAGE gel with Coomassie® blue staining to ensure adequate phosphoprotein concentration. 
The rest was stored at -80℃ until used for trypsin digestion. 
 
 
2.2.17. Coomassie® blue stain 
 
After electrophoresis to run protein on SDS-PAGE gel, the gels were transferred to the 
InstantBlue staining solution and incubated at room temperature overnight with constant 
agitation, protected from light. Approximate 20ml of the solution was used to ensure enough 
to cover the gel. Then, the gel was rinsed four times in ddH2O, and taken the images.  
 
 
2.2.18.  Isobaric tag for relative and quantitation (iTRAQ)  
 
 
2.2.18.1. Trypsin digestion 
 
TCEP which is a reducing agent to break disulfide bonds within and between proteins 
was prepared, diluting 500mM stock of TCEP in to the ratio of 1:10 with 1M TEAB buffer. 
MMTS which is an alkylating reagent that reversibly blocks cysteines and other sulfhydryl 
groups was prepared, diluting 10M stock MMTS with the ratio of 1:50 with isopropanol. Trypsin 
that contains 20μg in a vial was prepared, adding 5 ㎕ of trypsin resuspension buffer, which 
was 50mM acetic acid, and 35 ㎕ of 1M TEAB buffer to a vial.  
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Phosphoprotein volumes were calculated to take 85μg. Due to varying volume of each 
sample, the final volume was filled up to 20 ㎕ with 1M TEAB buffer. Then, 2 ㎕ of 20mM TCEP 
was added to the sample, vortexed well, spun down and incubated for 1 hour at 60℃. 
Afterwards, 1 ㎕ of 200mM MMTS was added to a sample, vortexed well, spun down and 
incubated at room temperature for 10 minutes. An aliquot equivalent to 5μg protein was taken 
and stored at -20℃, and it was run on the gel later to show ‘non-digested proteins’. Then, 
samples were trypsin-digested at 1:20 ratio (4μg trypsin to 80μg protein) at 37℃ overnight. An 
aliquot equivalent to 5μg protein was taken to be run on the gel for ‘digested sample’. The 
rests were stored at -80℃ until labelling. The aliquots taken for ‘non-digested’ and ‘digested 
samples’ were run on 10% SDS-PAGE gel and stained with Coomassie® blue for overnight at 
room temperature with constant agitation, protected from light.  
 
 
2.2.18.2. Labelling  
 
Peptides were labelled as shown in Table 4, using iTRAQ reagent 8PLEX Multi-plex kit 
(AB Sciex). Reagents tubes were spun down to make sure the yellow liquids were in the bottom 
of the tubes. 100 ㎕ of isopropanol was added to each tube and mixed well and spun down to 
recover the contents. All content in one tube was taken at once and transferred to one sample. 
It was then mixed well, spun down and incubated at room temperature for 2 hours in the dark. 
The samples were stored at -80℃ until used for fractionation. 
 
Table 4 Samples abbreviation and iTRAQ label 
Treatment details iTRAQ label 
Exp49. 0h 113 
Exp50. 0h 116 
Exp49. 6h C 114 
Exp50. 6h C 117 
Exp49. 6h LF 115 
Exp50. 6h LF 118 
Exp50. 24h C 119 
Exp50. 24h LF 121 
Exp, experiment; h, hours; C, control; LF, lumiflavin 
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2.2.18.3. HILIC fractionation  
 
Labelled 8 samples were combined and vacuum-concentrated. The combined peptides 
were fractionated using high resolution Hydrophilic Interaction Liquid Chromatography (HILIC)-
HPLC. Fractionation was performed on an Agilent 1100-series HPLC (Agilent, Berkshire UK), 
coupled to a PolyHYDROXYETHYL-A (5μm particle size, a column dimension of 200mm, 4.6mm 
ID, 200Å pore size, PolyLC) analytical HILIC column. This was carried out by Dr. Caroline Evans 
in the department of chemical and biological engineering at University of Sheffield. The 
column was run for 60 minuetes at a flow rate of 0.5ml/min with HILIC transfer buffer A: 80% 
acetonitrile, 10mM ammonium formate, pH 3.0 to remove salts, TCEP and unincorporated 
iTRAQ reagent. Peptides for analysis were eluted using a 30 minutes elution gradient with 
increasing HILIC buffer B (HILIC: 5% acetonitrile, 10mM ammonium formate, pH 5.0, 0.5ml/min) 
from 0-60% buffer B (from 10-40 minutes), followed by 60-100% buffer B (5minutes) and 100% 
buffer B (10 minutes) at a flow rate of 0.5ml/min. The column was isocratically washed in buffer 
B for another 5 minutes, and then re-equilibrated in 100% transfer buffer A until 66 minutes. 
Chromatography was monitored at 280nm using an Agilent 1100 ultraviolet detector module 
and Chromeleon software v.6.50 (Dionex, LC Packing, The Netherlands). 67 fractions were 
collected in LoBind tubes in 1 minute intervals and concentrated by a vacuum centrifugal dryer. 
Then, they were stored at -80℃ until used for sample desalting.  
 
 
2.2.18.4. Sample desalting  
 
Sample desalting was performed using UltraMicrospin columns (The NEST group) and 
buffers; buffer A (97% H2O and 0.1% formic acid), buffer B (97% acetonitrile and 0.1% formic 
acid) and buffer C (3% acetonitrile and 0.1% trifluoroacetic acid). 100 ㎕ acetonitrile was added 
to a column inserted to a tube without bubbles in a column, and spun down at 100xg for 10 
seconds. Acetonitrile in the column was washed out twice with 100 ㎕ HPLC grade H2O by 
centrifugation at 100xg for 30 seconds. During second washing, 100 ㎕ buffer C was loaded to 
dried sample, mixed well and pulsed. Dissolved sample in buffer C was added into columns 
and spun down at 100xg for 30 seconds. Then, buffer A was added to the column and 
centrifuged at 100xg for 30 seconds and this step was repeated so to be total two washings. 
The column was transferred to a fresh and labeled LoBind tube, and 50 ㎕ buffer B was added 
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and spun down at 200xg for 30 seconds. Another 50 ㎕ buffer B was added and pressed down 
by pipetting to allow buffer B to go through the column. Thus, desalted sample was collected 
in a LoBind tube and dried in vacuum centrifugal dryer for approximately 4 hours. 
 
 
2.2.18.5. Mass spectrometry  
 
Mass spectrometry was performed using a Q-STAR XL Hybrid ESI Quadrupole time-of-
flight tandem mass spectrometer (ESI-qQ-TOF-MS/MS) (Applied Biosystems; MDS-Sciex) 
coupled to an online Ultimate 3000 nano-LC system (Dionex, LC Packings, The Netherlands). 
These were carried out by Dr. Caroline Evans in the department of chemical and biological 
engineering at University of Sheffield. Each vacuum-dried peptide fractions were re-dissolved in 
loading buffer (0.1% formic acid and 3% acetonitrile), injected and captured into a 300μm ID 
C18-PepMap trap column. Trapped samples were then eluted to a 15cm, 75μm ID C18-PepMap 
analytical column. The LC gradient was with 3% buffer B (0.1% formic acid and 97% acetonitrile) 
and 97% buffer A (0.1% formic acid and 3% acetonitrile) for 3 minutes. Then, a 90-minutes LC-
MS/MS gradient program with 3-30% buffer B was followed. The mass spectrometer was set to 
acquire data with a selected mass range of 300-2000m/z. 3 seconds summation of MS/MS 
scan was followed with pre-selection for peptides with +2 to +4 charge states. The two most 
abundantly charged peptides above a five count threshold were selected for MS/MS, and 
dynamically excluded for 60 seconds with a ±50mmu mass tolerance (Glen et al., 2010).  
 
 
2.2.18.6. Protein identification and relative quantification 
 
MS/MS data generated from the QSTAR® XL was converted to MGF peaklists using Analyst QS 
v. 1.1 (Applied Biosystems, Sciex; Matrix Science). Swiss-Prot and Trembl Homo sapiens protein 
database (41070, 71449 ORFs respectively) were downloaded from UniProt, (April, 2013). Then 
peptide sequence and hence protein identification were performed using an in-house Phenyx 
algorithm cluster (binary version 2.6; Genebio Geneva Bioinformatics SA) at the ChELSI Institute, 
the University of Sheffield and ProteinPilot Software v2.0 (Applied Biosystems; MDS Sciex). 
Protein quantification was done using uTRAQ v4.0 which is an iTRAQ-based protein 
quantification software. Proteins were quantified by determining the iTRAQ reporters’ 
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intensities for peptides, thus producing protein fold changes. Median correction was applied 
for bias normalization. Protein fold change was analysed statistically using SignifiQuant v4.0 in 
a paired comparison way to determine alteration in protein level among samples. In order to 
assess significant pathways altered by an exposure to lumiflavin, overrepresentation analysis by 
a pathway database, Reactome v45 was carried out, using UniProt accession number of 
proteins showing a significant fold change compared with controls. 
 
 
2.2.19.  Cell cycle analysis by flow cytometry 
 
Caco-2 cells were treated with 40μM lumiflavin for 6, 24, and 48 hours, and time 0 hour 
and time-controls were set with 2% (v/v) of 0.1M NaOH in DMEM. Cell were harvested by 
trysinisation and splitted into single cells by repeated pipetting. Cells were washed with PBS 
twice. Pelleted 0.2×106cells were fixed in 1ml of ice cold 70% ethanol by adding drop by drop, 
then fixed cells in ethanol were stored at -20℃ until analysed. Cell samples were prepared in 
three replicates. 
Fixed cells were transferred to microtubes and washed in PBS twice. After centrifugation, 
supernatant was removed, leaving cell pellet. Then, 0.5ml of PI/RNase staining solution was 
added to cell pellet, and incubated for 30 minutes at room temperature, protected from light. 
Stained cells were analysed using BD LSR II Flow cytometer with 488nm excitation and a 
660/20 bandpass filter for emission. Data analysis was run by BD FACSDiva 7.0. 
 
 
2.2.20.  Statistical analysis  
 
Statistical analyses were carried out using SPSS 20.0 statistical software for Windows. 
Data were examined for distribution characteristics using Shapiro-Wilk and Kolmogorove-
Smirnov tests. Depending on the distribution of data, parametric test or non-parametric tests 
were selected. Data for cell growth, clonogenic assay, ROS and global phosphorylation by 
western blot and HCA were not normally distributed, and therefore, these variables were 
analysed using the non-parametric ANOVA, Kruskal-Wallis test. Duncan post hoc test using a 
rank or Dunnett T3 post hoc test using a rank were followed depending on the raw data 
homogeneity. A comparison of normal and lumiflavin-treated cells on intracellular flavin 
concentrations and GRAC was determined using one-way ANOVA followed by the Duncan post 
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hoc test. For analysis of intracellular ATP concentration and cell cycle analysis by flow 
cytometry, two-way ANOVA was used since the comparison involved two independent factors 
such as treatment and more than one time point. When a significant interaction between 
treatment and incubation time was found, one-way ANOVA followed by post-hoc test was 
performed to determine the effect of each treatment over incubation time and t-test was used 
for comparison of treatment. The results were considered significant if P-values were <0.05.  
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3.1. Introduction  
 
Nakano et al. developed a human intestinal cell model of riboflavin depletion culturing 
Caco-2 cells in riboflavin-free medium containing dialysed foetal calf serum (FCS) (Nakano et 
al., 2011). Developing the model was costly and also time-consuming. The cells required 3~4 
passages to achieve riboflavin depletion, exposing the cells to gradual reductions from a 
physiological level of riboflavin to severely depleted level. Furthermore, dialysation of FCS may 
lead to a depletion of other essential nutrients which may influence cell cycle progression.  
 
This study was therefore conducted to develop an improved model of intestinal 
riboflavin depletion, using lumiflavin, a structural analogue of riboflavin. As introduced in 
section 1.1.5.1, there are several reports in the literature that lumiflavin has an inhibitory effect 
on the uptake of riboflavin into cells, competitively saturating the riboflavin transporter (Said 
and Ma, 1994; Yonezawa et al., 2008; Yamamoto et al., 2009; Said et al., 2000). Lumiflavin 
specifically targets riboflavin interrupting uptake of riboflavin into cells. Furthermore, we 
expected that this would obviate the need for multiple cell passages and the need for dialysed 
FCS. 
 
Three intestinal cell lines; Caco-2, HCT116 and HT29 were used for this study in order to 
provide robust data for the effects of riboflavin depletion. All the cell lines are derived from 
human colon carcinoma, nevertheless they have been extensively used as a cell model to study 
the absorptive properties of the intestinal epithelium (Thomson et al., 1997; Yonezawa et al., 
2008; Hayashi et al., 2007). Indeed, Caco-2 cells have been a useful tool to investigate uptake 
of nutrients, as the cells behave like duodenal epithelial cells of small intestine (Said and Ma, 
1994; Zielinska-Dawidziak et al., 2008). Human riboflavin transporters have recently been 
identified and characterised using Caco-2 cell lines (Yonezawa et al., 2008), showing further 
validity to the use of this cell line as a model of human riboflavin depletion. Thus, the three 
intestinal cell lines were used to develop cell models of riboflavin depletion and they were 
compared with each other in terms of their proliferative ability and cellular riboflavin status in 
response to lumiflavin treatment. 
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3.2. Aims  
 
The overall aim was to develop and validate de novo human intestinal cell models of 
riboflavin depletion using lumiflavin. 
 
 
3.3. Methods 
 
 
3.3.1. Cell growth 
 
To identify an appropriate range of lumiflavin concentration, a preliminary experiment 
was performed using the Caco-2 cell line. After settling down on a culture plate for 24 hours 
after seeding, cells were incubated in 0.1, 0.5, 1, 10, 100, 200 and 500μM lumiflavin-containing 
DMEM for 24, 48, and 72 hours. Cells were harvested and the cell numbers were counted daily. 
Then, three intestinal cell lines; Caco-2, HCT116 and HT29 were treated with 10, 25, 40, 60, 75, 
90 and 100μM lumiflavin-containing DMEM for 24, 48 and 72 hours. Cell numbers then were 
counted daily. 
 
 
3.3.2. Intracellular flavin assay 
 
Intracellular riboflavin, FAD and FMN concentrations were determined using reverse-
phase HPLC as explained in section 2.1.4. For the assay, 40 and 80μM were chosen according 
to the findings for cell growth. Thus, the three intestinal cell lines were treated with 0, 40 and 
80μM lumiflavin-containing DMEM for 48 hours. Calculated flavins concentrations were 
corrected for protein concentrations. 
 
 
3.3.3. Glutathione reductase activation coefficient (GRAC) 
 
GRAC was determined using a modified method of erythrocyte GRAC which is a well-
established functional measure of riboflavin status (Powers, 1999; Hill et al., 2009). GRAC is the 
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ratio of stimulated : basal activity of glutathione reductase. Higher GRAC indicates less 
endogenous FAD. A value of >1.3 GRAC is conventionally considered to reflect poor riboflavin 
status in human studies (Powers, 1999). The three intestinal cell lines were treated with 0, 40 
and 80μM lumiflavin-containing DMEM for 48 hours, and then cells were harvested and GRAC 
determined as explained in section 2.2.5.  
 
 
3.3.4. Statistical analysis 
 
Data for cell growth were analysed using Kruskal-Wallis and Duncan post hoc test using 
a rank for the difference of cell numbers at 72 hours among treatments with various 
concentrations of lumiflavin. Data for intracellular flavin concentrations and GRAC were 
analysed using one-way ANOVA followed by the Duncan post hoc test for a comparison of 
normal and lumiflavin-treated cells. The results were considered significant at P<0.05. 
 
 
3.4. Results  
 
 
3.4.1. Effects of lumiflavin on cell growth 
 
As shown in Figure 14, there was a notable difference between the first group; 0 to 1μM 
and the second group; 100 to 500μM. At low concentrations of lumiflavin such as 0.1~10μM, 
cell growth was not significantly affected. Caco-2 cells showed arrested cell growth when 
exposed to  100μM lumiflavin. Cells were unable to survive at very high concentrations of 
lumiflavin; 200 and 500μM. Therefore, concentrations of lumiflavin for the main experiments 
used between 10 and 100μM.  
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Figure 14 Preliminary experiment for cell growth in Caco-2 cells treated with 
lumiflavin in a range of 0 to 500μM. 
Data are presented for a single experiment which was performed in triplicate. Data are expressed as 
mean±(SEM) 
 
 
Growth curves for the three cell lines treated with lumiflavin over the range of 0 to 
100μM are presented in Figure 15. Cell growth was inhibited by lumiflavin in all three cell lines, 
in a concentration-dependent manner. Kruskal-Wallis test showed a significant difference 
among treatments with lumiflavin in Caco-2 (P<0.05 at each incubation time), HCT116 and 
HT29 (P<0.01 for 48 and 72 hours incubation). In Caco-2 cells, lumiflavin at a concentration of 
60μM or greater led to a lower cell number than 0 to 40μM after only 24 hours (P<0.05, 
Duncan post-hoc test using rank) and effects were sustained. In HCT116 cells, lumiflavin at a 
concentration of 75μM or greater led a reduction in cell numbers from 48 hours, compared 
with lower concentrations (P<0.05, Duncan post-hoc test using rank), and this effect was 
sustained. In HT29 cells lumiflavin at a concentration of 60μM or above led to a reduction in 
cell number from 48 hours, compared with lower concentrations (P<0.05, Duncan post-hoc test 
using rank) and this effect was sustained. 
In summary, 40μM lumiflavin led to a 40% decrease in cell numbers in HCT116 and 
HT29 cells and 25% decrease in Caco-2 cells by 48 hours. This effect increased to a 50% 
decrease by 72 hours in all three cell lines. Cell growth was arrested by ≥75μM lumiflavin in 
HCT116 cells and by ≥60μM in Caco-2 and HT29 cells. Therefore, 40 and 80μM were selected 
for the next experiments. 
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A 
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C 
 
Figure 15 Cell growth in the three intestinal cell lines treated with lumiflavin in 
a range of 0 to 100μM. 
Data obtained from three independent experiments in three replicates and expressed as mean (±SEM). 
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3.4.2. Effects of lumiflavin on intracellular flavins concentration 
 
Intracellular riboflavin, FMN and FAD concentrations were determined by HPLC in cells 
treated with 0, 40 and 80μM lumiflavin for 48 hours. The data are presented in Figure 16. 
 
Intracellular riboflavin concentrations were significantly decreased in Caco-2 (P=0.002) 
and HT29 cells (P<0.001) by lumiflavin, compared with untreated cells, in a concentration-
dependent manner. Untreated HT29 cells had 1.5~2 fold higher concentration of intracellular 
riboflavin compared with the other two cell lines. Mean intracellular FAD concentrations 
showed a progressive fall with increasing lumiflavin concentrations, however effects were not 
statistically significant. In contrast, intracellular FMN concentrations were unchanged by 
exposure to lumiflavin, in all cell lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3. Development of intestinal cell models of riboflavin depletion 
72 
 
 
 
 
Figure 16 Effects of lumiflavin on intracellular flavins concentrations 
determined by HPLC. 
After incubation of cells with lumiflavin for 48 hours, cells were harvested and lysed. Flavin concentrations 
were measured in cell lysates and corrected for differences in protein concentration. Data are shown as 
mean (±SEM) from three independent experiments. One-way ANOVA showed a significant effect of 
treatment on the concentration of riboflavin in Caco-2 (P=0.002) and HT29 cells (P<0.001). * Significantly 
different (Duncan post hoc test) P<0.05. 
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3.4.3.  Effects of lumiflavin on glutathione reductase activation coefficient 
(GRAC) 
 
Glutathione reductase activation coefficient (GRAC) was determined in cells exposed to 0, 
40 and 80μM lumiflavin for 48 hours. This value is inversely related to riboflavin status. 
 
As shown in Figure 17, all three cell lines showed a significant increase in GRAC, in a 
concentration-dependent manner. The degree of increase in GRAC was higher in Caco-2 cells 
than in other two cell lines.  
A value of <1.30 GRAC reflects poor riboflavin status in human studies (Powers, 1999). 
Although HCT116 and HT29 cells showed significant increase in GRAC, the values were under 
1.30. However, GRAC in Caco-2 cells increased to about 1.50 when cells were exposed to 80μM 
lumiflavin. 
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C 
 
Figure 17 Glutathione reductase activation coefficient (GRAC). 
Cells were treated with lumiflavin for 48 hours, and GRAC was determined by kinetic assay. Data shows 
the mean (±SEM) from three independent experiments; each assay was performed in duplicate. One-way 
ANOVA showed a significant effect of treatment on GRAC in all cell lines; Caco-2 (P=0.001), HCT116 
(P=0.002) and HT29 (P=0.003). * Significantly different (Duncan post hoc test) P<0.05. 
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3.5. Discussion  
 
 
3.5.1.  Effects of lumiflavin on cell growth and intracellular flavins status 
 
The preliminary experiment showed that Caco-2 cells were unable to survive in over 
200μM lumiflavin. It also appeared that lumiflavin in a range of up to 100μM rapidly inhibited 
cell growth after only 72 hours in each of three intestinal cell lines in a concentration-
dependent manner. Nakano et al. (2011) used a protocol which required three passages, 
meaning approximately 10 days to achieve riboflavin depletion, associated with an arrest in cell 
growth. Therefore, compared with their model, the lumiflavin-based cell model showed a more 
rapid inhibition of cell growth. This suggests that lumiflavin competed effectively for sites on 
riboflavin transporters, consequently leading to its effect on cell growth.  
 
Intracellular riboflavin concentrations were decreased by lumiflavin in Caco-2 and HT29 
cells, in a concentration-dependent manner by 48 hours. An in vitro study investigated effects 
of lumiflavin on riboflavin uptake into Caco-2 cells (Said and Ma, 1994). Caco-2 cells were 
incubated with lumiflavin-containing growth medium at different concentrations for 48 hours. 
Riboflavin uptake into cells was decreased to 6.4, 3.87 and 1.94pmole/mg protein·3 minutes by 
0.055, 32 and 97μM lumiflavin respectively. They measured a rate of uptake of riboflavin into 
cells rather than intracellular riboflavin concentration. However, their findings are consistent 
with the results of this study where with the similar experimental condition, in which Caco-2 
cells were exposed to 40 and 80μM lumiflavin. Here, we found that intracellular riboflavin 
concentrations were decreased from 7.51 to 2.95 and 2.39 pmole/mg protein by 0, 40 and 
80μM lumiflavin respectively.  
 
Mean intracellular FAD concentration was decreased by lumiflavin in a concentration-
dependent manner, but it was modest and statistically not significant. All three cell lines 
showed only 20~25% fall in intracellular FAD concentration, whereas a fall of 50% in FAD was 
achieved in Nakano’s model (Nakano et al., 2011). 
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Figure 18 Correlation between GRAC and intracellular FAD concentration. 
Glutathione reductase (GR) is an FAD-dependent enzyme, and the activation coefficient of the enzyme 
indicates saturation of the enzyme with FAD, thus fully saturated GR will show 1.0 of GRAC.  
 
 
There was an inverse relationship between GRAC and intracellular FAD concentrations 
consistent with the literature (Hustad et al., 2002). As seen in Figure 18, the slope for this 
relationship in Caco-2 cells was much steeper than that for the other two cell lines, suggesting 
that GRAC in Caco-2 cells was more sensitive to a reduction in intracellular FAD concentration. 
Glutathione reductase (GR) is an FAD-dependent enzyme, thus the activation coefficient of the 
enzyme reflects actual saturation of the enzyme with FAD. GRAC in erythrocytes (EGRAC) is 
frequently employed to investigate riboflavin deficiency throughout human and animal studies 
(Powers, 1999), thus in this study, the method was adapted in order to identify functional 
riboflavin depletion in cells. The value >1.30 is conventionally considered as biochemically 
functional riboflavin deficiency in humans and animal models of riboflavin deficiency (Powers, 
1999).  
Exposure of each of three cell lines to lumiflavin for 48 hours led to an increase in GRAC. 
HCT116 and HT29 cells exposed to lumiflavin exhibited a modest but statistically significant 
increase in GRAC. In contrast, GRAC increased to over 1.50 in lumiflavin-treated Caco-2 cells 
suggesting a more severe riboflavin deficiency than the other two cell types. Evidently the 
sensitivity of cells to riboflavin depletion is cell-line dependent.  
GRAC values observed in this study ranged from 1.06±0.08 to 1.49±0.02 across the three 
cell types, and this is comparable with erythrocyte GRAC values reported in human studies 
(Bates et al., 2011). This suggests that the cell models of riboflavin depletion may be relevant 
to human populations. 
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Figure 19 Summary of results for intracellular flavin concentration 
Uptake of riboflavin into cells is inhibited by lumiflavin, leading to a fall in intracellular riboflavin 
concentration in Caco-2 and HT29 cells. Not significant fall in intracellular FMN and FAD concentration 
was observed in any of the three cell lines. Increased GRAC was observed in all three cell lines, reflecting 
functional FAD depletion 
 
 
In contrast to riboflavin and FAD, FMN concentrations were unchanged by lumiflavin in 
all three cell lines. According to an animal study of riboflavin depletion, there is an efficient 
FAD conservation system (Fass and Rivlin, 1969). FAD is conserved at the expense of FMN as 
the activity of FAD synthetase is elevated, thus FMN is decreased by riboflavin depletion 
compared with control. However, in this study, intracellular FMN concentrations were 
maintained at control values. It is thought there are two possible reasons. The first is that 
exposure to lumiflavin may have been too short (48 hours) for changes in FMN to be effected. 
Nakano et al (2011) showed that a prolonged depletion elicited a fall in intracellular FMN 
concentration in Caco-2 cells whereas a short depletion period did not. The second is that 
lumiflavin may interfere with the conversion of FMN to FAD by influencing the activity of FAD 
synthetase. This requires further investigation. Alternatively, investigation of effect of lumiflavin 
on ATP status may support the reason since the enzymes are ATP-dependent (Oka and 
McCormick, 1987), which will be addressed in the next chapter where determines changes in 
`intracellular ATP concentration. 
 
Taken together so far, lumiflavin resulted in a modest decrease in the flavin pool, a 
significant fall of intracellular riboflavin concentration, and this was associated with a significant 
reduction in cell growth.  
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3.6. Summary 
 
The study was performed to develop a human intestinal cell model of riboflavin 
depletion using lumiflavin, a structural analogue of riboflavin. Cell growth was determined in 
three human epithelial cell lines; Caco-2, HCT116 and HT29 cells, exposed to lumiflavin over 
the range of 10 to 100μM for up to 72 hours. To confirm riboflavin depletion of the cells, 
intracellular flavin concentrations and GRAC were determined in the three cell lines exposed to 
40 and 80μM lumiflavin for 48 hours. 
 
Cell growth was rapidly inhibited in all three cell lines, in a concentration-dependent 
manner within 72 hours. Riboflavin depletion was confirmed through a significant decrease in 
intracellular riboflavin concentration in Caco-2 and HT29 cell lines and a significant increase in 
GRAC in all three cell lines. 
Intestinal cell models of riboflavin depletion by lumiflavin have been developed and 
established. The next step of this project aimed to characterise the models in terms of various 
measures of cell function.  
  
 
 
 
 
 
 
 
 
 
CHAPTER 4  
CHARACTERISATION OF INTESTINAL CELL MODELS 
OF RIBOFLAVIN DEPLETION 
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4.1. Introduction 
 
 
Three intestinal epithelial cell lines were examined for their functional characteristics in 
response to riboflavin depletion induced by lumiflavin. Manthey et al.(2006) suggested tissue-
specific sensitivity of cells for developing riboflavin deficiency. Jurkat lymphoid cells were 
resistant to severe riboflavin deprivation (0.85 nmole/L) for 5 weeks (Camporeale and Zempleni, 
2003), whereas HepG2 liver cancer cells developed signs of riboflavin deficiency after only 4 
days in moderately riboflavin-deficient medium (3.1 nmole/L of riboflavin) (Werner et al., 2005). 
Caco-2 intestinal cells seem to be more resistant to riboflavin depletion compared with HepG2 
cells. Nakano et al (2011) found that growing Caco-2 cells in moderately riboflavin deficient 
medium (3.2 nmole/L) for 7days after 4days in a medium containing a physiological 
concentration of riboflavin led to a significant reduction in flavin concentration together with 
altered expression of genes that play a role in mitosis leading to cell cycle arrest in mitosis 
(Nakano et al., 2011). Nakano et al. (2011) suggested efficient flavin conservation mechanisms 
existed in Caco-2 cells to prevent developing riboflavin deficiency. This might be related to a 
different expression of riboflavin transporters in different tissues (Yonezawa and Inui, 2013) or a 
different distribution of riboflavin metabolising enzymes in different tissues (Stipanuk, 2013). 
However, others have not examined differences among cell lines derived from the same 
tissue type, even though studies of enterocytes have used several types of intestinal cell lines 
such as Caco-2, HCT116 and HT29 cells (Zielinska-Dawidziak et al., 2008; Thomson et al., 1997; 
Hayashi et al., 2007). Therefore, studies described here may reveal a different sensitivity of 
three intestinal cell lines to riboflavin depletion, thus providing a robust model showing a 
stronger case for any effects observed in a single cell line in the same tissue type. 
 
Riboflavin is important in ATP generation mechanisms because it plays a role as a 
cofactor for enzymes involved in ATP generating reactions. For instance, as described in 1.1.1.4, 
succinate dehydrogenase catalyses the oxidation of succinate to fumarate using FAD as an 
electron carrier in the citric acid cycle that is an ATP generating cycle. Riboflavin deficiency 
affects the activity of these enzymes, leading to accumulation of succinate and a reduction of 
ATP synthesis. Feeding a riboflavin-deficient diet to weanling rats for 5 weeks led to an 
increase in succinate and a decrease in fumarate concentration with a fall in ATP concentration 
in liver (Burch et al., 1970), Furthermore, a study using mitochondrial complex I deficient 
fibroblast cells derived from a patient reported that riboflavin improved ATP production to 
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close to normal (Bar-Meir et al., 2001). Another example of redox reactions to which riboflavin 
is related, is the glutathione redox cycle. Reduced glutathione, which is produced by FAD-
dependent glutathione reductase, has been considered as an endogenous antioxidant (Ashoori 
and Saedisomeolia, 2014). Reduced glutathione serves as a substrate for glutathione 
peroxidase which transfers hydrogen from reduced glutathione to peroxides such as lipid 
peroxide or hydroperoxide. Oxidized glutathione is in turn reduced by glutathione reductase to 
recover intracellular antioxidant status. 
Decreased activity of glutathione reductase leads to a fall in reduced glutathione 
concentration (Manthey et al., 2005; Camporeale and Zempleni, 2003), increasing oxidative 
stress through uncontrolled ROS. Culture of human lymphoid cells (Jurkat cells) in riboflavin-
deficient medium (0.85nmol/L of riboflavin) for 5 weeks led to a reduction in the activity of 
glutathione reductase and intracellular reduced glutathione concentration (Camporeale and 
Zempleni, 2003). Riboflavin deprivation for 8 days in human hepatoma cells HepG2 resulted in 
a reduced activity of glutathione reductase and a decrease in reduced glutathione, leading to 
an increase in carbonylated proteins, which reflect oxidative damage  to protein, and DNA 
strand breaks (Manthey et al., 2005; 2006). Therefore, riboflavin deficiency could lead to an 
increased production of ROS and thereby oxidative stress. ROS at physiologically low levels can 
be beneficial to cells through a function as a signal transporter in cell signalling. However 
excessive ROS induces oxidative damage in DNA and proteins, promoting altered regulation of 
cell cycle (Shackelford et al., 2000) and programmed cell death, apoptosis (Circu and Aw, 2010).  
 
We hypothesized that riboflavin depletion induced by lumiflavin will impair intracellular 
ATP status and result in oxidative stress. Furthermore we examined effects of lumiflavin on 
clonogenicity indicating proliferative ability with reversibility, and apoptotic cell death.  
 
 
4.2. Aim 
 
To characterise human intestinal cell models of intracellular riboflavin depletion by 
lumiflavin in terms of specific functional characteristics including intracellular ATP concentration, 
ROS production, clonogenicity and apoptotic DNA fragmentation. 
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4.3. Methods 
 
 
4.3.1. Intracellular ATP assay 
 
Intracellular ATP concentrations were determined using an ATP bioluminescent somatic 
cell assay kit, based on ATP-dependence of firefly luciferase (see section 2.2.6). All reagents and 
apparatus were prepared following the kit instruction. Three cell lines were incubated with 0, 
40 and 80μM lumiflavin for 24, 48 and 72 hours. Then, intracellular ATP concentrations were 
measured daily. ATP concentrations were corrected for differences in cell number by protein 
concentration. All samples were prepared and analysed in triplicate from three independent 
experiments.  
 
 
4.3.2. Measurement of intracellular ROS production 
 
Three intestinal cell lines were pre-incubated in lumiflavin-containing DMEM for 24, 48 
and 72 hours at concentrations of 0, 40 and 80μM. ROS production in the three cell lines after 
incubation with lumiflavin were monitored for up to 4 hours using the DCFDA method as 
described (see section 2.2.7). Fluorescence is directly proportional to the concentration of 
oxidised DCFDA thus indicating the level of ROS produced. The data were corrected for the 
difference in cell numbers (see section 2.2.8). Data presented here obtained from a single 
experiment in triplicate.. Several preliminary experiments to develop the assay were performed 
and the same pattern was observed as presented data, thus data for preliminary experiments 
are not presented. 
 
 
4.3.3. Clonogenic assay 
 
A clonogenic assay can be used to investigate the proliferative ability of cells by 
determining cells’ ability to form colonies, and can provide information about the cytotoxicity 
of lumiflavin and its reversibility. Three intestinal cell lines were pre-incubated with 0, 40 and 
80μM lumiflavin for 24, 48 and 72 hours. Then cells were split and seeded into 6-well plates 
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with low seeding densities, and incubated in lumiflavin-free DMEM until a single cell formed 
the proper size of colony which consists of over 50 cells. Colonies were fixed, stained and 
counted. Absolute clonogenicities were calculated by dividing colony number by seeded cell 
number and multiplying 100. Then, absolute clonogenicities were used to calculate relative 
clonogenicity of lumiflavin-treated cells compared with controls. Data are presented in Figure 
22 as relative clonogenicity. 
 
 
4.3.4. Apoptotic DNA fragmentation assay 
 
As it had been found that exposure to lumiflavin resulted in inhibition of cell growth, 
experiments were conducted to confirm whether this resulted from cell growth arrest or 
increased cell death through apoptosis. Apoptotic DNA fragments detection kit can also 
determine necrotic cell death.  
For the apoptotic DNA assay, the three intestinal cell lines were incubated with 0, 40 and 
80μM lumiflavin-containing DMEM for 48 hours. Then, floating cells in the used media were 
collected and adherent cells were harvested. DNA in detached and adherent cells were 
extracted and visualised as described (see section 2.2.11). Sodium butyrate-treated cells were 
used for a positive control. DNA was prepared from three independent experiments. The 
volume of extracted DNA loaded into a gel was adjusted in the second and third repeats in 
order to avoid too strong signals observed in the first repeat. 
 
 
4.3.5. Statistical analysis 
 
Intracellular ATP concentration was analysed by two-way ANOVA for comparison of two 
factors; treatment and time-course. A main effect of treatment was found in Caco-2 and HT29 
cells and an interaction of two factors in HCT116 cells was found, thus one-way ANOVA was 
used to determine the effect of each treatment at each experimental time point. Intracellular 
ROS concentrations produced at 240 minutes analysed by Kruskal-Wallis test followed by the 
Duncan post hoc test using a rank to determine the differences in treatments. Data for 
clonogenic assay were not normally distributed, thus Kruskal-Wallis test was used followed by 
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Dunnet T3 post hoc test using ranking, for a comparison of relative clonogenicity among 
treatment and incubation time. The results were considered significant at P<0.05. 
 
 
4.4. Results 
 
Lumiflavin-based intestinal cell models of riboflavin depletion were investigated for 
specific functional characteristics. Intracellular ATP concentration, intracellular ROS production, 
clonogenicity and apoptosis were measured.  
 
 
4.4.1. Effects of lumiflavin on intracellular ATP concentration 
 
The main effect of lumiflavin treatment was on intracellular ATP concentration, in Caco-2 
cells (P<0.001), HCT116 cells (P<0.001) and HT29 cells (P=0.019) and a significant effect of 
incubation time in HCT116 cells (P=0.012). There was no interaction between treatment and 
incubation time in any cell line. 
 
Exposure to lumiflavin resulted in a concentration-dependent decrease in ATP 
concentration of around 13% and 40% in Caco-2 cells exposed to 40 and 80μM lumiflavin 
respectively. ATP concentration in 80μM lumiflavin-treated cells was significantly lower than in 
cells treated with 40μM lumiflavin (Figure 20a). Incubation time did not influence ATP 
concentration.  
Intracellular ATP concentration in HCT116 and HT29 cells was significantly lower in cells 
incubated with 80μM lumiflavin compared with control. The decrease observed was around 28% 
and 23% in HCT116 and HT29 cells respectively. HCT116 cells showed a lower ATP 
concentration after incubation with 80μM lumiflavin for 48 and 72 hours compared with 24 
hours (Duncan post-hoc test at P<0.05).  
The absolute decrease in ATP concentration in cells exposed to 80μM lumiflavin was 
0.36~0.41 and 0.28nmole/mg protein in Caco-2 and HCT116 cells respectively, whereas it was 
about 0.16nmole/mg protein in HT29 cells. Results indicate a different sensitivity of each cell 
line to lumiflavin exposure. 
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Figure 20 Effects of lumiflavin on intracellular ATP status 
Cells were incubated with lumiflavin for 24, 48 and 72 hours and ATP concentration measured using an 
ATP bioluminescent somatic cell assay. ATP concentrations were corrected for differences in protein 
concentration. Data are shown as means (±SEM) for three independent experiments, each conducted with 
four replicates. Two way ANOVA showed a significant effect of lumiflavin in Caco-2 (P<0.001), HCT116 
(P<0.001) and HT29 cells (P=0.019) and of incubation time in HCT116 cells (P=0.012).  
* Significantly lower than control and 40μM lumiflavin (Duncan post-hoc test) P<0.05. 
§ Significantly different from 24 hours (Duncan post-hoc test) P<0.05. 
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4.4.2. Effects of lumiflavin on cellular ROS production 
 
Figure 21 shows the time course of ROS production in three cell lines according to 
lumiflavin treatment. Overall, there was significant increase in intracellular ROS production at 
240 minutes of incubation with 80μM lumiflavin compared with control or 40μM lumiflavin. An 
increase in ROS concentration was observed in all three cell lines, and the effect was greatest 
in Caco-2 cells.  
All three cell lines clearly showed that 80μM lumiflavin resulted in a significantly higher 
concentration of ROS compared with controls and 40μM lumiflavin. Exposure of Caco-2 cells to 
80μM lumiflavin led to a remarkable increase in ROS concentration, showing a time-
dependence; 2, 4.5 and 7 fold ROS concentrations of the control at 24, 48 and 72 hours 
respectively. Exposure to 40μM lumiflavin did not lead to a consistent effect on ROS 
concentration compared with the control.  
Caco-2 cells produced more ROS than the other two cell lines. Caco-2 cells produced 
about 5 to 13-fold and 4 to 5-fold more ROS than in HCT116 and HT29 cells respectively in 
the absence of any lumiflavin. Results implied Caco-2 cells were the most sensitive to lumiflavin 
exposure. 
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Figure 21 Time-course of reactive oxygen species (ROS) production.  
hr: hours. Cells pre-incubated with lumiflavin for up to 72 hours were monitored for ROS production over 
240 minutes as fluorescence using DCFDA. Data were corrected by cell numbers and expressed as means 
(±SEM) from a single experiment conducted in triplicate.  
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4.4.3. Effects of lumiflavin on clonogenicity 
 
Caco-2 cells exposed to lumiflavin showed a highly significant decrease in clonogenicity 
in a concentration-dependent manner but independent on incubation time (P<0.001, Kruskal-
Wallis test). A lot of floating cells were observed after setting up the clonogenic assay. It 
seemed that some of lumiflavin-treated Caco-2 cells were not attached onto a culture plate.  
Clonogenicity of HCT116 was inhibited by only 80μM lumiflavin in a time-dependent 
manner. In comparison with control (0μM), clonogenicity of 80μM lumiflavin-treated HCT116 
cells decreased to about 30, 65 and 70% by 24, 48 and 72 hours pre-incubation respectively 
(P<0.001, Kruskal-Wallis test).  
In contrast, the clonogenic ability of HT29 cells showed a different pattern from the 
other two cell lines. HT29 cells still showed clonogenic ability following pre-incubation in 
lumiflavin. Exposure to 40μM lumiflavin resulted in a small increase in clonognicity compared 
with control.  
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Figure 22 Effects of lumiflavin on clonogenicity. 
LF: lumiflavin. Cells were pre-incubated with lumiflavin for 24, 48 and 72 hours and then grown in normal DMEM until 
colonies of >50 cells were formed. Colonies were stained and counted. Data show mean (±SEM) of three independent 
experiments performed in four replicates. There were significant effects of lumiflavin on clonogenicity in Caco-
2 (P<0.001), HCT116 (P<0.001) and HT29 cells (P=0.008) (Kruskal-Wallis test).  
* Significantly different from control and § 40μM lumiflavin (Dunnett T3 post-hoc test using ranked data, 
P<0.05). 
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4.4.4. Effects of lumiflavin on apoptosis 
 
Three cell lines were incubated with 0, 40 and 80μM lumiflavin for 48 hours or with 
sodium butyrate which was used for a positive control for apoptotic DNA fragments. Dead 
cells which were detached and floating in medium and adherent cells were separately collected. 
Then the apoptotic DNA fragment assay was performed. It is well known that apoptotic DNA 
fragmentation is a key feature of apoptotic cells, thus distinct multiple bands of DNA 
fragments of oligonucleosomal size (180~200 bp lengths) can be imaged using DNA laddering 
assay kit (Bortner et al., 1995). 
 
Figure 23 shows three images of each cell line from three independent experiments. 
Apoptotic DNA fragment was not found in any detached or adherent Caco-2 cells (Figure 23.A). 
Only one case of apoptotic DNA fragment was found in detached dead HCT116 cells 
incubated with 80μM lumiflavin (an arrow of Figure 23.B), showing distinct DNA laddering.  
However, it was not observed in two other repeats. DNA laddering was not found in HT29 cells 
(Figure 23.C). 
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A, Caco-2   
 
 
 
 
 
 
 
 
 
B, HCT116   
 
 
 
 
 
 
 
 
 
C, HT29   
 
 
 
 
 
 
 
 
 
 
Figure 23 Determination of apoptotic DNA 
M; DNA marker, NaB; sodium butyrate, 0, 40 and 80; lumiflavin concentrations (μM). DNA were extracted 
from detached, (dead) cells and adherent cells exposed to sodium butyrate which was a positive control 
of apoptotic DNA fragment, 40 and 80μM lumiflavin. Three images for each cell line show three repeats 
from independent experiments. 
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4.5. Discussion 
 
In order to characterise the intestinal cell models of riboflavin depletion, intracellular ATP 
status, ROS production, clonogenicity and apoptotic DNA were investigated in the three 
intestinal cell lines after incubation with lumiflavin at concentrations of 0, 40 and 80μM for up 
to 72 hours. Such concentrations of lumiflavin were selected because earlier experiments had 
shown gradual inhibition and arrest of cell growth at 40 and 80μM (section 3.4.1).  
 
 
4.5.1. Effects of lumiflavin on intracellular ATP concentration  
 
Intracellular ATP concentrations were significantly decreased at the higher dose of 
lumiflavin in all three cell lines. Effect of lumiflavin on ATP concentration was greater in Caco-2 
cells than the other two cell lines. This finding suggests a different sensitivity to intracellular 
ATP generation in response to lumiflavin, depending on the cell line. 
 
Riboflavin in the form of FAD plays an important cofactor role for enzymes involved in 
ATP-yielding reactions such as succinate dehydrogenase and acyl CoA dehydrogenase. The 
activity of these enzymes is reported to be reduced in riboflavin-deficient animal models 
(Prentice and Bates, 1981b; 1981a; Olpin and Bates, 1982) leading to a decrease in ATP status 
(Burch et al., 1970). Burch et al. investigated changes in ATP concentration in the liver of rats 
fed riboflavin-deficient diet for 5 weeks. They reported riboflavin deficiency caused a 60% 
decrease in liver ATP concentration compared with weight-matched control animals. Consistent 
with these findings, this study showed cellular riboflavin depletion led to a significant fall in 
intracellular ATP in all three cell lines.  
 
The decrease in ATP concentration, reflecting a decrease in the energy status of the 
riboflavin-deficient cells, may limit the process of DNA synthesis and cell division. Sufficient 
energy provision influences DNA synthesis and cell progression through the cell cycle. Previous 
studies showed that an increase in intracellular ATP induced by extraneous stimulation with 
serum was associated with purine biosynthesis in 3T3 fibroblasts (Grummt et al., 1977), and 
stimulated ATP generation by hypoxanthine led to purine biosynthesis, regulating the G1/S 
transition and thereby cell growth (Kondo et al., 2000). Nakano et al. (2011) has shown that 
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severely riboflavin-deficient Caco-2 cells show impaired G2/M transit, and it is thought that this 
might be due, at least in part, to inadequate energy generation. 
 
 
4.5.2. Effects of lumiflavin on intracellular ROS production 
 
ROS production was monitored using the DCFDA probe method. Exposure to 80μM 
lumiflavin resulted in increased ROS production compared with controls in all three cell lines 
and the effects were greatest in Caco-2 cells. Therefore, a higher concentration of lumiflavin 
induced oxidative stress. This may have contributed to observed effects on cell proliferation.  
 
According to the literature, ROS are an important factor in the regulation of cell 
proliferation, playing a role as a signal transporter for cell cycle progression. Indeed, it has 
been reported that inhibition of ROS production induced cell cycle arrest leading to inhibition 
of cell proliferation (Scaife, 2004). ROS production was inhibited using the flavoprotein-specific 
inhibitor, diphenyleneiodonium (DPI) which inhibits the flavoprotein complex NAD(P)H oxidase, 
in various cancer and non-cancer cell lines such as Rat-1 fibroblasts, HepG2 human hepatoma 
cell, MCF-7 breast cancer cell lines. Exposure to DPI led to a block of progression of the cells 
into mitosis with impaired cyclin B1 accumulation which is, as the complex form with cyclin-
dependent kinase 1 (CDK1), required for the formation of mitotic spindle and initiation of 
G2/mitosis transition.  
However, excessive ROS production also inhibits cell proliferation influencing the cell 
cycle checkpoint. Excessive ROS induce oxidative damage in biological molecules including 
DNA and cell cycle checkpoint functions to prevent replication of damaged DNA, thus allowing 
additional time to repair it. (Shackelford et al., 2000). Russo et al. (1995) showed that an 
increase in ROS induced by diethylmaleate (DEM), which depletes the intracellular reduced 
glutathione (GSH), in Saos-2 human osteosarcoma cells and T98G human brain glioblastoma 
cells, , resulted in delayed progression of cell cycle in G1 and S phase and G2/M arrest which 
were mediated by induction of WAF1/CIP1 expression. WAF1/CIP1 family is cyclin-dependent 
kinase inhibitor proteins (CKIs), including p21, p27, and p57 functioning in most of phases of 
the cell cycle. 
 
Several in vitro and in vivo studies showed an association between riboflavin deficiency 
and oxidative stress measured as an imbalance in the glutathione redox cycle, consequently 
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leading to cell cycle arrest and apoptosis. According to Manthey et al (2005; 2006), HepG2 liver 
cells cultured in riboflavin-deficient medium exhibited oxidative stress and associated changes 
that caused cell cycle arrest. They found that riboflavin deficiency was related to a decrease in 
reduced glutathione (GSH). Protein carbonylation which is a product of protein oxidation and 
DNA fragmentation was also observed. Such changes led to G1 phase arrest of the cell cycle 
and an increased proportion of apoptotic cells with an increased expression of gene clusters 
that play a role in cell stress and apoptosis.  
Early-onset apoptosis in intestinal epithelial cells may cause a reduction in the villus 
population and thereby impair the absorptive function of the intestine. A recent animal study 
revealed that riboflavin supplementation rescues intestinal epithelial cells from apoptosis and 
associated changes induced by a chemotherapeutic agent (Bodiga et al., 2012). Riboflavin 
supplementation improved the causes of and sign of apoptosis in intestinal epithelium. For 
instance, supplementation of riboflavin individually or as multivitamin led to a decreased 
incidence of DNA fragmentation which is a key feature of apoptotic cells, a decrease in 
oxidative damage to lipid and protein, an increase in reduced glutathione, and an increased 
Bcl-2/Bax ratio. This suggests a protective effect on apoptosis as Bcl-2 is an anti-apoptosis 
protein and Bax is a stimulator of apoptosis. 
 
Taken together, results show that riboflavin depletion was associated with increased 
oxidative stress, measured as an increased ROS formation in lumiflavin-treated cells. This might 
contribute to the observed effect of lumiflavin on cell proliferation.  
 
 
4.5.3. Effects of lumiflavin on clonogenicity  
 
The effects of lumiflavin on clonogenicity were specific to the cell line. The effect was the 
most pronounced in Caco-2 and least so in HT29 cells. Clonogenicity of HCT116 cells appeared 
to be unaffected by 40μM lumiflavin, however it was decreased by 80μM lumiflavin by about 
30 to 70% of controls in a time-dependent manner. Thus, a high concentration of lumiflavin 
(80μM) in HCT116 cells led to irreversible loss of proliferative ability of the cells.  
 
In Caco-2 cells, lumiflavin resulted in a concentration-dependent loss of colony number 
even by 24 hours. Nakano’s in vitro model showed only a 25% decrease in clonogenicity by 72 
hours. In contrast, Caco-2 cells in this study showed about 50 and 95% decrease by 40 and 
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80μM lumiflavin respectively after only 24 hours. Furthermore, since lumiflavin induced a more 
modest decrease in intracellular flavin concentration than Nakano’s model, the results of 
clonogenic assay in Caco-2 cells may be due to lumiflavin itself rather than riboflavin depletion. 
When the clonogenic assay for Caco-2 cells was set up, although the same number of cells 
was seeded, more floating cells were observed at the higher concentration of lumiflavin. The 
cells seemed to have a problem attaching to the culture plate. Nakano’s model of riboflavin-
deficient Caco-2 cells also showed that the cell number after 24 hours of seeding was 
approximately half (Nakano et al., 2011), indicating half of seeded cells successfully attached to 
the culture plate.  
 
In contrast, clonogenicity of HT29 cells was not affected by lumiflavin. The clonogenic 
assay is used to investigate effects of drugs on cell proliferative ability. Also this approach can 
reveal information about the cytotoxicity of a drug and the ability of cells to recover following 
removal of the drug (Franken et al., 2006). Thus, the fact that clonogenicity was unaffected in 
HT29 may reflects more efficient detoxification. This may be attributable to better uptake of 
riboflavin. Indeed intracellular riboflavin concentration in lumiflavin-untreated HT29 cells was 
approximately two fold higher than in the other two cell lines. Therefore, HT29 cells were less 
affected and thus more resistant to riboflavin depletion induced by lumiflavin treatment. 
 
 
4.5.4. Effects of lumiflavin on apoptosis  
 
DNA laddering assay showed distinct DNA fragments in only one case in floating dead 
HCT116 cells exposed to 80μM lumiflavin for 48 hours, however the finding was not consistent 
throughout three independent experiments. Furthermore, Caco-2 and HT29 cells did not show 
DNA laddering. Therefore, in this study, none of the three intestinal cell models of riboflavin 
depletion induced by lumiflavin showed DNA fragmentation.  
 
This does not necessarily mean that lumiflavin does not cause apoptosis. DNA strand 
breaks occur at a much later time during discrete stages of surface morphological and nuclear 
morphological changes in apoptosis. For this reason, it does not mean that an absence of 
laddering reflects no apoptosis, and thus the possibility of apoptosis cannot be ruled out 
(Collins et al., 1997). Manthey et al. (2006) has reported that severe riboflavin deprivation in 
liver cancer cells led to an increased incidence of DNA strand breaks and increased proportion 
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of cells in apoptosis, accompanying increased expression of genes involved in the apoptosis 
pathway in comparison with riboflavin-sufficient cells.  
Therefore, although no DNA fragmentation was found in the models of intestinal 
cellular riboflavin depletion, it is too early to conclude that there was no association of 
riboflavin depletion with apoptosis. This study observed a reduction in cell growth and a loss 
of clonogenicity in Caco-2 cells exposed to lumiflavin, thus the cells may be undergoing cell 
cycle arrest or an earlier stage of apoptosis prior to DNA strand breaks in the progress of cell 
death. Further studies should be conducted to explore effects of lumiflavin on the cell cycle 
and also the earlier stage of apoptosis or throughout apoptosis pathways. 
 
Finally, different responses to lumiflavin were observed between the three cell lines; for 
instance Caco-2 cells showed the most pronounced effects on intracellular ATP concentration, 
higher ROS production and biggest loss of clonogenicity. In contrast, HT29 cells produced 
negligible effects compared with Caco-2 and HCT116 cell lines. This may reflect differences 
between three cell lines in terms of their efficiency of uptake of riboflavin. As seen in chapter 3 
(see section 3.4.2 and 3.4.3), HT29 cells themselves had a higher intracellular riboflavin 
concentration and lower GRAC than the other two cell lines, probably reflecting a more 
effective riboflavin handling in HT29 cells thereby enabling these cells to protect themselves 
against cellular and biochemical dysfunctions. In contrast to HT29 cells, Caco-2 cells, which 
were the most sensitive to lumiflavin, is thought as the most appropriate cell models to study 
the putative role of riboflavin on cell signalling. 
 
 
4.6. Summary 
 
Riboflavin depletion in intestinal cell models induced by lumiflavin resulted in increased 
oxidative stress and a disruption of energy generation, which may contribute to the observed 
inhibitory effects on cell proliferation. Exposure to lumiflavin did not lead to DNA 
fragmentation, which is a key feature of apoptosis.  
There were different responses to lumiflavin between cell lines and such differences 
between cell lines may be related to differences in functional riboflavin depletion and in the 
efficiency of cells to take up riboflavin.  
  
 
 
 
 
 
 
 
 
 
CHAPTER 5.  
LUMIFLAVIN INDUCED CHANGES IN CELL 
SIGNALLING 
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5.1. Introduction 
 
 
Previous findings in an animal study suggested a role for riboflavin as a signalling 
molecule for intestinal cell proliferation (Yates et al., 2003). They examined the effects of 
luminal absence of riboflavin on intestinal development in weaning rats fed a riboflavin-
deficient diet, but supplied intraperitoneal injection of FMN. Systemic riboflavin status, 
determined using the EGRAC, liver flavin concentration was not different between luminally 
deficient rats and rats fed a complete diet. In spite of systemic riboflavin status maintained as 
much as controls, it appeared impaired gastrointestinal development in luminal riboflavin-
deficient weanling rats. Duodenal crypt hypertrophy associated with an increase in crypt depth 
and cellularity was observed, but crypt cell proliferative index BrdU and crypt bifurcation were 
lower than controls. A reduction in crypt cell proliferation led to a low incidence of crypt 
bifurcation, causing increased cellularity and crypt depth. Such abnormal development can 
affect ensuring villus population. The authors suggested that the binding of riboflavin to an 
apical riboflavin transporter may influence signalling pathways that drive gene expression 
which may be associated with enterocyte proliferation and crypt fission. Thus, it hypothesised 
that riboflavin may act as a signalling molecule, regulating cell proliferation in the lumen.  
 
Based on Yates’ study, the simplified diagram for hypothesis of this study is presented in 
Figure 24. Riboflavin may influence phosphorylation of certain proteins when bound to an 
apical receptor/transporter in the lumen, bringing signalling cascade which may be responsive 
to cell proliferation (see the red box in Figure 24). Lumiflavin more specifically targets to 
riboflavin because it competes for sites on riboflavin transporter thereby inhibits the uptake of 
riboflavin into cells (see section 1.1.5.1), presumably leading to different patterns in cell 
signalling pathways. Therefore, lumiflavin was expected to be a useful tool to reveal a role of 
riboflavin on cell signalling.  
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Figure 24 Diagram of hypothesis based on Yates’ animal model of luminal 
riboflavin depletion 
LF; lumiflavin, p; a phosphate group, RF; riboflavin, RFT; riboflavin transporter. Left side in simplified 
diagram of an intestinal epithelial cell shows the mechanism of regulation of cell proliferation by 
riboflavin transported from lumen as its primary role. Right side shows hypothesised mechanism that 
riboflavin binds to apical riboflavin transporter/receptor, which may affect the phosphorylation of other 
proteins thus bring signalling cascade to regulate cell proliferation (Yates et al., 2003). 
 
 
According to Yates’ study, it assumed that changes due to riboflavin depletion are not 
necessary for developing experimental protocols because riboflavin may independently exhibit 
an effect on cell signalling pathway. Reflecting this point, experimental conditions were 
developed. Indeed, this study showed that higher dose of lumiflavin resulted in several 
dysfunctions on energy generation and oxidative stress, however lower dose i.e. 40μM led to 
effects on cell growth inhibition and a fall in intracellular riboflavin, but not such dysfunctions. 
Following studies therefore were conducted using the concentration 40μM of lumiflavin. 
Additionally, the previous part of this study showed most sensitive responses to lumiflavin in 
Caco-2 cells than HCT116 and HT29. Caco-2 cells exposed to 40μM lumiflavin for a short time 
period (24 hours) showed impaired proliferation without changes in ROS and ATP status 
compared with untreated cells. Therefore, Caco-2 cells were used for the following proteomic 
studies against short treatment with lumiflavin. 
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Studies were designed to determine whether riboflavin depletion induced by lumiflavin 
causes an inhibitory effect on cell proliferation through alteration of cell signalling pathways. 
As described (see section 1.1.4), phosphorylation is an important process for the activation of 
proteins, initiating downstream cell signalling (Schulze, 2010; White, 2008). Therefore, changes 
in phosphorylation can be evidence of cell signalling. Phosphorylation occurs mainly on some 
amino acids of protein; serine, threonine and tyrosine. Conveniently, probing of pan-specific 
antibodies against the amino acid residues are commonly used for detection of 
phosphorylated proteins in gel-based methods (Schmelzle and White, 2006; Sawasdikosol, 
2010).  
Recent advanced high-throughput proteomics enables the investigation of 
phosphoprotein-specific alterations, such as the isobaric tag for relative and absolute 
quantification (iTRAQ). iTRAQ allows simultaneous identification of proteins and quantitative 
comparison of protein abundance in multiplexing of up to eight separately labelled samples 
(Hultin-Rosenberg et al., 2013). This provides more accurate and reproducible quantification of 
peptides and proteins through peptide-based detection by tandem mass spectrometry (Zhang 
et al., 2005). Works were performed to assess changes in global phosphorylation using probes 
of pan-specific phospho-amino acid residues and also to investigate phosphoprotein profiling 
using iTRAQ which provided all-encompassing analysis for proteins altered by lumiflavin 
treatment. Then, studies for validation of findings were followed. 
 
 
5.2. Aims 
 
To explore changes in phosphorylation and phosphoprotein profiling using proteomic 
approach by an exposure of Caco-2 cells to lumiflavin and to validate findings. 
 
 
5.3. Methods 
 
Figure 25 presents overall workflow of chapter 5 including determination of changes in 
global phosphorylation, phosphoprotein profiling and the cell cycle. Caco-2 cells exposed to 
40μM lumiflavin were used. Changes in global phosphorylation were determined by western 
blot and HCA for the different time periods, focusing on the short term, and then intracellular 
flavin concentration was determined for the early period up to 24 hours. iTRAQ was used to 
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determine changes in phosphoprotein profile, followed western blot and cell cycle analysis 
using HCA and flow cytometry were carried out to confirm the findings.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 Experiment scheme in chapter 5. 
HCA; high content analysis, iTRAQ; isobaric tag for relative and absolute quantitation. Caco-2 cells 
exposed to 40μM lumiflavin were used for investigation of global phosphorylation using western blot and 
high content analysis (HCA) and intracellular flavin assay was followed for changes in intracellular flavin 
concentration in the same period. Phosphoprotein profile was determined using iTRAQ and western blot 
and cell cycle analysis by HCA and flow cytometry were followed to validate iTRAQ findings. 
 
 
5.3.1. Western blot for global phosphorylation 
 
For global phosphorylation, cell lysates for western blot were prepared as incubated in 
40μM lumiflavin-containing DMEM and 2% of 0.1M NaOH in DMEM as a control for 0, 3, 6, 17 
and 24 hours. Western blot was performed using probing pan-specific antibodies against 
phospho-tyrosine and phospho-serine/threonine.  
 
 
5.3.2. High content analysis 
 
Caco-2 cells in a 96 well plate were treated with 40μM lumiflavin for 0, 1, 2, 3, 4 and 6 
hours. For HCA, cells were fixed and immunostained using pan-specific antibodies against 
Caco-2 cells exposed to 40μM lumiflavin  
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phospho-tyrosine and phospho-serine/threonine. The plate was sent to be analysed by Imagen 
Biotech. in Manchester, UK. 
 
 
5.3.3. Intracellular flavin assay in early stage depletion 
 
Intracellular flavin concentrations were monitored following short term exposure to 
lumiflavin. Caco-2 cells were incubated in 40μM lumiflavin for 3, 6, 17, and 24 hours. Cells were 
harvested and lysed at each time and stored at -80℃ until analysed. Intracellular riboflavin, 
FAD and FMN concentrations were determined using reverse-phase HPLC as explained in 
section 2.2.4. 
 
 
5.3.4. Preparation of phosphoprotein and iTRAQ 
 
 
Figure 26 Workflow of sample preparation and iTRAQ  
Caco-2 cells with different treatments shown in Figure 27 were used to purify phosphoprotein and the 
integrity of phosphoprotein was identified by phosphoprotein-specific gel stain method. As 
phosphoprotein was purified as diluted, samples were concentrated and then samples were prepared and 
run for iTRAQ. Proteins altered by lumiflavin treatment were identified and quantified. Reactome, a 
pathway database, was used to reveal a change in cell signaling pathway. 
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Figure 26 shows the workflow of phosphoprotein preparation, iTRAQ and data analysis. 
As shown in Figure 27, Caco-2 cells were incubated with 40μM lumiflavin for 6 and 24 hours, 
and 0 hour control and time-controls were also prepared. Cell pellets were harvested and 
stored in -80℃ until analysed. Cell pellets then were used to purify phosphoproteins using a 
phosphoprotein purification kit (see section 2.2.14). Purified phosphoproteins were visualised 
by staining with Pro-Q Diamond phosphoprotein and SYPRO® ruby as described in section 
2.2.15.  
 
 
 
 
Figure 27 Cell sample preparation of iTRAQ 
LF; lumiflavin. Five groups with the different treatment and duration were prepared; Caco-2 cells 
incubated in 40μM lumiflavin-containing DMEM for 6 and 24 hours, in free lumiflavin and free NaOH -
DMEM which considered as 0 hour, in 2% (v/v) of 0.1M NaOH in DMEM for 6 and 24 hours as time-
controls. Then, three of five groups were used for iTRAQ in replicate; 0 hour, LF and time-control for 6 
hours (see Table 4 for iTRAQ labelling in section 2.2.18.2). Thus, total eight samples were used for iTRAQ. 
 
 
As described in section 2.2.18.2, eight samples were used for sample preparation to 
proceed to iTRAQ, which were five of 0 hour, 6 hours control, 6 hours lumiflavin, 24 hours 
control and 24 hours lumiflavin and three of 0 hour, 6 hours control and 6 hours lumiflavin in 
replicates. Concentrated samples were digested and labelled with iTRAQ reagent. Peptides 
were fractionated by HILIC and each of fractions was desalted. Samples were run by mass 
spectrometry (LC-MS/MS). Further data analysis for protein identification and quantification 
was carried out as described in section 2.2.18.6. Significant pathways that altered by lumiflavin 
treatment were analysed by overrepresentation analysis using Reactome v45. 
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5.3.5. Western blot for serine/arginine-rich splicing factor (SR) protein 
 
For validation of the findings of proteomic analysis, SR proteins were examined using 
western blot. Antibodies against SR proteins family and phospho-SR proteins were used. It can 
detect multiple SR proteins including SRSF4 at the protein size 75kDa, SRSF6 at 55kDa, SRSF5 
at 40kDa, SRSF1 or SRSF 9 at 30kDa, and SRSF3 at 20kDa. Caco-2 cells were prepared by 
incubation with 40μM lumiflavin for 0, 6, 24 and 48 hours. Time controls were also prepared. 
Proteins were extracted and western blotting was performed as described. 
 
 
5.3.6. Cell cycle analysis by HCA 
 
Using the plate which used to investigate global phosphorylation in section 5.3.2, it was 
requested to Imagen Biotech. for cell cycle analysis. The duration of lumiflavin treatment was 
for 1, 2, 3, 4, and 6 hours.  
 
 
5.3.7. Cell cycle analysis by flow cytometry 
 
Caco-2 cells were treated with 40μM lumiflavin for 6, 24, and 48 hours, and time 0hour 
and time-controls were set with 2% (v/v) of 0.1M NaOH in DMEM. Cells were fixed and stained 
in PI/RNase staining solution, then cell cycle was analysed by flow cytometer BD LSR II. PI 
fluorescence dye stains DNA in the cells, and the fluorescence intensity of the stained cells 
reflects the DNA contents. S phase of the cell cycle leads to double amount of DNA of cells, 
and the fluorescence of cells in the G2/M phase is around twice as high as that of cells in the 
subG1/G1 phase. Therefore, the relative amount of cells can be determined (Krishan, 1975). 
 
 
5.3.8. Statistical analysis 
 
Data for global phosphorylation using western blot was analysed by two-way ANOVA for 
a comparison of two factors; Treatment and incubation time, followed Mann-Whitney U test 
was carried out to compare between 0 hour and each time point. HCA data for global 
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phosphorylation was analysed by Kruskal-Wallis test for a comparison across incubation time 
points. Data for intracellular flavin concentration and SR proteins using western blot were 
compared by two-way ANOVA for interaction between treatment and incubation time and the 
main effect of each factor. Cell cycle data using flow cytometry were analysed by two-way 
ANOVA for interaction of treatment and incubation time. Following one-way ANOVA was used 
for main effects of incubation time on each phase in each of treatment, and t-test was used for 
difference between treatments at each time point. The results were considered significant if P-
values were <0.05. 
 
 
5.4. Results 
 
 
5.4.1. Global phosphorylation by western blot 
 
Figure 28 shows images of western blots probed using pan-specific phospho-tyrosine (A) 
and phospho-serine/threonine antibodies (B).  
 
 
  
 
 
 
 
 
 
 
 
 
Figure 28 Western blot for pan-specific phosphorylated tyrosine and 
serine/threonine. 
Caco-2 cells exposed to 40μM lumiflavin and time-controls were used. Western blot was performed using 
probing for pan-specific phospho-tyrosine (A) and phospho-serine/threonine (B). Multiple bands in each 
lane were quantified and presented in Figure 29. 
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In Figure 29, signals on blots were quantified and plotted on graphs and data were 
obtained from three independent experiments. There was no significant effect of treatment and 
incubation time, analysed by two-way ANOVA. However, Mann-Whitney U test showed a 
significant decrease in phospho-tyrosine at 3 and 6 hours compared with 0 hours (P=0.037). 
No significant difference in phospho-serine/threonine was observed. Relative changes in 
phosphorylation against controls suggested a modest decrease in phospho-tyrosine and 50% 
increase in phospho-serine/threonine by short treatment (3 and 6 hours) with lumiflavin, but 
these changes were not statistically significant. Taken together, Caco-2 cells exposed to 40μM 
lumiflavin showed a decrease in phosphorylation on tyrosine evident after only 3 and 6 hours. 
 
  
    
 
Figure 29 Quantified signals of western blot by densitometry  
Py; phospho-tyrosine, Ps/t; phospho-serine/threonine. Y axis shows relative signal density against 0 hour. 
Caco-2 cells exposed to 40μM lumiflavin and time-controls were examined by western blot and multiple 
bands were quantified for signal strength and corrected by quantified signals of ß-actin. Signal of 0hour 
was assigned to 1 and others were expressed as relative values. Data were obtained from three 
independent experiments and expressed as mean±(SEM). Relative changes against time-controls were 
calculated in each experiments and expressed as mean±(SEM).  
* Significant different from 0hour (P<0.05, Mann-Whitney U test) 
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5.4.2. Global phosphorylation by HCA 
 
There was no significant effect of lumiflavin treatment on phosphor-serine/threonine or 
phosphor-tyrosine after 3 or 6 hours exposure. Cell numbers on a fixed plate were seen to be 
uneven (left of each panel in Figure 30), thus it is thought that this might have led to large 
variations in measuring fluorescence intensity.  
 
 
 
 
    
 
     
 
Figure 30 Cell numbers and fluorescence levels for phospho-tyrosine and 
phospho-serine/threonine by HCA. 
Caco-2 cells were incubated in 40μM lumiflavin or control for up to 6 hours and then fluorescence-
immunostained with pan-specific phospho-tyrosine (A) and phospho-serine/threonine (B). The numbers of 
cells examined for fluorescence strength (left of each panel) and global phosphorylation level 
(fluorescence strength) (right of each panel) were presented. Data was obtained from a single experiment 
in three replicates and expressed as mean (±SEM). Statistical significance was not found in any phospho-
levels. 
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5.4.3. Intracellular flavin concentration in early stage depletion 
 
Effect of lumiflavin on intracellular flavin concentration in early stage depletion was 
determined. Short term exposure to lumiflavin did not elicit a decrease in intracellular flavins 
concentrations (two-way ANOVA). It suggests that the observed phosphorylation changes were 
not linked to riboflavin depletion induced by lumiflavin. 
 
 
 
 
Figure 31 Effects of lumiflavin on intracellular flavins concentration in early 
stages of lumiflavin treatment, determined by HPLC. 
Caco-2 cells were incubated in 40μM lumiflavin or control for up to 24 hours. Cells were used for 
determination of intracellular flavin concentration using HPLC. Data was obtained from three independent 
experiments and expressed as mean (±SEM). Two-way ANOVA showed no significance on interaction or 
main effects on treatment and incubation time. 
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5.4.4. Preparation of phosphoprotein for iTRAQ 
 
 
Steps of sample preparation 
 
 
Caco-2 cells treated with 40μM lumiflavin for 6 and 24 hours and controls (0, 6 and 24 
hours) were used to prepare phosphoproteins. In order to enrich phosphorylation in samples 
thereby to increase sensitivity for the proteomic analysis, phosphoproteins were purified from 
the stored cell pellets as detailed in section 2.2.14. Phosphorylated proteins are bound with 
high specificity to phosphoprotein purification resin, while unphosphorylated proteins flow 
through the resin without binding there and thus can be found in the flow-through fraction. 
Retained Phosphoproteins were eluted and collected in the elution buffer, and this process was 
repeated for six times. As seen on A of Figure 32, elution of retained proteins in the resin was 
maximized at 3rd elution as guided by the manufacturer instruction. Each eluted fractions were 
loaded in the SDS-PAGE gel, stained and visualised, and the strengths of signals were 
consistent to the graph of protein. Figure 32 confirmed that all phosphoproteins were eluted 
and collected.  
 
   
 
Figure 32 Protein concentration of purified phosphoprotein in each elution 
and the SDS-PAGE gel stained with Coomassie blue stain 
h; hours, M; protein marker, Std; phosphoprotein standard, 1~6; first to sixth elution. Protein contents 
determined for each eluted fraction (A) and the gel stained with coomassie blue for whole proteins (B) 
are presented. The graph and the image confirmed that almost all phosphoproteins were eluted. 
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Steps of sample preparation 
 
 
Integrity of purified phosphoproteins were confirmed using staining with Pro-Q Diamond 
phosphoprotein gel stain and SYPRO® ruby total protein gel stain and western blot probing 
with pan-specific phospho-serine/threonine antibody (Figure 33). Loaded protein amounts into 
gels were different; 10μg of cell lysates, 1~1.5μg of 10 ㎕ flow through fraction and 1.5~2μg of 
10 ㎕ pooled eluted fraction. 
Intact protein bands of phosphoproteins were found in eluted fractions (Figure 33, A). 
Unphosphorylated proteins were in flow-through fraction since no signals on the gel stained 
with Pro-Q Diamond stain appeared (Figure 33, A), but clear signals were on the gel stained 
with SYPRO® ruby (Figure 33, B). Clear signals on eluted fractions were observed even though 
total protein was much less than cell lysate. Furthermore, it needs a caution to interpret the 
figures because the amounts of loaded protein were different for cell lysates and fractions. 
Figure 33 (C) shows a confirmation of that using western blot for phospho-serine/threonine. 
Taken together, the phosphoproteins were successfully enhanced. 
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1 Phosphoprotein molecular weight standard, positive and negative controls 
2 0h 
3 6h control 
4 6h lumiflavin 
5 24h control 
6 24h lumiflavin 
 
Figure 33 Purified phosphoproteins stained with Pro-Q Diamond 
phosphoprotein stain and SYPRO® ruby total protein stain and western blot 
probed with phospho-serine/threonine antibody 
M; protein marker, h; hours. Products of phosphoprotein purification and cell lysates loaded into a gel 
were stained with Pro-Q Diamond phosphoprotein (A) and SYPRO® ruby total protein (B). (C); further 
confirmation was done by western blot using phospho-serine/threonine. Loaded protein amounts into 
gels were 10μg of cell lysates, 1~1.5μg of 10 ㎕ flow through fraction and 1.5~2μg of 10 ㎕ pooled 
eluted fraction. 
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Steps of sample preparation 
 
 
 
Phosphoprotein was purified as diluted on the process of purification. Thus, each eluted 
fractions were pooled and concentrated by centrifugal filtration. Eight samples were selected 
for 8plex of iTRAQ and concentrated. Figure 34 presents coomassie blue gel stain for 
concentrated phosphoproteins. Strength of signals was similar across the lanes even when 
compared with the signals of cell lysates. Also, as seen on the additional table of Figure 34, the 
volumes of concentrated samples equivalent to 10μg protein were approximately around one 
tenth of cell lysate volume. Therefore, purified phosphoproteins which had been much diluted 
were successfully concentrated. 
 
 
 
Treatment 0h  6C  6LF  0h  6C  6LF  24C  24LF  Cell lysate  
Protein concentration 
after filtration (mg/ml) 
10.86 7.75 6.78 6.91 7.98 7.54 8.07 7.21 
 
Volume equivalent  
to 10μg protein (μl) 
0.92 1.29 1.48 1.45 1.25 1.33 1.24 1.39 15 
 
 
 
 
Figure 34 Concentrated phosphoproteins using filtration 
h; hour, C; control, LF; lumiflavin, M; protein marker. Eight samples were concentrated using centrifugal 
filtration, and protein concentration was determined. Phosphoprotein equivalent to 10μg was run on a gel 
and stained with coomassie blue.  
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Steps of sample preparation 
 
 
 
As iTRAQ is a proteomic analysis based on tag-labeling on peptides, concentrated 
purified phosphoproteins were digested to peptides using trypsin. Before and after digestion, 
aliquots equivalent to 5μg protein were run on a gel and stained with coomassie blue as 
presented in Figure 35. Non-digested proteins appeared similar as an image of Figure 34 which 
is a gel image of concentrated phosphoprotein. Since trypsin-treated proteins were digested to 
small size peptides, they appeared at the lowest bottom where the bands were stronger than 
non-digested. 
 
 
 
 
    
 
Figure 35 Trypsin-digested peptides stained with coomassie blue 
M, protein marker; h, hour; C, control; LF, lumiflavin. Phosphoproteins before and after trypsin-digestion, 
equivalent to 5μg protein, were run on a gel and stained with coomassie blue.  
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5.4.5. Phosphoprotein profiling by iTRAQ 
 
Trypsin-digested peptides were fractionated by HILIC and analysed by mass 
spectrometry (LC-MS/MS) for identification of peptide sequence, thereby allowing protein 
identification and quantification. Results are expressed as fold change compared with control. 
 
300 proteins were identified and quantified, and then the relative fold changes were 
calculated and subjected to paired comparison analysis using SignifiQuant v4.0. Summaries of 
proteins that were significantly altered by lumiflavin treatment for 6 and 24 hours compared 
with the time-controls are presented in Table 5 and Figure 36. Such proteins were sorted 
through and assessed by overrepresentation analysis in Reactome v45 to investigate relevant 
pathways represented by identified proteins. Summaries of the number of proteins that were 
significantly changed in comparison with 0 hour baseline are presented in Table 10. 
 
For the comparisons between treatments, the Venn diagram (Figure 36) shows seven 
proteins that were significantly altered by lumiflavin over the time course. Four of these 
proteins which showed increased fold changes (i.e changes in phosphoprotein level) were 
related to mRNA processing particularly mRNA splicing, and two proteins that decreased in 
fold changes plays a role on protein synthesis and nucleosome (Table 6). One of seven proteins, 
drebrin, was excluded due to no relevance because it is a brain protein functioning on the 
process of neuronal growth and found in brain and also other tissues except the intestine. The 
fold changes of these six proteins were plotted on graphs, shown in Figure 37.  
145 proteins that were significantly altered by 24 hours lumiflavin treatment compared 
with time-control were analysed by Reactome to identify significant pathways represented by 
such proteins (Figure 38). Each event is coloured in blue to red according to the probability 
values from 1.00 to 3×10-10, and probabilities coloured from yellow to red are considered as 
significant. Significant pathways identified include mRNA processing on gene expression and 
apoptosis pathway as seen below :  
 
1. mRNA processing on gene expression, relating to processing of capped intron-
containing pre-mRNA on mRNA splicing (the last child event P=8.7e-13, 13/112) 
2. Post-elongation processing of the transcript, particularly of intron-containing pre-
mRNA (the last child event P=8.5e-11, 8/34) 
3. RNA polymerase II transcription termination (the last child event P=8.5e-11, 8/43) 
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4. Apoptosis(P=1.6e-06, 9/154) 
 
Table 7 lists the 13 proteins which matched proteins for mRNA processing and/or RNA 
polymerase II transcription. Table 8 shows the 9 proteins which matched for apoptosis pathway. 
The fold changes of the proteins were plotted on graphs shown in Figure 39 and Figure 40.  
 
Lumiflavin led to delay or suppression of dephosphorylation on proteins related to gene 
expression, particularly to mRNA processing and RNA polymerase II transcription and on 
apoptosis-related proteins. In Figure 39, the 6 proteins emphasised in red boxes showed clear 
differences from controls over the time course. Phosphorylation of such proteins was 
maintained around baseline (0 hour) or increased approximately 10% by lumiflavin, while cells 
under the control condition showed a fall in the fold changes of such proteins. The differences 
between lumiflavin and control were more remarkable at 24 hours up to approximately 30%. 
Figure 40 presents the fold changes of 9 proteins that matched apoptosis pathway. 5 proteins 
coloured in red boxes showed greater than 10% changes in fold changes at 24 hours 
compared with the time-controls. Lumiflavin led to suppress changes in phosphorylation of 
proteins related to apoptosis. For instance, the fold change of 14-3-3 protein sigma of time-
controls cells were increased, while the fold change of the protein in lumiflavin-treated cells 
was maintained at the level of 0 hour control. Phosphorylation of HMGB1, HMGB2 and PSMB7 
was maintained at the control level (0 hour) in cells exposed to lumiflavin, but decreased in 
time-controls. 
 
Of the 13 and 9 proteins which matched gene expression and apoptosis, proteins with 
largest changes over the time course were listed according to rank. Proteins showing fold 
changes less than 10% changes by lumiflavin were excluded in order to select proteins 
showing clear changes. Finally, the top 15 proteins of interest showing the largest fold changes 
were selected. The proteins were ranked according to the highest absolute level of fold change 
against control. Absolute fold changes against time-control at each time point were calculated 
and ranked. The larger absolute fold change goes to the higher rank. Then, the two ranks at 
the two time points were summed, and the final ranks were made as the lower sum of ranks 
goes to the higher rank. The summary and rank of such proteins is listed in Table 9. The top-
ranked proteins belonged to serine/arginine-rich splicing factors (SR) proteins family. Therefore, 
to validate these findings of proteomic analysis was performed using western blot for SR 
proteins family.  
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In addition, Table 10 presents the summaries of protein showing significant changes in 
comparison with 0 hour baseline. It found less phosphorylated proteins in the lumiflavin-
treated cells than in the control at 24 hours. This suggests that lumiflavin may suppress 
phosphorylation on proteins that is normally induced by riboflavin under control conditions. It 
was sorted through the fold changes of individual proteins, and all proteins showing obvious 
changes both between treatments and across time course had already been included in the 
final 15 proteins of interest. 
 
 
Table 5 The numbers of proteins showing different fold changes under 
lumiflavin treatment compared with time-controls. 
(P=0.05, MTC off) 6h LF vs 6h C 24h LF vs 24h C 
↑ 5 82 
↓ 2 63 
Total 7 145 
P; probability, MTC; multiple test correction, h; hours, LF; lumiflavin, C; control, ↑/↓; higher or lower in 
fold change than time-control. 7 proteins were significantly changed by exposure to lumiflavin for 6 hours 
compared with 6 hour control. Exposure to lumiflavin for 24 hours led to significant changes in 
phosphorylation of 145 proteins compared with 24 hours control. 
 
 
 
Figure 36 Venn diagram of proteins showing different fold changes under 
lumiflavin treatment compared with time-controls. 
h; hours, LF; lumiflavin, C; control. All 7 proteins showing significant difference in comparison between 6 
hours treatments were continuously altered over the time course up to 24 hours. 
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Table 6 Summaries of seven proteins included in coaggregated part on venn 
diagram of Figure 36 
Change Name UniProt 
ID 
Phospho-site Related pathways 
↑ HNRNPC 
Isoform C1 of 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 
P07910-2 Ser-260 & 299 in the 
resting cell,  Ser-253, & 
238 in the response to 
hydrogen peroxide 
mRNA processing, splicing 
↑ SRSF1 
Serine/arginine-rich 
splicing factor 1 
J3KTL2 Ser-2, 199, 201, 205, 
231, 234 & 238 
mRNA processing, splicing 
↑ SRSF6 
Serine/arginine-rich 
splicing factor 6 
Q13247 Extensively 
phosphorylated on 
serine residues in the RS 
domain 
mRNA processing, splicing 
↑ DBN1 
Drebrin 
Q16643 Ser-141, 142, 337, 339 & 
342, Thr-331, 335 & 346 
A cytoplasmic actin-binding 
protein, related to neuronal 
growth. Developmentally-
regulated brain protein 
↑ LUC7L3 
Cisplatin resistance-
associated overexpressed 
protein, isoform CRA_b 
/Luc7-like protein 3 
J3KPP4 
/O95232 
Ser-3, 110, 420, 425 & 
431 
RNA splicing, interacting 
with SFRS1. 
↓ eEF2 
Elongation factor 2 
P13639 Thr-54, 57, 59 & 435, 
Ser-502 
Protein biosynthesis  
Translation elongation; Gene 
expression; Metabolism of 
proteins; Translation 
↓ HIST1H2BH 
Histone H2B type 1-H 
Q93079 Ser-7 & 15 by 
STK4/MST1, Ser-37 by 
AMPL, Tyr-43, Ser-79, 
Ser-113;alternate, 
Core component of 
nucleosome 
Cell cycle; chromosome 
maintenance; nucleosome 
assembly; telomer 
maintenance 
Ser; serine, Thr; threonine, Tyr; tyrosine, ↑/↓; higher or lower in fold change than time-control, 
STK4/MST1; serine/threonine-protein kinase 4 (EC2.7.11.1), AMPL; cytosol aminopeptidase (EC 3.4.11.1). 
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Figure 37 Fold changes of proteins listed on Table 6. 
For all graphs, X axis shows hours and Y axis shows relative fold changes against 0 hour. Title of each 
graph shows abbreviated gene name and UniProt accession number. Fold changes of 6 proteins which 
showed significant changes by exposure to lumiflavin for 6 and also 24 hours compared with time-
controls were plotted.  
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Statistically over-represented events in hierarchy 
Each Event is coloured according to the un-adjusted, i.e. not corrected for multiple testing, probability 
(from hypergeometric test) of seeing given number or more genes in this Event by chance. Only the ‘child’ 
events are shown which have a p-value lower than the ‘parent’ event. The top-level (root) Events are 
ordered according to the lowest p-value of their components. Colour key for probabilities: 
1e+00 3e-01 1e-01 3e-02 1e-02 3e-03 1e-03 3e-04 1e-04 3e-05 1e-05 3e-06 1e-06 3e-07 1e-07 3e-08 1e-08 3e-09 1e-09 3e-10 > 
Gene Expression1.1e-08, 25/1031 
Processing of Capped Intron-Containing Pre-mRNA1.5e-12, 13/117 
mRNA Splicing8.7e-13, 13/112 
mRNA Processing1.1e-11, 13/136 
Processing of Capped Intron-Containing Pre-mRNA1.5e-12, 13/117 
mRNA Splicing8.7e-13, 13/112 
Post-Elongation Processing of the Transcript6.4e-10, 8/43 
Post-Elongation Processing of Intron-Containing pre-mRNA8.5e-11, 8/34 
Transcription9.9e-06, 8/145 
RNA Polymerase II Transcription6.5e-07, 8/101 
RNA Polymerase II Transcription Termination6.4e-10, 8/43 
Apoptosis1.6e-06, 9/154 
Metabolism of proteins8.3e-04, 12/574 
Translation1.3e-05, 8/151 
Cell Cycle1.5e-04, 12/478 
Chromosome Maintenance1.0e-04, 6/103 
Meiosis3.0e-03, 4/81 
Meiotic Synapsis8.1e-04, 4/57 
Telomere clustering at the nuclear membrane3.9e-04, 4/47 
Binding and Uptake of Ligands by Scavenger Receptors4.3e-01, 2/195 
Scavenging by Class F Receptors1.1e-03, 2/7 
 
Figure 38 Reactome analysis of the pathways represented by 145 proteins 
significantly altered by 24 hours lumiflavin treatment compared with time-
control  
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Statistically over-represented events in hierarchy 
Each Event is coloured according to the un-adjusted, i.e. not corrected for multiple testing, probability 
(from hypergeometric test) of seeing given number or more genes in this Event by chance. Only the ‘child’ 
events are shown which have a p-value lower than the ‘parent’ event. The top-level (root) Events are 
ordered according to the lowest p-value of their components. Colour key for probabilities: 
1e+00 3e-01 1e-01 3e-02 1e-02 3e-03 1e-03 3e-04 1e-04 3e-05 1e-05 3e-06 1e-06 3e-07 1e-07 3e-08 1e-08 3e-09 1e-09 3e-10 > 
Mitotic M-M/G1 phases4.7e-02, 5/266 
M Phase3.0e-02, 5/235 
Mitotic Metaphase and Anaphase1.2e-02, 5/185 
Mitotic Anaphase1.2e-02, 5/184 
Nuclear Envelope Reassembly4.0e-03, 2/13 
Disease3.4e-02, 12/915 
Amyloids6.3e-03, 3/51 
Serum amyloid P binds DNA and chromatin1.1e-03, 3/28 
HIV Infection2.4e-02, 5/221 
Host Interactions of HIV factors1.8e-02, 4/135 
Signal Transduction1.0e+00, 6/1847 
Signalling by ERBB23.3e-01, 2/158 
CHIP (STUB1) mediates ubiquitination of ERBB21.9e-03, 2/9 
CUL5 mediates ubiquitination of ERBB21.9e-03, 2/9 
Metabolism of RNA2.3e-03, 7/249 
3' -UTR-mediated translational regulation8.6e-03, 4/109 
Immune System9.9e-01, 5/1397 
Adaptive Immune System9.6e-01, 3/866 
Class I MHC mediated antigen processing & presentation4.3e-01, 3/320 
Antigen processing-Cross presentation9.3e-02, 3/145 
ER-Phagosome pathway7.2e-02, 3/130 
Proteasomal cleavage of substrate4.9e-02, 2/48 
Total number of events assessed: 7726 
Number of matching events (i.e. individual hypergeometric tests performed): 250 
Number of genes matching submitted identifiers: 52 
 
Figure 38 Reactome analysis of the pathways represented by 145 proteins 
significantly altered by 24 hours lumiflavin treatment compared with time-
control (continued) 
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Table 7 A summary of 13 proteins which matched mRNA processing and/or 
RNA polymerase II transcription 
Change Name UniProt 
ID 
Phospho-site Related pathways 
↑ SRSF3 
Serine/arginine-rich 
splicing factor 3 
P84103 Ser-5, 23 & 148 mRNA processing, splicing in 
relation with cellular 
proliferation and/or maturation. 
↑ SRSF9 
Serine/arginine-rich 
splicing factor 9 
Q13242 Tyr-192 & Ser-193, 195, 
204, 208, 211 & 216 
mRNA processing, splicing 
↑ SRSF6 
Serine/arginine-rich 
splicing factor 6  
Q13247 Ser-45, 81, 84, 299, 303, 
314 & 316 
mRNA processing, splicing 
↑ U2AF1 
Splicing factor U2AF 35 
kDa subunit 
Q01081 Ser-61 constitutive and enhancer-
dependent splicing by 
mediating protein-protein 
interactions and protein-RNA 
interactions required for 
accurate 3'-splice site selection. 
↑ U2AF2 
Splicing factor U2AF 65 
kDa subunit  
P26368 Ser-2 &79 pre-mRNA splicing.  
↑ SRSF5 
Serine/arginine-rich 
splicing factor 5 
Q13243 Ser-227, 229, 231, 233, 
248, 250, 253, 263, 265, 
267 & 270 
mRNA processing, splicing 
↑ SNRNP70 
U1 small nuclear ribo-
nucleoprotein 70 kDa 
P08621 Ser-268, 320 & 410 Pre-mRNA splicing 
↑ SNRNP200 
U5 small nuclear 
ribonucleoprotein 200 
kDa helicase  
O75643 Ser-26, 225, 2133 & 2135 
& Thr-2131 
RNA helicase that required for 
pre-mRNA splicing and 
involved in spliceosome 
assembly, activation and 
disassembly 
↑ SNRPD2 
Small nuclear ribo-
nucleoprotein Sm D2 
P62316 Thr-12 pre-mRNA splicing. Required 
for snRNP biogenesis 
Ser; serine, Thr; threonine, Tyr; tyrosine, ↑/↓; higher or lower in fold change than time-control. 
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Table 7 A summary of 13 proteins which matched mRNA processing and/or 
RNA polymerase II transcription (Continued) 
Change Name UniProt 
ID 
Phospho-site Related pathways 
↑ HNRNPK 
Isoform 3 of 
Heterogeneous nuclear 
ribonucleoprotein K 
P61978-3 Ser-116, 214, 216, 284 & 
379 & Tyr-380 
One of the major pre-mRNA-
binding proteins 
↑ RBM8A 
RNA-binding protein 8A 
Q9Y5S9  Ser-24, 42, & 56 mRNA processing, splicing, 
transport, termination of RNA 
polymerase II transcription 
↓ NUDT21 
Cleavage and poly-
adenylation specificity 
factor subunit 5 
O43809 Tyr-40 Component of the cleavage 
factor Im (CFIm) complex that 
plays a key role in pre-mRNA 
3'-processing 
↓ SF3B1 
Splicing factor 3B 
subunit 1  
O75533 Ser-129, 194, 332, 344, 
349, 400, 488 & Thr-142, 
203, 207, 211, 223, 227, 
244, 248, 267, 278, 296, 
299, 313, 326, 328, 341, 
350, 354, 434 & 436 
mRNA processing, splicing 
Ser; serine, Thr; threonine, Tyr; tyrosine, ↑/↓; higher or lower in fold change than time-control. 
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Figure 39 Fold changes of 13 proteins listed on Table 7, which matched mRNA 
processing and/or RNA polymerase II transcription 
X axis shows hours and Y axis shows relative fold changes against 0 hour. Title of each graph shows 
abbreviated gene name and UniProt accession number. Fold changes of 13 proteins were plotted on 
graphs, which showed significant changes by exposure to lumiflavin for 24 hours compared with time-
controls and matched mRNA processing and RNA polymerase II transcription in gene expression pathway. 
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Table 8 A summary of 9 proteins which matched apoptosis 
Change Name UniProt 
ID 
Phospho-site Related pathway 
↑ SFN 
14-3-3 protein sigma 
P31947 Ser-5, 64, 216, 248 Apoptotic signalling pathway in 
response to DNA damage,  
Keratinocyte differentiation & 
proliferation 
Regulations of cell proliferation & of 
cyclin-dependent protein 
serine/threonine kinase activity 
involved in G1/S transition and/or 
G2/M transition 
↑ UBA52 
Ubiquitin-60S ribosomal 
protein L40 
P62987 Ser-57, 65 Apoptotic signalling pathway and 
related to broad pathways. 
↓ HMGB1 
High mobility group 
protein B1 
P09429 Ser-35, 100 Apoptotic execution phase 
Negative regulation of apoptotic cell 
clearance  positive regulation of 
apoptotic process 
↓ HMGB2 
High mobility group 
protein B2 
P26583 Ser35 Apoptotic execution phase 
Positive regulation of protein 
insertion into mitochondrial 
membrane involved in apoptotic 
signalling pathway 
↓ PSMB7 
Proteasome subunit beta 
type-7 
Q99436 Tyr154 ATP-dependent proteolytic activity 
↑ HIST1H1B 
Histone H1.5 
P16401 Ser-2, 18, 173 & Thr-4, 
11, 39, 138 
Nucleosome assembly 
↑ HIST1H1C; 
Histone H1.2 
P16403 Ser-2,104 by PKC, & 
Thr-146 
Nucleosome assembly 
↓ NMT1 
Glycylpeptide N-
tetradecanoyltransferase 1 
P30419 Ser-31, 47 Intrinsic apoptotic signalling pathway 
↓ LMNA 
Prelamin-A/C 
P02545 Cell cycle regulation; 
Thr-19, Ser-22 & 392, 
Cytoskeletal 
reorganization; Ser-22 
& 525, activity, 
induced; Ser-22, 390, 
392, 652 & 657, 
intracellular 
localization; Ser-22, 
390, 392, 403, 404, 
652, & 657 
Components of the nuclear lamina, a 
fibrous layer on the nucleoplasmic 
side of the inner nuclear membrane. 
Role in nuclear assembly, chromatic 
organization, nuclear membrane and 
telomere dynamics.  
Ser; serine, Thr; threonine, Tyr; tyrosine, ↑/↓; higher or lower in fold change than time-control, PKC; 
protein kinase C (EC 2.7.11.13). 
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Figure 40 Fold changes of 9 proteins listed on Table 8 which matched 
apoptosis pathway 
X axis shows hours and Y axis shows relative fold changes against 0 hour. Title of each graph shows 
abbreviated gene name and UniProt accession number. Fold changes of 9 proteins were plotted on 
graphs, which showed significant changes by exposure to lumiflavin for 24 hours compared with time-
control and matched apoptosis pathway. 
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Table 9 Rank of fold changes of final 15 proteins altered by lumiflavin  
Rank Comparison 
with control 
UniProt  
ID 
Name 
1 ↑  P84103  SRSF3 Serine/arginine-rich splicing factor 3 
1 ↑  Q07955 SRSF1 Serine/arginine-rich-splicing factor 1 
3 ↑  Q13242  SRSF9 Serine/arginine-rich splicing factor 9 
4 ↑  Q13247  SRSF6 Serine/arginine-rich splicing factor 6 
5 ↑  Q01081  U2AF1 Splicing factor U2AF 35 kDa subunit, 
6 ↑  P26368  U2AF2 Splicing factor U2AF 65 kDa subunit 
8 ↑ Q99436 PSB7 Proteasome subunit beta type-7 
9 ↑  P07910-2  hnRNP C1/C2 Isoform C1 of Heterogeneous nuclear 
ribonucleoproteins C1/C2  
12 ↑  Q13243  SRSF5 Serine/arginine-rich splicing factor 5 
14 ↑  P31947 SFN 14-3-3 protein sigma  
15 ↑ P62987  UBA52 Ubiquitin-60S ribosomal protein L40 
7 ↓  Q93079  HIST1H2BH Histone H2B type 1-H  
10 ↓  P13639  eEF2 Elongation factor 2 
11 ↓  P26583  HMGB2 High mobility group protein B2 
12 ↓  P09429  HMGB1 High mobility group protein B1 
↑/↓; higher or lower in fold change than time-control. Upper 11 protein showed higher fold changes 
than time-control and bottom 4 protein showed lower fold changes than time-controls.  
 
 
Table 10 The number of proteins showing different fold changes under 
lumiflavin treatment in comparison with 0 hour 
(P=0.05, MTC off) 
Comparison 
with 0 hour 
6 hours 24 hours 
Control 
↑ 1 46 
↓ 0 57 
Lumiflavin 
↑ 5 14 
↓ 9 15 
P; probability, MTC; multiple test correction, ↑/↓; higher or lower in fold change than time-control. Table 
shows the number of proteins changed under each condition compared with 0 hour. For example, 103 
proteins were significantly changed under 24 hours control condition compared with 0hour, while 29 
proteins were changed by 24 hours lumiflavin compared with 0 hour. 
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5.4.6. Validation of proteomic analysis by western blot 
 
Out of 15 proteins of interest, some of serine/arginine-rich splicing factor proteins (SR 
protein) showed biggest changes by treatment of Caco-2 cells with lumiflavin. Members of SR 
protein family contain the same SR domain on their sequences, thus multiple proteins can be 
detected using the same antibody. Hence, western blotting of both whole cell lysates and the 
phosphoprotein used for iTRAQ was performed using antibodies against SR proteins and 
phosphorylated SR proteins. 
 
Cell lysates were prepared from Caco-2 cells treated with 40μM lumiflavin for 6, 24 and 
48 hours, and time-controls and 0 hour control were set up. The signals of phospho-SR 
proteins found at 40, 30 and 20kDa were identified as SRSF5, SRSF1 or 9, and SRSF3 
respectively (Figure 41 A). Also, the corresponding SR proteins were found at the same sizes, 
even though the bands at 40 and 30kDa were weak (Figure 41 B). Protein expression was 
quantified by densitometry (Figure 42), and the proportion of phospho-SR protein to total SR 
protein was calculated. Contrary to the iTRAQ data, there were no significant differences 
between treatments on these SR proteins and their phosphorylated proteins in the cell lysates.  
 
Purified phosphoproteins were the same samples used for iTRAQ, thus samples consisted 
of 8 samples in total; 0 hour, 6 hour control, 6 hour lumiflavin in duplicate, 24 hour control and 
24 hour lumiflavin. 
Due to limited volumes of purified phosphoproteins, the blot was stripped after probing 
for the total SR protein and reused for phosphor-SR proteins. It is possible that insufficient 
stripping may have interfered with the phospho-SR protein signal. Nevertheless, an increase in 
phospho-SRSF1/9 with lumiflavin treatment was detected at 30kDa, while the total SRSF1/9 
protein was unaffected by treatment. Therefore, such an increase in phospho-SRSF1/9 was not 
from increased expression of SRSF1/9 but increased phosphorylation itself, as supported by the 
proportion (Figure 44 A).  
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A  Anti-phospho-SR 
 
 
 
 
 
 
 
 
 
 
B  Anti-SR 
 
 
 
 
 
 
 
 
 
Figure 41 Western blot for SR and phospho-SR proteins using cell lysates 
M; protein marker, h; hour, C; control, and LF; lumiflavin-treated. The numbers show durations of 
treatment (hours). Caco-2 cells exposed to 40μM lumiflavin for 6, 24 and 48 hours, time-controls and 
0hour control were used to prepare cell lysates. Western blot was performed using antibodies for anti-SR 
protein family and anti-phospho-SR proteins clone 1H4. 
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A  SRSF5_40kDa   
 
  
B  SRSF1/9_30kDa   
 
  
C  SRSF3_20kDa   
 
  
 
 
 
Figure 42 Quantified western blot bands for phospho-SR protein and whole SR 
protein and the proportions of phospho-proteins using cell lysates 
X axis shows incubation time (hours) and Y axis shows relative signal density against 0 hour. Caco-2 cells 
exposed to 40μM lumiflavin for 6, 24 and 48 hours, time-controls and 0 hour control were used to 
prepare cell lysates. Western blot was performed using antibodies for anti-SR protein family and anti-
phospho-SR proteins clone 1H4. Signals were quantified by densitometry and the ratio of phospho-SR 
protein to total SR proteins was calculated. 
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 A  Anti-phospho-SR 
 
 
 
 
 
 
 
 
 
 
 
B  Anti-SR 
 
 
 
 
 
 
 
 
 
 
 
Figure 43 Western blot for SR and phospho-SR proteins using purified 
phospho-proteins 
M means protein marker, h; hour, C; control, and LF; lumiflavin-treated. The numbers show incubation 
time. Western blot was performed using antibodies for anti-SR protein family and anti-phospho-SR 
proteins clone 1H4 in phosphoproteins which were used for iTRAQ.  
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A  SRSF1/9_30kDa   
 
  
 
B  SRSF3_20kDa 
  
 
  
 
 
 
Figure 44 Quantified western blot bands for phospho-SR protein and whole SR 
protein and the proportions of phospho-proteins using purified phospho-
protein 
X axis shows incubation time (hours) and Y axis shows relative signal strength against 0 hour. 
Phosphoproteins which were used for iTRAQ were used for confirmation of iTRAQ data performed by 
western blot. Western blot was performed using antibodies for anti-SR protein family and anti-phospho-
SR proteins clone 1H4. Signals were quantified by densitometry and the ratio of phospho-SR protein to 
total SR proteins was calculated. 
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5.4.7. Effect of lumiflavin on the cell cycle 
 
Proteomic analysis revealed that lumiflavin treatment resulted in changes in gene 
expression pathways, particularly mRNA processing and the apoptosis pathway. Cell cycle 
analysis was performed to confirm these findings. Changes in mRNA processing in gene 
expression pathways may be associated with changes in the cell cycle. Also, cell cycle analysis 
allows an investigation of apoptotic cells and aneuploidy cells observed in Nakano’s model 
(Nakano et al., 2011). Thus, the effect of lumiflavin on each stage of the cell cycle in Caco-2 
cells was investigated using two methods; HCA for the effect of short treatment up to 6 hours 
and flow cytometry for longer treatment up to 48 hours. 
 
Figure 45 shows the percentage of cells in each stage of the cell cycle analysed by HCA. 
Lumiflavin led to a progressive reduction in cells in S phase in a time-dependent manner. 
Although not statistically significant, cells in G1 phase were slightly increased by 3 hours then 
decreased, while cells in G2 and above G2 phase were increased at 4 and 6 hours. In addition, 
it is known that apoptotic cells can be detected in sub G1 phase however there was no clear 
pattern in the time course.  
 
Figure 46 shows the cell cycle data analysed by flow cytometry in Caco-2 cells treated 
with 40 μM lumiflavin for 6, 24 and 48 hours. A progressive decrease in cells in G1 phase by 
lumiflavin across all time points was observed (P=0.04 by one-way ANOVA). Duncan post-hoc 
analysis showed a significant reduction of cells in G1 phase at 48 hours compared to 0 and 6 
hours. Two-way ANOVA showed that there was interaction effect between treatment and 
incubation time at only S phase (P=0.006). Analysis to determine the main effects, showed that 
the proportion of cells in S phase was significantly increased by lumiflavin treatment at 24 and 
48 hours (P=0.006 by one-way ANOVA), and was also increased compared with time controls 
(P<0.05 by t-test). Lumiflavin led to a significant decrease of cells in G1 phase compared with 
the time control at 48 hours (P=0.001, t-test), while it resulted in an increase of cells in G2/M 
phase (P=0.014, t-test). There were no differences in sub G1, where apoptotic cells are detected. 
Slightly more polyploidy cells were found in lumiflavin-treated cells however, this did not reach 
statistical significance. In contrast to lumiflavin-treated cells, controlled cells showed no 
differences across incubation time in all phases, as analysed by one-way ANOVA. Taken 
together, the data suggests that lumiflavin impaired the progress of the cell cycle, leading to 
slow progression of the cell cycle, particularly in S phase. 
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In addition, the data from HCA showed a decrease of cells in S phase, whereas flow 
cytometry data showed no changes by lumiflavin treatment by 6 hours. However, due to 
missing of time-controls on HCA experimental set, there was limitation to interpreting the 
effect of lumiflavin itself on the cell cycle. 
 
 
  
  
 
 
 
 
 
  
Figure 45 Cell cycle analysis by HCA 
X axis shows hours, and Y axis shows percentage (%) of cells in each phase. Data are shown as mean (± 
SEM) from three wells of a single experiment. Percentage of cells in S phase were statistically significantly 
different over the time course (P=0.037, Kruskal-Wallis). Points not sharing the same letter were 
significantly different (P<0.05 by Duncan post-hoc using rank). 
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Figure 46 Cell cycle analysis by flow cytometry 
X axis shows hours and Y axis, percentage (%) cells in each phase. Two-way ANOVA showed significant 
interaction between treatment and incubation time at only S phase (P=0.006). To determine main effects, 
it compared the differences between treatment at each time points by t-test and across incubation time 
in separated groups by one-way ANOVA. Asterisk Shows significant difference between control and 
lumiflavin at each time point by t-test (P=0.001 at G1, P<0.05 at S, P=0.014 at G2/M phase). Letters 
shows significant difference across time points (P=0.04 at G1, P=0.006 at S by one-way ANOVA). Points 
not sharing the same letter were significantly different (P<0.05 by Duncan post-hoc test). 
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5.5. Discussion 
 
 
5.5.1. Effects of lumiflavin on global phosphorylation 
 
Caco-2 cells exposed to 40μM lumiflavin were examined for global phosphorylation. 
There was a significant decrease in phosphorylation on tyrosine after only 3-6 hours of 
lumiflavin treatment, but there was no significant effect on global phospho-serine/threonine. 
Therefore, global phosphorylation results indicate a limited effect of lumiflavin-induced 
riboflavin depletion on cell signalling. 
It was then required to investigate whether changes to global phosphorylation resulted 
from riboflavin depletion or from lumiflavin itself. Intracellular flavins concentrations in all the 
forms of riboflavin were not significantly changed by lumiflavin over a short time period; up to 
24 hours. It suggests that such changes in global phosphorylation were not linked to riboflavin 
depletion induced by lumiflavin.  
 
 
5.5.2. Effects of lumiflavin on phosphoprotein profile by iTRAQ 
 
Caco-2 cells exposed to 40μM lumiflavin for 6 and 24 hours were examined for 
phosphoprotein profile. Phosphoproteins were purified and validated for successful purification 
of phosphoproteins and their intact integrity through various staining methods for 
phosphoproteins and western blotting.   
 
Proteomic analysis allowed the identification of alterations in the phosphorylation of the 
15 key proteins affected by lumiflavin treatment. These proteins were related to pathways of 
mRNA processing (splicing) on gene expression, protein synthesis or apoptosis that were 
significantly altered by exposure to lumiflavin. Top ranked proteins were related to pre-mRNA 
splicing, which were of the serine/arginine-rich splicing factor (SRSF) family showing higher 
fold change than 0 hour and also time-controls. In contrast, the fold change in control cells 
was decreased with time. This suggests that lumiflavin treatment led to delay or suppression of 
the process of pre-mRNA splicing, mRNA transcription and further protein synthesis, which is 
supported by the lower fold changes in proteins related to protein synthesis compared with 
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time controls. In addition, the fold change described here indicates changes in phosphoprotein 
level rather than changes in the level of phosphorylation. Furthermore, it has found that when 
all treatment groups were compared with 0 hour baseline, lumiflavin-treated cells had fewer 
phosphorylated proteins than time-controls, suggesting inhibitory effects of lumiflavin on 
pathways that are normally induced by riboflavin. In other words, in comparison with 0 hour 
baseline, more phosphoproteins were significantly different in the 24 hour control than in 24 
hour lumiflavin treatment. This may be due to changes in cell growth and cell density thus 
increasing density of cell signalling transducers and accumulation of signalling events, thereby 
changing the proteome. For instance, an in vitro study reported that phosphorylation of signal 
transducers and activators of transcription 3 (STAT3), which is involved in cytokine signalling, 
was increased with cell density resulting in binding to DNA and activation of transcription 
thereby enhancing cell proliferation in melanoma cells (Kreis et al., 2007). 
 
Lumiflavin is thought to alter the regulation of apoptosis that should occur in riboflavin-
rich condition through impaired phosphorylation of proteins related to apoptosis. For example, 
phosphorylation of 14-3-3 protein sigma (SFN, UniProt accession No. P31947) was inhibited by 
lumiflavin. 14-3-3 protein sigma promotes cell survival as it binds to BAD phosphorylated by 
AkT, disrupting the binding of BAD to Bcl2 thus inhibiting apoptosis (Datta et al., 2000; Won et 
al., 2003). High mobility group box 1 & 2 complex (HMGB1 and HMGB2 complex, UniProt 
accession No. P09429 & P26583) stimulates DNA cleavage in apoptosis pathway (Kalinowska-
Herok and Widlak, 2008). Proteasome subunit beta type-7 (PSMB7, UniProt accession No. 
Q99436) is related to ATP-dependent trypsin-like proteolytic activity (Rho et al., 2008). 
Lumiflavin led to maintain the phosphorylation of these proteins at the control level (0 hour), 
but they were decreased under control condition. This suggests that cells under normal 
condition were primed to undergo cell proliferation with suppression of apoptosis, whereas 
lumiflavin suppressed such normal responses of cells under riboflavin-rich condition. In other 
words, these findings may contribute to the observed inhibitory effect of lumiflavin on cell 
proliferation. 
 
In an iTRAQ-based proteomic analysis using human prostate cancer cells, Glen et al. 
(2008) considered a 50% fold change (±0.50) as biologically significant in up or down 
regulation of proteins, to identify candidate proteins involved in prostate cancer progression 
and metastasis. We also showed a range of fold change from 0.34 to 1.54 (see Appendix 3). 
However, the cut-off fold change 50% may not be applicable to this study since extracted 
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phosphoproteins rather than entire proteins were used. There have been very few studies using 
iTRAQ for phosphoproteins extracted from Caco-2 or other colon-cancer cell lines, thus there 
was no available information on fold changes to be expected. However, since this study was 
designed to lead to modest effects of riboflavin depletion preceding biochemical dysfunctions, 
a moderate range of fold change was expected.  
 
This study used only phosphoproteins for iTRAQ analysis which resulted in limited 
outcomes to changes in phosphorylation, however if whole proteins were used, more 
information would have been produced such as protein expression levels. To take into account 
this limitation, a validation analysis using western blot with phospho-SR and also total SR 
proteins was performed.  
 
In addition, an alternative method of iTRAQ could have been 2D DIGE (difference gel 
electrophoresis) method followed by phosphorylated-protein expression profiling, where up to 
two different protein samples can be labelled separately and run in two-dimensional 
electrophoresis (Raggiaschi et al., 2005).  
 
There may be some potential off-target effects of lumiflavin. It is known that riboflavin in 
milk can be photodegraded to lumiflavin or lumichrome and the resultants catalyse the 
oxidation of lipids to lipid peroxides and methionine to methional which result in milk odour 
(Bender, 2003). It has not been studied influence of lumiflavin on oxidation of lipids from foetal 
calf serum in cell culture medium. Only a few studies have reported effects of irradiation of 
riboflavin-containing culture medium. In one such in vitro study, riboflavin-containing normal 
growth medium in μM concentrations was irradiated and used to culture leukaemia cells (de 
Souza et al., 2006). They reported leukaemia cell-specific induction of apoptosis with activation 
of Fas cascade; Fas and FasL overexpression followed by activation of caspase 8 and 
mitochondrial amplification mechanisms, involving the stimulation of ceramide production. 
These cascades led to an inhibition of mitogen activated protein kinases: JNK, MEK and ERK 
and the survival mediators PKB and IAP1, and upregulation of cell cycle progression regulators 
such as p21. These effects of irradiated riboflavin were not found in normal human 
lymphocytes. However, their study did not consider the potential side-effects of undetermined 
materials produced by irradiation of riboflavin. Here, an alternative method to overcome 
potential confounding effect of lumiflavin and to confirm that the findings of this study are 
true effects on signalling via riboflavin transporter is the reduction of apical riboflavin 
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transporter expression by gene knockdown. It has been reported recently that mutation of 
cysteine residues, particularly on C463 and C467 of human riboflavin transporter-2 (hRFT-2) 
ablated riboflavin uptake (Subramanian et al., 2011a). Their group also investigated effects of 
hRFT-2 gene-specific siRNA knockdown on intestinal riboflavin uptake driving the similar 
adverse effect on riboflavin uptake (Subramanian et al., 2011b).  
 
 
5.5.3. Effects of lumiflavin on SR proteins 
 
Proteomic analysis showed that some of serine/arginine-rich splicing factor proteins were 
ranked as biggest effects of lumiflavin on the phosphorylated SR proteins, compared with 
control treatment. For this reason, SR proteins were selected to validate the findings of the 
proteomic analysis by probing SR proteins and their corresponding phospho-SR proteins using 
western blot. Difference between treatments on phosphorylation status of SR proteins against 
their corresponding SR proteins; SRSF5, SRSF1/9 and SRSF3 was not found in whole cell lysates. 
However, increased phosphorylation in SRSF1/9 detected at 30kDa by lumiflavin was found in 
purified phosphoproteins, in agreement with iTRAQ data. It is supposed because purification of 
phosphoprotein amplifies such significance.  
Serine/arginine-rich splicing factor proteins family, called as SR protein, play an 
important role in alternative pre-mRNA splicing. Briefly, RNA splicing is a RNA-processing step 
during which the entire length of the gene, including exons and introns, is transcribed into 
RNA and intron sequences are removed from the long RNA by RNA splicing, producing much 
shorter RNA, and then RNA as mRNA directs the synthesis of a particular protein (Alberts, 
2008). Alternative pre-mRNA splicing is an important process during RNA transcription and 
further synthesis of different proteins from the same gene. SR proteins are involved in 
constitutive and alternative RNA splicing (Shepard and Hertel, 2009). 
The phosphorylation status of the SR proteins is key to the role in alternative pre-mRNA 
splicing (Shepard and Hertel, 2009). Phosphorylation enhances the ability of the SR protein, 
important for early steps of spliceosome assembly in the alternative splicing. Phosphorylation 
of the SR protein facilitates the recruitment of components of the spliceosome such as U1 
small nuclear ribonucleoprotein (U1 snRNP) and U2AF35 to intronic splice sites, whilst 
dephosphorylation causes negative regulation of spliceosome assembly. Walsh et al. (2013) 
suggested the regulation of nutrients in alternative pre-mRNA splicing. Phosphorylation and 
also abundance of SRSF3 protein was increased in response to insulin and arachidonic acid 
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during culture of rat hepatomacytes in high glucose-containing medium. These changes were 
related to enhanced splicing and expression of glucose-6-phosphate dehydrogenase RNA.  
However, this study is not able to identify target proteins of these SR proteins altered by 
lumiflavin treatment influence. From the proteomic analysis data, it is possible that alteration in 
SR protein may target apoptosis-related proteins which observed as significantly altered by 
lumiflavin treatment. Therefore, further study is required to investigate the association of SR 
proteins and proteins involved in apoptosis pathway. 
 
 
5.5.4. Effects of lumiflavin on the cell cycle 
 
Cell cycle analysis was performed to confirm the findings of proteomics analysis, in 
which exposure to lumiflavin resulted in an impairment in mRNA processing and apoptosis 
pathway, associated with progression of the cell cycle. In addition, aneuploidy cells observed in 
Nakano’s model (Nakano et al., 2011) and apoptotic cells were investigated by cell cycle 
analysis. Thus, the cell cycle was anlaysed in Caco-2 cells exposed to 40μM lumiflavin for a 
short period up to 6 hours and longer up to 48 hours by HCA and flow cytometry respectively. 
There is a limitation on interpretation due to missing of time-controls on HCA. However, when 
referred flow cytometry data up to 6 hours, we can suppose that lumiflavin was related to 
impaired progression of the cell cycle even only up to 6 hours. There was a progressive fall in S 
phase by lumiflavin treatment for up to 6 hours and cells in G2/M phase were slightly 
increased, suggesting impaired progression of S and G2/M phase. 
 
Flow cytometry data revealed significant changes in cell cycle progression by longer 
exposure to lumiflavin. The proportion of cells in G1 phase was progressively decreased, but 
cells in S phase were accumulated by lumiflavin and a subsequent G2/M phase arrest.  
These findings suggest that lumiflavin caused slow progression of the cell cycle 
particularly in S phase. According to literatures, it is possible that arrest of cells in S phase may 
be as a result of DNA damage, driving cells to apoptosis. Incompletely replicated DNA leads to 
cell arrest in S phase and delayed onset of mitosis (Alberts, 2008), and apoptosis can coincide 
with an accumulation of cells in S phase and a subsequent G2/M phase block in folate-
deficient HepG2 liver cells (Huang et al., 1999).  
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 An increased proportion of cells in G2/M phase was observed in lumiflavin-treated cells 
at 48 hours, suggesting longer exposure of Caco-2 cells to lumiflavin led to impaired G2/M 
phase progression. However, further analysis is required to distinguish between arrest in G2 
and M phase. Proteomic analysis found a decreased fold change of approximately 35% in 
histone H3 (UniProt accession No. K7EK07) at 24 hours exposure to lumiflavin compared with 
the time-control (Appendix 3, Appendix 6). Phosphorylated histone H3 is considered as a 
marker of mitosis, appearing at high levels in mitotic nuclei (Hendzel et al., 1997; Tsuta et al., 
2011). Therefore, it can be suggested that the observed G2/M phase arrest is likely to be in G2 
rather than in mitosis, however this requires further confirmation. 
Such cell cycle arrest can result in physiologically important implications, in that the 
resultant impaired cell proliferation can decrease the renewal of tissues particularly the small 
intestine that depends on rapid cell proliferation (Heath, 1996).  
 
 
 
5.6. Summary 
 
1. Lumiflavin led to small but significant fall in the global phosphorylation of tyrosine after 
only 3~6 hours.  
 
2. Such changes occurred without a significant fall in intracellular flavins concentrations. 
 
3. Proteomic analysis showed that lumiflavin may suppress phosphorylation of some proteins 
that should occur in riboflavin-rich condition. Also, it found that significant pathways 
altered by lumiflavin were related to gene expression particularly in mRNA processing and 
apoptosis pathway. The key 15 proteins were found, showing significant changes by 
exposure to lumiflavin. 
 
4. On validation of the findings of proteomic analysis, there were no significant changes 
caused by exposure to lumiflavin on SR proteins and phospho-SR proteins in cell lysates. 
However changes on phospho-SRSF1 and 9 were found in purified phosphoproteins, 
which is consistent with the proteomic analysis. 
 
 
Chapter 5.Lumiflavin induced changes in cell signalling 
141 
 
5. Cell cycle analysis revealed that lumiflavin caused slow progression of the cell cycle 
particularly in S phase with progressive fall in cells in G1 across incubation time but 
increased cells in G2/M phase at 48 hours. 
  
 
 
 
 
 
 
 
 
 
CHAPTER 6.  
DISCUSSION AND CONCLUSION 
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6.1. Conclusions 
 
 
It was hypothesised that lumiflavin leads to a depletion of flavins in intestinal cells 
associated with adverse functional effects and an interruption of the putative role of riboflavin 
as a signalling molecule in the regulation of intestinal cell proliferation. Investigation of the 
hypothesis entailed four elements of research; development of intestinal epithelial cell models 
of riboflavin depletion using lumiflavin; characterisation of the models; investigation of 
alterations in cell signalling in terms of candidate signalling pathways and related proteins; 
validation of findings in terms of SR proteins and the cell cycle. Three intestinal epithelial cell 
lines; Caco-2, HCT116 and HT29 were used for development and characterisation of the cell 
models, and Caco-2 cells were used for the signalling studies. The findings were as follows;. 
 
1. Lumiflavin led to a rapid inhibition of cell growth in a concentration-dependent manner in 
all three cell lines exposed to lumiflavin over a concentration up to 100μM.  
2. Exposure of three cell lines to 40 and 80μM lumiflavin led to a fall in intracellular riboflavin 
concentration but not in FMN and FAD concentrations, and an increase in GRAC, an 
indicator of functional riboflavin deficiency. 
3. Riboflavin depletion induced by lumiflavin resulted in a reduction in intracellular ATP 
concentration and enhanced ROS production, suggesting disruption of energy generation 
and enhanced oxidative stress.  
4. A cell-specific irreversible loss of clonogenicity was observed. 
5. Such biochemical and cellular consequences of riboflavin depletion induced by lumiflavin 
were cell-specific. Overall, Caco-2 cells were relatively sensitive, whereas HT29 cells were 
more resistant to riboflavin depletion. 
6. No effect of lumiflavin on apoptotic DNA fragmentation was found in any of the three cell 
lines. 
7. 40μM lumiflavin in Caco-2 cells caused changes in the global phosphorylation of tyrosine 
at 3 and 6 hours, which is suggestive of an effect on cell signalling. Such changes 
preceded cellular riboflavin depletion. 
8. Exposure of Caco-2 cell to 40μM lumiflavin led to a suppression in phosphorylation of 
some proteins, suggesting that lumiflavin interrupts cell signalling that occurs under 
conditions of riboflavin adequacy.  
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9. Exposure to lumiflavin led to an alteration in mRNA processing in gene expression 
pathway and apoptosis pathway, delaying or suppressing the process of pre-mRNA 
splicing, mRNA transcription and further protein synthesis and also stimulating apoptosis 
pathway which may contribute to observed effects on cell proliferation. 
10. Phosphorylation of SRSF1/9 was consistent with the proteomics analysis data, validated in 
purified phosphoproteins. 
11. Lumiflavin resulted in accumulation of cells in S phase with subsequent G2/M phase arrest. 
 
 
6.2. Discussion 
 
Caco-2 and HT29 cell lines were chosen to develop intestinal cell models of riboflavin 
depletion in order to study roles of riboflavin on cell proliferation and HCT116 was used for 
the comparison with the two cell lines. Caco-2 and HT29 cell lines are considered to be useful 
models of human small intestinal epithelial cell function. Recently Christensen et al. (2012) 
concluded that Caco-2 cells are the most suitable in vitro model for oral drug absorption, 
following in vitro model HT29 cells. They are the most similar to small intestinal enterocytes 
with respect to expression of transporters important to absorptive function. Also, the most 
dominant gene expression profile in differentiated Caco-2 and HT29 cells was similar to that of 
normal small intestinal epithelium. Such similarities were greater in differentiated Caco-2 and 
HT29 than other colon cancer-derived cell lines including HCT116, HCT15 and SW620. Indeed, 
the Caco-2 cell line is the most frequently used cell line as a model of small intestinal cell 
function (Said and Ma, 1994; Zielinska-Dawidziak et al., 2008; Subramanian et al., 2011b), and 
the HT29 cell lines has been suggested as a useful alternative cell model to Caco-2 (Collett et 
al., 1996).  
 
Considering the available evidence it was decided that undifferentiated Caco-2 and HT29 
cells would provide useful alternative cell models to normal small intestinal cells. 
Undifferentiated state of the cell lines is on proliferative status implying the different regulation 
from differentiation. In addition, we have reported the consistent results of intracellular flavins 
concentration with an in vitro study used differentiated Caco-2 monolayer exposed to 
lumiflavin (Said and Ma, 1994) mentioned in section 3.5.1. This suggests that undifferentiated 
Caco-2 cells may also show the similar effects on riboflavin uptake with differentiated Caco-2 
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cellls. Finally, the cell lines present several advantages such as availability, proliferability, 
homogeneity and reproducibility (Bourgine et al., 2012).  
However, it must be noted that undifferentiated Caco-2 and HT29 cell lines are not fully 
representative of the normal small intestinal epithelium. There have been inconsistent 
similarities on gene expression among differentiated and undifferentiated Caco-2 and HT29 
cells and normal small intestinal epithelium. Christensen et al.(2012) performed principal 
component analysis of gene expression data with human colon cell lines, laser-dissected tissues 
of normal human colonocytes, tumour cells and small intestinal enterocytes. Undifferentiated 
Caco-2 and HT29 were less similar to normal small intestinal enterocytes in most dominant 
gene expression but closer to HCT116 which was most different from small intestinal 
enterocytes. In contrast, Tremblay et al.(2006) showed the inconsistency between differentiated 
and undifferentiated Caco-2 cells on some particular gene expression involved in cell 
proliferation. For instance, cell division cycle 34 showed the similar expression between 
undifferentiated and differentiated Caco-2 cells, however BRCA2 and CDKN1A interacting 
protein (TOK1) showed different expression.  
Taken together, undifferentiated Caco-2 and HT29 cell lines would be useful cell models 
for this study, however there is a limitation which they are not fully representative of the 
normal small intestinal epithelium particularly in that they may show the difference on gene 
expression.  
 
We compared these three cell lines in terms of their response to lumiflavin treatment 
and riboflavin depletion. The effects of riboflavin depletion induced by lumiflavin were different 
between the three cell lines. The effects on clonogenicity, ROS production and ATP 
concentration were the most pronounced in Caco-2 cells and least so in HT29 cells. This may 
reflect differences in functional riboflavin depletion (elevated GRAC) and in the efficiency of 
uptake of riboflavin.. While Caco-2 cells showed the greatest change in GRAC by lumiflavin and 
the lowest concentration of intracellular riboflavin, HT29 cells were the most resistant to 
lumiflavin. HT29 cells maintained GRAC in the range of non-functional deficiency under 
lumiflavin treatment and furthermore the cells possessed the highest intracellular riboflavin 
concentration, implying less vulnerability to riboflavin deficiency. Additionally, Caco-2 cells 
produced more ROS than the other two cell lines under normal conditions, suggestive of cell-
specific differences for ROS requirement for ordinary cell signal transduction. As mentioned in 
section 4.5.2, ROS play an important role as signal transporters for the regulation of cell cycle 
progression, as suggested by Scaife’s study (2004). ROS production was inhibited using the 
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flavoprotein-specific inhibitor, DPI in in vitro models, and this led to cell cycle arrest in G2 
phase thereby inhibiting cell proliferation. Taken together, this study suggests that Caco-2 cells 
are the most appropriate tool for studying the role of riboflavin on intestinal cell proliferation. 
 
Effects of lumiflavin on cell growth were rapid and marked in all three cell lines, with a 
clear dose response, even though lumiflavin resulted in modest intracellular flavin depletion 
and a decline in functional flavins status. In spite of the modest riboflavin depletion, lumiflavin 
resulted in a more pronounced decrease in clonogenicity than that shown after 72 hours of 
growth of Caco-2 cells in a riboflavin-depleted medium in Nakano’s model (Nakano et al., 
2011). These findings suggest that lumiflavin competed effectively for sites on the riboflavin 
transporter, hence resulting in effective interruption of cell proliferation with appearance of 
more rapid inhibition of cell proliferation than growth in a riboflavin-deficient medium alone. 
 
Exposure of cells to lumiflavin influenced flavin homeostasis. While intracellular riboflavin 
concentration was decreased by lumiflavin, an observed gradual decrease in mean FAD 
concentration did not reach statistical significance, and intracellular FMN concentrations were 
unchanged by exposure to lumiflavin in all three cell lines. This result is consistent with our 
previous study in Caco-2 cells grown in riboflavin-depleted medium, in which FMN 
concentrations were maintained at control values within the same duration of treatment  
(Nakano et al., 2011). The maintenance of FMN concentration in our model may be related to 
the observed reduction in intracellular ATP concentration in response to lumiflavin. It has been 
reported that riboflavin depletion leads to a decreased expression of mRNA for both riboflavin 
kinase and FAD synthetase in HepG2 cells (Werner et al., 2005) and a reduction in activities of 
both enzymes was observed in the liver of riboflavin-deficient rats (Lee and McCormick, 1983). 
Both enzymes are ATP-dependent, however riboflavin kinase has a Km about 20-fold lower than 
that for FAD synthetase. This indicates a strong affinity of riboflavin kinase for ATP substrate 
and thus relative insensitivity to changes in intracellular ATP status. The disruption of ATP 
conservation in our lumiflavin-based model of riboflavin depletion may have compromised 
activity of FAD synthetase, whilst having less effect on riboflavin kinase. This would have 
maintained the FMN concentration. 
 
Riboflavin depletion induced by lumiflavin compromised antioxidant status. In this study, 
GRAC was significantly increased by exposure to lumiflavin, reflecting a decreased activity of 
glutathione reductase due to a compromised supply of FAD to the enzyme. This would limit 
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the production of the antioxidant glutathione. FAD-dependent glutathione reductase is an 
important enzyme in the glutathione redox cycle, producing a reduced glutathione, which is an 
endogenous antioxidant. In vitro studies used hepatoma cancer cells showed that riboflavin 
deficiency led to a decrease in activity of glutathione reductase, reflecting a decrease in 
reduced glutathione content, and an increase in carbonylated protein, the product of oxidative 
damage in proteins, and DNA strand breaks (Manthey et al., 2005; 2006). Furthermore, an in 
vitro study reported that enhanced oxidative stress also affects activity and mRNA expression 
of glutathione reductase, diminishing an anti-apoptotic role against oxidative stress (Kim et al., 
2010). Exposure of human hepatoma cells to hydrogen peroxide (H2O2) resulted in a fall in 
activity and mRNA expression of glutathione reductase. This led to a decrease in reduced 
glutathione status, measured as a fall in the ratio of GSH/GSSG and a decrease in total GSH 
content. There was an associated increased incidence of apoptosis with an increased activity of 
caspase-3. However, induction of overexpression of glutathione reductase restored these 
apoptotic changes in cell viability, ROS level, total GSH content, caspase-3 activity and the 
proportion of apoptotic cells.  
 
Exposure to lumiflavin led to an enhanced production of ROS in all cell types, which may 
have contributed to arrest of cells in S phase and thus the observed effect on cell proliferation. 
As described, excessive ROS production can induce oxidative damage to cellular substrates, 
including DNA, and impair cell cycle checkpoint function to prevent replication of damaged 
DNA, thus allowing additional time for DNA repair namely arrest of the cell cycle in S phase 
(Shackelford et al., 2000). Indeed, this study found that lumiflavin led to arrest of cells in S 
phase with subsequent G2/M phase arrest. 
Dysregulation of control over the cell cycle, whenever or wherever acquired in foetal and 
early neonatal life or adulthood, is likely to be strongly associated with developmental or 
differentiating defects in certain tissues including the GI tract. Previous studies have produced 
evidence that riboflavin depletion leads to abnormal development of the GI track and that this 
may be modulated by aberrant mitosis of its cells. In a rat model of riboflavin deficiency during 
the postnatal period, crypt hypertrophy and decreased proliferation were observed in the small 
intestine, implying a failure to secure normal development of the villus (Powers, 2003; Williams 
et al., 1995; Yates et al., 2001). Furthermore, a more recent study found fewer crypt cell 
divisions with significantly shorter and less cellular crypts in the colon of adult gastroscopy 
patients with low riboflavin status, compared with normal controls (Nakano et al., 2011). In the 
subsequent in vitro study using Caco-2 cells, riboflavin deficiency led to inhibition of cell 
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proliferation by the arrest of cell cycle in mitosis and a significant increase in the proportion of 
aneuploid cells, with alterations in genes involved in the regulation of mitosis.  
 
A difference in effects on the cell cycle between this model and Nakano’s cell model was 
found. S phase arrest was observed in this lumiflavin-induced riboflavin depletion model but 
arrest in mitosis was observed in Nakano’s model (Nakano et al., 2011). However, it may be 
unwise to make a direct comparison of the two models because of the very different protocols 
used to achieve riboflavin deficiency and differences in the degree of riboflavin deficiency. This 
lumiflavin-based model resulted in modest riboflavin depletion within the shorter period; only 
72 hours, compared with Nakano’s model. Nakano et al. (2011) used a protocol of culturing 
cells with a gradual depletion from medium with physiological level of riboflavin to riboflavin-
free medium for approximately 10 days. The prolonged depletion of riboflavin induced severe 
degree of riboflavin deficiency meaning significantly falls in the concentrations of FAD and 
FMN; approximately 80% fall in intracellular FMN concentration and approximately 50% fall in 
intracellular FAD concentration. Therefore, the different effects on the cell cycle between the 
two models may be caused from the different degrees of riboflavin deficiency achieved.  
 
This study found changes in phosphorylation of proteins through determination of 
global phosphorylated amino acid residues and phosphoprotein profiling by proteomic analysis. 
Such changes were not linked to riboflavin depletion. Lumiflavin is known to inhibit the uptake 
of riboflavin into cells by competing for sites on the riboflavin transporter (Said and Ma, 1994; 
Fujimura et al., 2010). Therefore, in this cell signalling study, the term ‘riboflavin depletion 
induced by lumiflavin’ actually means obstruction of lumiflavin in the role of riboflavin itself 
rather than exhausting flavins pool. 
 
Phosphoproteomic analysis revealed that lumiflavin may suppress cell signalling 
pathways that normally occur in riboflavin-rich condition. Pathways that significantly altered by 
lumiflavin were gene expression pathway particularly in mRNA processing and apoptosis 
pathway. Exposure to lumiflavin led to sustained phosphorylation in some of serine/arginine-
rich splicing factor proteins family (the SR protein).  
According to literatures, observed changes in the SR protein may be related to 
regulation of the cell cycle and apoptosis. Recent studies suggested that alternative splicing 
network is closely related to from cell cycle control to apoptosis. An in vitro study reported 
that SRSF1 downregulation or knockout promoted proapoptotic splicing of pre-mRNAs of Bcl2 
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family; Bcl-x, Mcl1 and caspase-9, and SRSF1 directly binds to mRNAs of these proteins and 
regulates expression (Moore et al., 2010). Another showed that SRSF3 played an important role 
in the regulation of G1 to S phase progression and apoptosis through association with Bcl2 in 
HCT116 colon cancer cells (Kurokawa et al., 2014). HCT116 cells were treated with siRNA for 
SRSF3 for 24 hours, synchronised in the G1 phase by serum starvation for the next 48 hours, 
and then stimulated with 10% FCS for 24 hours. SRSF3 knockdown reduced mRNA and protein 
levels of G1/S checkpoint such as cyclins (D1, D3 and E1), E2F1 and E2F7, and led to 
hypophosphorylation of retinoblastoma protein (Rb), thereby resulting in G1 phase arrest and 
an increase in apoptotic cells. Rb is a tumour suppressor protein, inhibiting progression of 
G1/S transit when dephosphorylated by cyclin-dependent kinases (CDKs) which consisted of 
cyclin D and E. When Rb is dephosphorylated, it binds to E2F and restricts the function of E2F 
complex on G1/S transit. Also, they showed that siRNA knockdown for SRSF3 for 24, 48 and 72 
hours led to a time-dependent increase in apoptotic cells with a reduction in expression of Bcl-
2.  
 
Exposure of Caco-2 cells to lumiflavin led to a change in the cell cycle. An increased 
proportion of cells in S phase were observed in Caco-2 cells exposed to lumiflavin with 
subsequent accumulation of cells in G2/M phase. Therefore iTRAQ analysis might be expected 
to produce changes in phosphorylation of DNA damage/repair-linked proteins or proteins 
involved in S phase progression. For instance, CDK2 (cyclin-dependent kinase) acts at the G1/S 
transition and also in DNA replication and transition from S phase to G2/M phase. CDK2 
regulates early and late stage of DNA replication by interacting with cyclin E and cyclin A to 
permit G1/S transition and to regulate S phase (De Boer et al., 2008; Flores et al., 2010). CDK2 
activity is changed during S and G2 phase by phosphorylation and dephosphorylation on 
different sites (Gu et al., 1992). CDK2 phosphorylates some proteins in response to DNA 
damage for instance BRCA2, p53 and so on. CDK2 phosphorylates the carboxy-terminal region 
of BRCA2, where the essential recombination protein RAD51 directly interacts, and blocks the 
interactions between BRCA2 and RAD51 (Esashi et al., 2005). DNA damage stimulates 
dephosphorylation of BRCA2 and increasing interactions with RAD51 which binds to single and 
double-stranded DNA and initiates DNA strand exchange (Baumann et al., 1996). CDK2 is also 
required for p53-independent G2/M checkpoint activation by balancing S phase regulatory 
proteins such as Cdc6 (cell division control protein 6) (Chung and Bunz, 2010).  Cdc6 acts in 
the initiation of DNA replication and is associated with the DNA damage sensor ATR 
 
Chapter 6 Discussion and conclusion 
150 
 
(serine/threonine-protein kinase ATR (Ataxia telangiectasia and Rad3-related protein)) to 
control completion of DNA replication before initiation of mitosis. (Ayad, 2005).   
Unfortunately, the proteomic analysis in this study revealed no significant pathways in 
which such proteins are involved. This may be due to insufficient exposure time to lumiflavin to 
emerge accumulated effects on changes in such proteins, thus it requires further study using 
longer time periods.  
However, significant changes in various types of histones were observed in this study. 
Fewer phosphorylated histone proteins were found in lumiflavin-treated cells compared with 
time-controls; Histone H2, H3 and H4 (HIST1H2BH, UniProt accession No. Q93079; HIST1H2AJ, 
UniProt accession No. Q99878; H3F3B, UniProt accession No. K7EK07; HIST1H4A, UniProt 
accession No. P62805). Purposes of phosphorylation of histone are histone deposition and 
chromatin decondensation during S phase and chromatin condensation during mitosis. Thus, 
phosphorylation of histones may be induced in response to DNA damage for DNA repair 
(Banerjee and Chakravarti, 2011). In this study, histone H4 showed approximately 40% lower 
fold change by lumiflavin compared with time-control. The fold changes of histone H4 were 
increased by time in control conditions, but not changed by lumiflavin. This suggests that 
phosphorylation of histone H4 may naturally occur in riboflavin-rich condition and lumiflavin 
may suppress the normal response. DNA breaks can be formed in normal conditions by 
endogenous ROS that are produced as a result of metabolic processes (Podhorecka et al., 
2010). Approximately 99% of DNA breaks are repaired, whilst approximately 1% of DNA breaks 
become DNA double-strand breaks (DSBs) during DNA replication, which is the most 
dangerous type of DNA damage resulting in severe consequences for chromosome aberrations, 
genomic instability and severe clinical implications such as cancer. A study using yeast has 
reported that phosphorylation on Ser1 of histone H4 occurs for the repair of DNA damage 
independent of cell-cycle stage (Cheung et al., 2005). This modification has been found in 
mammals as well (Banerjee and Chakravarti, 2011). DNA damage stimulates casein kinase II (CK 
II) leading to phosphorylation on Ser1 of histone H4 (H4S1) in regions close to double-strand 
breaks (Cheung et al., 2005). Rossetto et al (2012) suggested that phosphorylation of H4S1 
may act to stabilise nucleosomes that are newly reassembled during restoration of chromatin 
structure by preventing the acetylation of the histone H4 tail by the NuA4 HAT. However, this 
study revealed no information of phosphorylation sites on peptide sequences so it is not clear 
whether the observed changes in histone H4 is derived from phosphorylation of the specific 
site Serine 1 of histone H4.  
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Apoptotic DNA fragment, which is a key feature of apoptosis, was not found in cells 
exposed to lumiflavin. However, phosphoproteomic analysis revealed that apoptosis pathway 
was significantly altered by exposure to lumiflavin with changes in the related genes. As 
described, DNA fragmentation is a late event during apoptosis, therefore further study may 
confirm the finding through investigation of early changes represented as a predictor of 
apoptosis such as caspases (McIlwain et al., 2013).  
 
In conclusion, results were compatible with the first two hypotheses in that exposing 
intestinal cells to lumiflavin resulted in riboflavin depletion and functional riboflavin deficiency. 
Also, lumiflavin-treated, thus flavin-depleted, cells showed cellular and biochemical dysfunction 
associated with a reduced capacity to generate energy, a reduced antioxidant status and 
enhanced production of ROS. Lumiflavin-induced changes in cell signalling included modest 
changes in global phosphorylation. No specific candidate pathways were identified, however 
we found that lumiflavin induced suppression of normal cell signalling of riboflavin-rich 
condition, induction of apoptosis pathway and changes in mRNA processing.  
 
6.3. Limitations 
 
1. An attempt was made to measure FAD-dependent succinate dehydrogenase activity, in 
order to strengthen the finding that exposure to lumiflavin disrupted ATP generation. 
However this proved unsuccessful and an alternative protocol needs to be developed. For 
example, determination of substrate or products of succinate dehydrogenase; succinate or 
furmarate may be useful. 
 
2. A comparison of response to lumiflavin between the cell lines in terms of phosphorylation 
using western blot and proteomic analysis could not be made because of cost limitations. 
HT29 cells which were resistant to lumiflavin could behave differently from Caco-2 cells 
used for signalling study. 
 
3. Phosphoprotein profiling by iTRAQ in cells exposed to lumiflavin for 24 hours and time-
control was determined in a single experiment, due to limitations of cost and number of 
labelling. Determination in replicate would increase reliability of results. 
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6.4. Future work 
 
In order to build on the finding of the results described in this study, the following 
studies are proposed. 
 
1. Early events in apoptosis should be measured to determine effects of exposure to 
lumiflavin in the apoptosis pathway, despite a lack of evidence for DNA fragmentation. For 
example, determination of caspases may be useful. 
 
2. Determination of mitosis-specific markers could reveal a distinct effect of exposure to 
lumiflavin on mitosis. Cell cycle data using flow cytometry provided the combined 
proportion of cells in both G2 and mitosis phase. For example, phosphorylated histone H3 
(pHH3) is widely used as a mitosis marker. 
 
3. Total protein profiling using proteomic analysis might reveal effects of exposure to 
lumiflavin on SR protein and gene expression of certain proteins which may be 
consequently regulated through aberrant phosphorylation in SR proteins.   
 
4. Investigation of apoptosis-related proteins in cells exposed to lumiflavin and induced for 
overexpression of SR protein may reveal the association. 
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Appendix 1 Reactome analysis of the pathways represented by 145 proteins 
significantly altered under 24hours lumiflavin treatment compared with time-
control with matching proteins. 
 
Statistically over-represented events in hierarchy 
Each Event is coloured according to the un-adjusted, i.e. not corrected for multiple testing, probability 
(from hypergeometric test) of seeing given number or more genes in this Event by chance. Only the ‘child’ 
events are shown which have a p-value lower than the ‘parent’ event. The top-level (root) Events are 
ordered according to the lowest p-value of their components. Colour key for probabilities: 
1e+00 3e-01 1e-01 3e-02 1e-02 3e-03 1e-03 3e-04 1e-04 3e-05 1e-05 3e-06 1e-06 3e-07 1e-07 3e-08 1e-08 3e-09 1e-09 3e-10 > 
Gene Expression1.1e-08, 25/1031 
Matching identifiers 
Q13247 SRSF6 
P20042 EIF2S2 
Q13242 SRSF9 
P62316 SNRPD2 
P26368 U2AF2 
P05387 RPLP2 
Q9NZI8 IGF2BP1 
P62753 RPS6 
Q01081 U2AF1 
Q01105 SET 
Q9Y5S9 RBM8A 
P13639 EEF2 
P84103 SRSF3 
P61978-3 HNRNPK 
Q9Y5M8 SRPRB 
O75643 SNRNP200 
P08621 SNRNP70 
Q13263-2 TRIM28 
O43809 NUDT21 
P24534 EEF1B2 
O76094 SRP72 
Q99436 PSMB7 
Q13243 SRSF5 
P62987 UBA52 
O75533 SF3B1 
Processing of Capped Intron-Containing Pre-mRNA1.5e-12, 13/117 
Matching identifiers 
Q13247 SRSF6 
P84103 SRSF3 
Q13242 SRSF9 
P61978-3 HNRNPK 
P62316 SNRPD2 
P26368 U2AF2 
P08621 SNRNP70 
O75643 SNRNP200 
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Appendix 1 (continued) 
O43809 NUDT21 
Q01081 U2AF1 
Q13243 SRSF5 
Q9Y5S9 RBM8A 
O75533 SF3B1 
 
mRNA Splicing8.7e-13, 13/112 
Matching identifiers 
Q13247 SRSF6 
P84103 SRSF3 
Q13242 SRSF9 
P61978-3 HNRNPK 
P62316 SNRPD2 
P26368 U2AF2 
P08621 SNRNP70 
O75643 SNRNP200 
O43809 NUDT21 
Q01081 U2AF1 
Q13243 SRSF5 
Q9Y5S9 RBM8A 
O75533 SF3B1 
mRNA Processing1.1e-11, 13/136 
Matching identifiers 
Q13247 SRSF6 
P84103 SRSF3 
Q13242 SRSF9 
P61978-3 HNRNPK 
P62316 SNRPD2 
P26368 U2AF2 
P08621 SNRNP70 
O75643 SNRNP200 
O43809 NUDT21 
Q01081 U2AF1 
Q13243 SRSF5 
Q9Y5S9 RBM8A 
O75533 SF3B1 
Processing of Capped Intron-Containing Pre-mRNA1.5e-12, 13/117 
Matching identifiers 
Q13247 SRSF6 
P84103 SRSF3 
Q13242 SRSF9 
P61978-3 HNRNPK 
P62316 SNRPD2 
P26368 U2AF2 
P08621 SNRNP70 
O75643 SNRNP200 
O43809 NUDT21 
Q01081 U2AF1 
Q13243 SRSF5 
Q9Y5S9 RBM8A 
O75533 SF3B1 
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Appendix 1 (continued) 
mRNA Splicing8.7e-13, 13/112 
Matching identifiers 
Q13247 SRSF6 
P84103 SRSF3 
Q13242 SRSF9 
P61978-3 HNRNPK 
P62316 SNRPD2 
P26368 U2AF2 
P08621 SNRNP70 
O75643 SNRNP200 
O43809 NUDT21 
Q01081 U2AF1 
Q13243 SRSF5 
Q9Y5S9 RBM8A 
O75533 SF3B1 
Post-Elongation Processing of the Transcript6.4e-10, 8/43 
Matching identifiers 
Q13247 SRSF6 
P84103 SRSF3 
Q13242 SRSF9 
P26368 U2AF2 
O43809 NUDT21 
Q01081 U2AF1 
Q13243 SRSF5 
Q9Y5S9 RBM8A 
Post-Elongation Processing of Intron-Containing pre-mRNA8.5e-11, 8/34 
Matching identifiers 
Q13247 SRSF6 
P84103 SRSF3 
Q13242 SRSF9 
P26368 U2AF2 
O43809 NUDT21 
Q01081 U2AF1 
Q13243 SRSF5 
Q9Y5S9 RBM8A 
Transcription9.9e-06, 8/145 
Matching identifiers 
RNA Polymerase II Transcription6.5e-07, 8/101 
Matching identifiers 
Q13247 SRSF6 
Appendix 1 (continued) 
P84103 SRSF3 
Q13242 SRSF9 
P26368 U2AF2 
O43809 NUDT21 
Q01081 U2AF1 
Q13243 SRSF5 
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Q9Y5S9 RBM8A 
RNA Polymerase II Transcription Termination6.4e-10, 8/43 
Matching identifiers 
Q13247 SRSF6 
P84103 SRSF3 
Q13242 SRSF9 
P26368 U2AF2 
O43809 NUDT21 
Q01081 U2AF1 
Q13243 SRSF5 
Q9Y5S9 RBM8A 
Apoptosis1.6e-06, 9/154 
Matching identifiers 
Q6UYC3 LMNA 
P31947 SFN 
P16403 HIST1H1C 
P26583 HMGB2 
P09429 HMGB1 
P16401 HIST1H1B 
P62987 UBA52 
Q99436 PSMB7 
P30419 NMT1 
Metabolism of proteins8.3e-04, 12/574 
Matching identifiers 
Q6UYC3 LMNA 
P51858 HDGF 
P20042 EIF2S2 
P13639 EEF2 
Q9Y5M8 SRPRB 
P05387 RPLP2 
P62753 RPS6 
O00567 NOP56 
P24534 EEF1B2 
P27797 CALR 
O76094 SRP72 
P62987 UBA52 
Translation1.3e-05, 8/151 
Matching identifiers 
P62753 RPS6 
P24534 EEF1B2 
P20042 EIF2S2 
P13639 EEF2 
Q9Y5M8 SRPRB 
O76094 SRP72 
P62987 UBA52 
Appendix 1 (continued) 
P05387 RPLP2 
Cell Cycle1.5e-04, 12/478 
Matching identifiers 
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Q6UYC3 LMNA 
P07437 TUBB 
O75531 BANF1 
O60832 DKC1 
P06748 NPM1 
Q99878 HIST1H2AJ 
P62805 HIST1H4A 
Q93079 HIST1H2BH 
Q9Y266 NUDC 
P07900 HSP90AA1 
Q99436 PSMB7 
P62987 UBA52 
Chromosome Maintenance1.0e-04, 6/103 
Matching identifiers 
Q6UYC3 LMNA 
O60832 DKC1 
P06748 NPM1 
Q99878 HIST1H2AJ 
P62805 HIST1H4A 
Q93079 HIST1H2BH 
Meiosis3.0e-03, 4/81 
Matching identifiers 
Q6UYC3 LMNA 
Q99878 HIST1H2AJ 
P62805 HIST1H4A 
Q93079 HIST1H2BH 
Meiotic Synapsis8.1e-04, 4/57 
Matching identifiers 
Q6UYC3 LMNA 
Q99878 HIST1H2AJ 
P62805 HIST1H4A 
Q93079 HIST1H2BH 
Telomere clustering at the nuclear membrane3.9e-04, 4/47 
Matching identifiers 
Q6UYC3 LMNA 
Q99878 HIST1H2AJ 
P62805 HIST1H4A 
Q93079 HIST1H2BH 
Binding and Uptake of Ligands by Scavenger Receptors4.3e-01, 2/195 
Matching identifiers 
P27797 CALR 
P07900 HSP90AA1 
Appendix 1 (continued) 
Scavenging by Class F Receptors1.1e-03, 2/7 
Matching identifiers 
P27797 CALR 
P07900 HSP90AA1 
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Mitotic M-M/G1 phases4.7e-02, 5/266 
Matching identifiers 
Q6UYC3 LMNA 
O75531 BANF1 
Q9Y266 NUDC 
Q99436 PSMB7 
P62987 UBA52 
M Phase3.0e-02, 5/235 
Matching identifiers 
Q6UYC3 LMNA 
O75531 BANF1 
Q9Y266 NUDC 
Q99436 PSMB7 
P62987 UBA52 
Mitotic Metaphase and Anaphase1.2e-02, 5/185 
Matching identifiers 
Q6UYC3 LMNA 
O75531 BANF1 
Q9Y266 NUDC 
Q99436 PSMB7 
P62987 UBA52 
Mitotic Anaphase1.2e-02, 5/184 
Matching identifiers 
Q6UYC3 LMNA 
O75531 BANF1 
Q9Y266 NUDC 
Q99436 PSMB7 
P62987 UBA52 
Nuclear Envelope Reassembly4.0e-03, 2/13 
Matching identifiers 
Q6UYC3 LMNA 
O75531 BANF1 
Disease3.4e-02, 12/915 
Matching identifiers 
O75531 BANF1 
P06748 NPM1 
Q99878 HIST1H2AJ 
P62805 HIST1H4A 
Q93079 HIST1H2BH 
P05387 RPLP2 
Appendix 1 (continued) 
P07686 HEXB 
P62753 RPS6 
P07900 HSP90AA1 
Q99436 PSMB7 
P62987 UBA52 
P30419 NMT1 
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Amyloids6.3e-03, 3/51 
Matching identifiers 
Q99878 HIST1H2AJ 
P62805 HIST1H4A 
Q93079 HIST1H2BH 
Serum amyloid P binds DNA and chromatin1.1e-03, 3/28 
Matching identifiers 
Q99878 HIST1H2AJ 
P62805 HIST1H4A 
Q93079 HIST1H2BH 
HIV Infection2.4e-02, 5/221 
Matching identifiers 
O75531 BANF1 
P06748 NPM1 
Q99436 PSMB7 
P62987 UBA52 
P30419 NMT1 
Host Interactions of HIV factors1.8e-02, 4/135 
Matching identifiers 
O75531 BANF1 
P06748 NPM1 
Q99436 PSMB7 
P62987 UBA52 
Signal Transduction1.0e+00, 6/1847 
Matching identifiers 
P62753 RPS6 
P08254 MMP3 
P07900 HSP90AA1 
Q99436 PSMB7 
P62987 UBA52 
P30419 NMT1 
Signaling by ERBB23.3e-01, 2/158 
Matching identifiers 
P07900 HSP90AA1 
P62987 UBA52 
CHIP (STUB1) mediates ubiquitination of ERBB21.9e-03, 2/9 
Matching identifiers 
P07900 HSP90AA1 
Appendix 1 (continued) 
P62987 UBA52 
CUL5 mediates ubiquitination of ERBB21.9e-03, 2/9 
Matching identifiers 
P07900 HSP90AA1 
P62987 UBA52 
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Metabolism of RNA2.3e-03, 7/249 
Matching identifiers 
P62753 RPS6 
P62316 SNRPD2 
Q01105 SET 
Q99436 PSMB7 
P62987 UBA52 
 
Q9Y5S9 RBM8A 
P05387 RPLP2 
3' -UTR-mediated translational regulation8.6e-03, 4/109 
Matching identifiers 
P62753 RPS6 
P20042 EIF2S2 
P62987 UBA52 
P05387 RPLP2 
Immune System9.9e-01, 5/1397 
Matching identifiers 
P09429 HMGB1 
P27797 CALR 
P07900 HSP90AA1 
Q99436 PSMB7 
P62987 UBA52 
Adaptive Immune System9.6e-01, 3/866 
Matching identifiers 
P27797 CALR 
Q99436 PSMB7 
P62987 UBA52 
Class I MHC mediated antigen processing & presentation4.3e-01, 3/320 
Matching identifiers 
P27797 CALR 
Q99436 PSMB7 
P62987 UBA52 
Antigen processing-Cross presentation9.3e-02, 3/145 
Matching identifiers 
P27797 CALR 
Q99436 PSMB7 
P62987 UBA52 
Appendix 1 (continued) 
ER-Phagosome pathway7.2e-02, 3/130 
Matching identifiers 
P27797 CALR 
Q99436 PSMB7 
P62987 UBA52 
Proteasomal cleavage of substrate4.9e-02, 2/48 
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Matching identifiers 
Q99436 PSMB7 
P62987 UBA52 
 
Total number of events assessed: 7726 
Number of matching events (i.e. individual hypergeometric tests performed): 250 
Number of genes matching submitted identifiers: 52 
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Appendix 2 List of proteins altered by lumiflavin treatment for 6 hours 
compared with time-control  
UniProt 
ID 
6h 
Name 
Fold 
change 
P07910-2 HNRNPC 
Isoform C1 of Heterogeneous nuclear 
ribonucleoproteins C1/C2  
1.072  
J3KTL2 SRSF1 
Serine/arginine-rich-splicing factor 1  
1.143  
Q13247 SRSF6 
Serine/arginine-rich splicing factor 6  
1.126  
D6R9W4 DBN1 
Drebrin (Fragment) 
1.107  
J3KPP4 LUC7L3 
Cisplatin resistance-associated 
overexpressed protein, isoform CRA_b 
1.101  
P13639 EEF2 
Elongation factor 2  
0.907  
Q93079 HIST1H2BH 
Histone H2B type 1-H 
0.906  
Fold changes against 1 of control (P<0.05, MTC off) 
 
 
Appendix 3 List of proteins altered by lumiflavin treatment for 24 hours 
compared with time-control  
UniProt 
ID 
24h 
Name 
Fold 
change 
 UniProt 
ID 
24h 
Name 
Fold 
change  
Q9H1E3 UCKS1  
Nuclear ubiquitous casein and cyclin-
dependent kinase substrate 1  
1.538  M0QXS5 HNRNPL 
Heterogeneous nuclear 
ribonucleoprotein L (Fragment) 
0.342  
Q13242 SRSF9  
Serine/arginine-rich splicing factor 9 
1.390  P62805 HIST1H4A  
Histone H4 
0.607  
P84103 SRSF3 
Serine/arginine-rich splicing factor 3 
1.372  K7EK07 H3F3B 
Histone H3 (Fragment) 
0.646  
E7ET93 GABRE  
REVERSED Gamma-aminobutyric acid 
receptor subunit epsilon 
1.354  P07437 TUBB  
Tubulin beta chain 
0.705  
C9JAB2 SRSF7 
Serine/arginine-rich-splicing factor 7 
1.328  Q99878 HIST1H2AJ  
Histone H2A type 1-J 
0.719  
J3KTL2 SRSF1 
Serine/arginine-rich-splicing factor 1 
1.315  B4DTG2 EEF1G  
Elongation factor 1-gamma 
0.737  
B8ZZQ6 PTMA 
Thymosin alpha-1 
1.297  Q15233 NONO 
Non-POU domain-containing 
octamer-binding protein 
0.739  
P19338 NCL 
Nucleolin 
1.259  J3QK90 NSFL1C  
NSFL1 cofactor p47 
0.740  
P26368 U2AF2 
Splicing factor U2AF 65 kDa subunit 
1.253  F5H5D3 TUBA1C  
Tubulin alpha-1C chain 
0.755  
Q13247 SRSF6 
Serine/arginine-rich splicing factor 6 
1.250  P07237 P4HB 
Protein disulfide-isomerase 
0.759  
E7EX17 EIF4B 
Eukaryotic translation initiation factor 
4B 
1.246  P23246 SFPQ  
Splicing factor, proline- and 
glutamine-rich 
0.761  
Fold changes against 1 of control (P<0.05, MTC off) 
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Appendix 3 List of proteins altered by lumiflavin treatment for 24 hours 
compared with time-control (continued) 
UniProt 
ID 
24h 
Name 
Fold 
change 
 UniProt 
ID 
24h 
Name 
Fold 
change 
E7ES08 HMGB3 
High mobility group protein B3 
(Fragment) 
1.243  Q93079 HIST1H2BH 
Histone H2B type 1-H 
0.817  
Q99436 PSMB7 
Proteasome subunit beta type-7 
1.243  P20042 EIF2S2 
Eukaryotic translation initiation factor 
2 subunit 2 
0.823  
P62995 TRA2B 
Transformer-2 protein homolog beta 
1.242  Q16555 DPYSL2 
Dihydropyrimidinase-related protein 
2 
0.833  
H7BYM6 HMGA1 
High mobility group protein HMG-
I/HMG-Y 
1.229  E9PB51 RBM4 
RNA-binding protein 4 (Fragment) 
0.843  
P49006 MARCKSL1 
MARCKS-related protein 
1.227  F8VXL2 DYNLL1 
Dynein light chain 1, cytoplasmic 
0.850  
P20290 BTF3  
Transcription factor BTF3 
1.227  P13639 EEF2 
Elongation factor 2 
0.851  
P07686 HEXB  
Beta-hexosaminidase subunit beta 
1.227  P62987 UBA52 
Ubiquitin-60S ribosomal protein L40 
0.862  
M0QXD6 GTF2F1 
General transcription factor IIF subunit 
1 (Fragment) 
1.217  Q9NZI8 IGF2BP1 
Insulin-like growth factor 2 mRNA-
binding protein 1 
0.862  
Q14498 RBM39 
RNA-binding protein 39 
1.209  J3QLI9 SNRPD1  
Small nuclear ribonucleoprotein Sm 
D1 
0.869  
F5H7R9 PTMS 
Parathymosin (Fragment) 
1.207  P31947 SFN  
14-3-3 protein sigma 
0.876  
P26583 HMGB2 
High mobility group protein B2 
1.204  Q8NC51 SERBP1 
Plasminogen activator inhibitor 1 
RNA-binding protein 
0.877  
Q92688 ANP32B  
Acidic leucine-rich nuclear 
phosphoprotein 32 family member B 
1.197  G8JLB6 HNRNPH1 
Heterogeneous nuclear 
ribonucleoprotein H 
0.878  
Q9Y5S9 RBM8A  
RNA-binding protein 8A 
1.191  P27797 CALR  
Calreticulin 
0.884  
Q01081 U2AF1 
Splicing factor U2AF 35 kDa subunit 
1.189  Q9Y2X3 NOP58 
Nucleolar protein 58 
0.889  
Q5JWU6 TPD52L2 
Tumor protein D52-like 2, isoform 
CRA_e 
1.178  F8WA83 PDIA6 
Protein disulfide-isomerase A6 
0.889  
P07910-2 HNRNPC  
Isoform C1 of Heterogeneous nuclear 
ribonucleoproteins C1/C2 
1.176  O43143 DHX15 
Putative pre-mRNA-splicing factor 
ATP-dependent RNA helicase DHX15  
0.894  
P05387 RPLP2 
60S acidic ribosomal protein P2 
1.169  Q9Y5M8 SRPRB  
Signal recognition particle receptor 
subunit beta 
0.896  
B4E135 LIG1  
DNA ligase 1 
1.164  O60884 DNAJA2 
DnaJ homolog subfamily A member 
2 
0.899  
P09429 HMGB1 
High mobility group protein B1 
1.161     
D6R9W4 DBN1 
Drebrin (Fragment) 
1.158     
E9PM92 C11orf58 
Protein C11orf58 (Fragment) 
1.158     
Fold changes against 1 of control (P<0.05, MTC off) 
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Appendix 3 List of proteins altered by lumiflavin treatment for 24 hours 
compared with time-control (continued) 
UniProt 
ID 
24h 
Name 
Fold 
change 
 
G3V1X9 CBX5 
Chromobox homolog 5 (HP1 alpha 
homolog, Drosophila), isoform CRA_a  
1.155  
O75531 BANF1 
Barrier-to-autointegration factor 
1.150  
P08254 MMP3 
Stromelysin-1 
1.144  
P62753 RPS6 
40S ribosomal protein S6 
1.143  
Q7Z6L1 TECPR1 
REVERSED Tectonin beta-propeller 
repeat-containing protein 1 
1.141  
B1AKZ5 PEA15 
Astrocytic phosphoprotein PEA-15 
1.139  
A8MYV2 LUC7L  
LUC7-like (S. cerevisiae) 
1.136  
P08621 SNRNP70 
U1 small nuclear ribonucleoprotein 70 
kDa 
1.136  
J3KPP4 LUC7L3 
Cisplatin resistance-associated 
overexpressed protein, isoform CRA_b 
1.132  
H0YN26 ANP32A  
Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
1.131  
Q13243 SRSF5  
Serine/arginine-rich splicing factor 5 
1.126  
Q5QPL9 RALY  
RNA-binding protein Raly (Fragment) 
1.117  
H7C2Q8 EBNA1BP2 
EBNA1 binding protein 2, isoform 
CRA_d 
1.116  
F5H8H3 STARD10 
PCTP-like protein 
1.114  
P51858 HDGF 
Hepatoma-derived growth factor 
1.114  
Q9BR76 CORO1B  
Coronin-1B 
1.112  
Q9Y266 NUDC  
Nuclear migration protein nudC 
1.112  
Q9Y383-2 LUC7L2 
Isoform 2 of Putative RNA-binding 
protein Luc7-like 2 
1.108  
K7ELL7 PRKCSH 
Glucosidase 2 subunit beta 
1.105  
Q9UHB6 LIMA1 
LIM domain and actin-binding protein 
1 
1.105  
E7EUT4 GAPDH 
Glyceraldehyde-3-phosphate 
dehydrogenase 
1.103  
Fold changes against 1 of control (P<0.05, MTC off) 
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Appendix 4 List of proteins altered by 6 hours lumiflavin compared with 0hour 
control  
UniProt 
ID 
6h LF 
Name 
Fold 
change 
Q13242 SRSF9 Serine/arginine-rich splicing factor 9 1.135 
F5GWN7 SNAP91 Clathrin coat assembly protein AP180 1.131 
P84103 SRSF3 Serine/arginine-rich splicing factor 3 1.130 
J3KTL2 SRSF1 Serine/arginine-rich-splicing factor 1 1.111 
P07910-2 
HNRNPC  
Isoform C1 of Heterogeneous nuclear 
ribonucleoproteins C1/C2 
1.083 
P16401 HIST1H1B  Histone H1.5 0.859 
P16403 HIST1H1C  Histone H1.2 0.859 
Fold changes against 1 of control (P<0.05, MTC off) 
 
 
Appendix 5 List of proteins altered by 24 hours control compared with 0hour 
control  
UniProt 
ID 
24h control 
Name 
Fold 
change 
 UniProt 
ID 
24h control 
Name 
Fold 
change 
P62805 HIST1H4A  
Histone H4 
1.432   Q9H1E3 NUCKS1 
Nuclear ubiquitous casein and cyclin-
dependent kinase substrate 1 
0.714  
P07437 TUBB  
Tubulin beta chain 
1.366   B8ZZQ6 PTMA  
Thymosin alpha-1 
0.733  
Q99878 HIST1H2AJ  
Histone H2A type 1-J 
1.337   P49006 MARCKSL1 
MARCKS-related protein 
0.751  
P07237 P4HB 
Protein disulfide-isomerase 
1.325   E7ES08 HMGB3 
High mobility group protein B3 
(Fragment) 
0.766  
Q15233 NONO  
Non-POU domain-containing 
octamer-binding protein 
1.318   Q13242 SRSF9  
Serine/arginine-rich splicing factor 9 
0.783  
P23246 SFPQ  
Splicing factor, proline- and 
glutamine-rich 
1.308   P05387 RPLP2 
60S acidic ribosomal protein P2 
0.784  
J3QK90 NSFL1C  
NSFL1 cofactor p47 
1.244   C9JAB2 SRSF7 
Serine/arginine-rich-splicing factor 7 
0.787  
Q93079 HIST1H2BH  
Histone H2B type 1-H 
1.233   P53999 SUB1 
Activated RNA polymerase II 
transcriptional coactivator p15 
0.787  
F5H5D3 TUBA1C 
Tubulin alpha-1C chain 
1.229   P19338 NCL 
Nucleolin 
0.794  
Q9NZI8 IGF2BP1 
Insulin-like growth factor 2 mRNA-
binding protein 1 
1.214   P28074 PSMB5 
Proteasome subunit beta type-5 
0.797  
M0R2B8 SNRPA  
U1 small nuclear ribonucleoprotein A 
(Fragment) 
1.200   P84103 SRSF3 
Serine/arginine-rich splicing factor 3 
0.802  
Fold changes against 1 of control (P<0.05, MTC off) 
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Appendix 5 List of proteins altered by 24 hours control compared with 0hour 
control (continued) 
UniProt 
ID 
24h control 
Name 
Fold 
change 
 UniProt 
ID 
24h control 
Name 
Fold 
change 
P34931 HSPA1L  
Heat shock 70 kDa protein 1-like 
1.181   P16401 HIST1H1B  
Histone H1.5 
0.808  
F8VXL2 DYNLL1 
Dynein light chain 1, cytoplasmic 
1.162   E9PM92 C11orf58  
Protein C11orf58 (Fragment) 
0.812  
P20042 EIF2S2 
Eukaryotic translation initiation factor 
2 subunit 2 
1.150   Q92688 ANP32B  
Acidic leucine-rich nuclear 
phosphoprotein 32 family member B 
0.813  
G8JLB6 HNRNPH1 
Heterogeneous nuclear 
ribonucleoprotein H 
1.142   P26583 HMGB2 
High mobility group protein B2 
0.815  
E9PRY8 EEF1D  
Elongation factor 1-delta 
1.142   E7ET93 GABRE  
REVERSED Gamma-aminobutyric acid 
receptor subunit epsilon 
0.816  
E9PJF4 CLNS1A  
Methylosome subunit pICln 
1.138   F5H7R9 PTMS  
Parathymosin (Fragment) 
0.817  
Q8NC51 SERBP1 
Plasminogen activator inhibitor 1 
RNA-binding protein 
1.127   P16403 HIST1H1C  
Histone H1.2 
0.819  
Q12906-
4 
ILF3 
Isoform 4 of Interleukin enhancer-
binding factor 3 
1.124   J3KTL2 SRSF1 
Serine/arginine-rich-splicing factor 1 
0.822  
O43143 DHX15 
Putative pre-mRNA-splicing factor 
ATP-dependent RNA helicase DHX15 
1.124   Q01105 SET  
Protein SET 
0.826  
I3L4N8 ACTG1 
Actin, cytoplasmic 2, N-terminally 
processed (Fragment) 
1.119   Q13247 SRSF6  
Serine/arginine-rich splicing factor 6 
0.827  
P24534 EEF1B2 
Elongation factor 1-beta 
1.116   D6R9W4 DBN1 
Drebrin (Fragment) 
0.837  
Q9Y5M8 SRPRB  
Signal recognition particle receptor 
subunit beta 
1.115   P09429 HMGB1 
High mobility group protein B1 
0.842  
H3BRV0 EIF3C  
Eukaryotic translation initiation factor 
3 subunit C 
1.111   Q9Y5S9 RBM8A  
RNA-binding protein 8A 
0.843  
B7TY16 ACTN1 
Actinin alpha 1 isoform 3 
1.110   G3V1X9 CBX5 
Chromobox homolog 5 (HP1 alpha 
homolog, Drosophila), isoform CRA_a 
0.844  
F8WA83 PDIA6  
Protein disulfide-isomerase A6 
1.106   P62995 TRA2B  
Transformer-2 protein homolog beta 
0.845  
P13667 PDIA4 
Protein disulfide-isomerase A4 
1.103   Q99436 PSMB7 
Proteasome subunit beta type-7 
0.849  
    E7EX17 EIF4B  
Eukaryotic translation initiation factor 
4B 
0.850  
    B1AKZ5 PEA15 
Astrocytic phosphoprotein PEA-15 
0.851  
    P07686 HEXB  
Beta-hexosaminidase subunit beta 
0.858  
    P26368 U2AF2 
Splicing factor U2AF 65 kDa subunit 
0.862  
    Q5JWU6 TPD52L2 
Tumor protein D52-like 2, isoform 
CRA_e 
0.863  
    H0YN26 ANP32A  
Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
0.865  
Fold changes against 1 of control (P<0.05, MTC off) 
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Appendix 5 List of proteins altered by 24 hours control compared with 0hour 
control (continued) 
 UniProt 
ID 
24h control 
Name 
Fold 
change 
 O14737 PDCD5 
Programmed cell death protein 5 
0.876  
 B5MD17 CBX1 
Chromobox protein homolog 1 
(Fragment) 
0.876  
 M0QXD6 GTF2F1 
General transcription factor IIF subunit 
1 (Fragment) 
0.880  
 P51858 HDGF  
Hepatoma-derived growth factor 
0.887  
 Q9BQ61 C19orf43 
Uncharacterized protein C19orf43 
0.889  
 H7BYM6 HMGA1 
High mobility group protein HMG-
I/HMG-Y 
0.891  
 P08254 MMP3 
Stromelysin-1 
0.893  
Fold changes against 1 of control (P<0.05, MTC off) 
 
 
Appendix 6 List of proteins altered by 24 hours lumiflavin compared with 
0hour control  
UniProt 
ID 
24h LF 
Name 
Fold 
change 
P16401 HIST1H1B  Histone H1.5 0.724 
P16403 HIST1H1C  Histone H1.2 0.739 
K7EK07 H3F3B  Histone H3 (Fragment) 0.763 
P28074 PSMB5 Proteasome subunit beta type-5 0.780 
P53999 
SUB1 
Activated RNA polymerase II 
transcriptional coactivator p15 0.837 
P14625 HSP90B1 Endoplasmin 0.896 
B4DN89 SRSF2 Serine/arginine-rich-splicing factor 2 1.136 
E7ET93 
GABRE  
REVERSED Gamma-aminobutyric 
acid receptor subunit epsilon 1.100 
Fold changes against 1 of control (P<0.05, MTC off) 
 
 
